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Antibiotic resistance is a major threat to public health worldwide which, urgently requires the 
discovery and development of novel antimicrobial drugs with new modes of action. The 
principal goal of this project is the discovery of new bioactive secondary metabolites that may 
lead to the discovery of new antibiotics to help fight against the antibiotic resistance crisis. The 
marine environment is a unique habitat where deep-sea microorganisms, because of their 
ability to adapt to this extreme environment, have the potential to produce novel secondary 
metabolites with potent biological activities. Furthermore, microbes associated with marine 
sponges are exposed to highly competitive environments both physiologically and nutritionally 
which is likely to promote the production of novel secondary metabolites. The genus 
Streptomyces produces secondary metabolic compounds that are rich in biological activity and 
marine Streptomyces strains host abundant small molecule biosynthetic gene clusters 
(smBGCs) which encode polyketides, Non ribosomal peptide synthases (NRPS), siderophore, 
bacteriocin and lantipeptides. In this respect, by focusing on Streptomyces samples taken from 
sponges in marine environments off the Irish coast, we aimed to characterize new marine 
derived bacterial strains and to explore their bioactive potential. In order to maximize the 
number of potential novel bioactive metabolites that could be be identified from each 
Streptomyces strain, and to generate the most detailed information underpinning their 
associated metabolic pathways, the One Strain MAny Compounds (OSMAC) approach, 
combined with a multi-omics approach, was employed in this project.  
In total, the Streptomyces isolates (B226SN104, SM3 and SM9), produced 612 metabolites 
including but not limited to, Bisucaberin B, Maculosin, Desferrioxamine B, Desferrioxamine 
E, Concanamycin B, Lipoamicoumacin B, Probestin, Surugamide A, Fiscalin B, Gibbestatin B 




of antimicrobial-resistant microorganisms categorized as an “Urgent” or “Serious” threat by 
the World Health Organization (WHO), including Acinetobacter baumannii, Pseudomonas 
aeruginosa, Staphylococcus aureus and Candida spp. In addition, other activities of biomedical 
interest were identified, namely anti-cancer, anti-inflammatory and antioxidant activities.  
Furthermore, the omics approach allowed us to predict 19 potential bioactive and potential 
novel promising molecules from the Streptomyces SM9 isolate. 
Taken together, this project demonstrated the significant potential the modified OSMAC/multi-
omics approach could have in expanding the number of novel secondary and bioactive 
metabolites that could be generated from existing environmental microbial isolates. 
Furthermore, it has contributed to the fight against antimicrobial resistance by identifying as 


















1 Chapter 1: Introduction 
 
1.1 The antimicrobial resistance crisis 
1.1.1 The AMR world threat and the need for new bioactive antimicrobial 
compounds. 
 
Antimicrobial resistance (AMR) has already been recognized as a serious global health threat 
to public health systems in the world. This has resulted in a large number of high-level policy 
initiatives, such as The World Health Organisation (WHO), the United Nations (UN), 
Transatlantic Taskforce on Antimicrobial Resistance (TATFAR), the Global Antibiotic 
Resistance Partnership (GARP), the Global Health Security Agenda (GHSA), the Joint 
Programming Initiative on Antimicrobial Resistance (JPIAMR),  the European Antimicrobial 
Resistance Surveillance Network (EARS-Net) and the Central Asian and Eastern European 
Surveillance of Antimicrobial Resistance (CAESAR). (Mushtaq, 2016; WHO, 2015a; 
WHO, 2011; Nahrgang et al., 2018; IACG.2019; WHO, O’Neill.2014).  Indeed worldwide 
reports and studies have shown the alarming signs of the drug-resistance crisis and the potential 
disastrous consequences of AMR, including the ground breaking report from the Interagency 
Coordination Group on Antimicrobial Resistance (IAGC) to the secretary-general of the 
United Nations on April 2019; which stipulates that if no action is taken, that drug resistant 
diseases could cause around 10 million deaths worldwide each year by 2050, force up to 24 
million people into extreme poverty by 2030 and damage  the economy to an extent that would 
be as catastrophic as the 2008-2009 global financial crisis (UN Ad hoc Interagency 
Coordinating Group on Antimicrobial Resistance; WHO, O’Neill. 2014). Furthermore, 
Dadgostar. 2019 and O’Neill. 2014, have both detailed the morbidity and mortality 




due to AMR by 2050 will be 10 million, (Figure 1), which confirm the 10 Million deaths due 
to AMR predicted by IACG. 2019. They predicted  approximately 4.7 million deaths in Asia; 
4.1 million in Africa; 390,000 in Europe; 509,000 in America and 22,000 in Oceania 
(Dadgostar. 2019; O’Neill. 2014) (Figure 1). 
 
 
Figure 1: Schematic illustration of the number of deaths attributable to Antimicrobial 
Resistance (AMR) every year compared to major causes of death by 2050 worldwide 
(Source: O’Neill, 2014). 
 
Currently across the world, at least 700,000 individuals lose their lives because of drug-
resistant infections each year, including approximately 230,000 people who die from 
multidrug-resistant tuberculosis (IACG. 2019; O’Neill 2016). In addition, alarming levels of 
resistance have been reported in countries of all income levels, with the result that common 
diseases, including respiratory tract infections, sexually transmitted infections and urinary tract 
infections, are becoming untreatable and lifesaving medical procedures riskier to perform. 
(IACG. 2019; Fadela.2019). Indeed, many surgery procedures, including medical lifesaving 
procedures and routine procedures, such as hip operations, caesarean sections, bowel surgery, 
appendectomy, bone fracture repair, amputation and others, rely completely on the use of 




Lopez. 2014; O’Neill.2014). This is even worse when considering organ transplantation, cancer 
treatment and childbirth. Indeed, organ transplantation exposes the patients to different 
infections, thus it will increase the likelihood of transplant failure and death (Dadgostar.2019, 
Santoro-Lopez.2014). Modern cancer treatments also suppress the patients’ immune systems, 
making them more vulnerable to infections. Therefore without appropriate and effective 
antibiotics to prevent or treat infection, chemotherapy will also become a much riskier 
proposition and may lead to an increase in deaths due to cancer (O’Neill. 2014). Regarding the 
safety of childbirth, including caesarean sections, the consequences of increased antibiotic 
resistance in clinical isolates will also lead to increases in both maternal and infant mortality 
(O’Neill. 2014). Also, in a world without effective antibiotics and increased AMR, the 
spreading of nosocomial infections in hospitals may even result in the closure of hospital wings 
(Dadgostar. 2019). 
 
In addition to the mortality rates, the IACG report also highlights the high financial cost of 
delaying investments and action against AMR by stipulating that the world will have to pay far 
more in the future to cope with the disastrous impact of uncontrolled antimicrobial resistance 
(IACG. 2019). This was also mentioned in both the O’Neill 2014 review and by 
Dadgostar.2019: which stipulate that if no action is being taken to tackle AMR, a total of $100.2 
GPD trillion will be lost by 2050 (Figure 2). Multi drug resistant Tuberculosis alone could cost 







Figure 2: Schematic illustration of financial Antimicrobial Resistance’s impact on 
World GDP in trillion of USD, by 2050 (Source: O’Neill, 2014). 
 
The slow pace of new antibiotics discovery as well as the decline in investment by both industry 
and public funders in the area, have exacerbated the AMR problem. Indeed, for the last three 
decades from 1986 to 2016, not a single new class of antibiotic drug has been discovered and 
even when a new discovery does happen, it can take around 15-20 years for it to be developed 
from initial discovery to a clinical drug (Birkett et al., 2010). In the private sector, pharmaceutical 
companies and venture capital funds both tend to favour areas that have a higher commercial 
return. For example, the O’Neill 2016 report highlighted the comparison of development 
pipeline between oncology and antibiotics in 2014, with 800 new products in the development 




true for venture capital funds, the same method for focusing research on lucrative area is also 
observable, as highlighted in the O’Neill 2016 report which  reported that of the 38 billion USD 
venture capital invested in pharmaceutical R&D between 2003 and 2013, only 1.8 billion USD 
was invested in antimicrobials research.  
 
1.1.2 List of AMR Priorities 
 
The Center for Disease Control and Prevention (CDC) released an antibiotic resistance threats 
report containing a list of bacteria and fungi which are of urgent, serious or concerning threats 
to human health (AR Threats Report, 2019) and in parallel, the WHO released a global list of 
human microbial pathogens which are of critical, high, and medium priority for R & D for new 
antibiotics based on specific prioritization criteria such as mortality, community burden, health-
care burden, proof/prevalence of resistance, transmissibility and treatability (WHO antifungal 
report, 2020 ; WHO, 2020; Asokan et al.2019 ; WHO, 2017; Fair & Tor, 2014). By combining 
these two reports it became clear that the major pathogens belonged to the ESKAPE group 
including Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aeruginosa, Enterobacteriaceae; however other pathogens such as 
Clostridium difficile, Candida ssp, Human Immunodeficiency Virus (responsible for acquired 
immunodeficiency syndrome AIDS) and Plasmodium falciparum (responsible for malaria) 




















Bacteria Acinetobacter baumannii carbapenem-resistant Critical Urgent 
threats 
Bacteria Pseudomonas aeruginosa carbapenem-resistant Critical Urgent 
threats 





Bacteria Clostriduim difficile rifamycins, quinolones, 













- Escherichia coli 
- Enterobacter spp.  
- Klebsiella 
pneumoniae 
- Serratia spp., 
- Proteus spp., 
- Providencia spp., 
- Morganella spp 
 
 
- Salmonellae ssp. 














































(Fair & Tor, 2014) 
HIGH Urgent 
threats 
Bacteria Mycobacterium tuberculosis rifampicin resistant TB- 
multi drug resistant TB 
(who) 
 
all classes except 





Bacteria Campylobacter ssp. fluoroquinolone-resistant HIGH Serious 
threats 






Bacteria Enterococcus faecium,  vancomycin-resistant HIGH Serious 
threats 
Bacteria Enterococci sp. vancomycin-resistant  
β-lactams, glycopeptides, 




Bacteria Helicobacter pylori clarithromycin-resistant HIGH  






Bacteria Staphylococcus aureus β-lactams, glycopeptides 




and resistant  
HIGH Serious 
threats 







Table 1: Emergent microbial threats. Adapted from Fair & Tor, 2014 including data from 
2019 AR Threats Report; Asokan et al,. 2019; WHO antifungal report; WHO 2020; WHO 
2017. 
* Mycobacterium tuberculosis, the cause of human tuberculosis, was originally not subjected 
to review for inclusion in the WHO 2020 prioritization list as it is already a globally established 
priority for which innovative new treatments are urgently needed. However it is included in 
this table as part of the urgent threats. 
 
 
1.1.3 Counter methods including new drug discovery 
 
To counter the increasing rise in AMR, a global united multisectoral approach across many 
countries is required. As the threat is worldwide, the solution needs to be worldwide as well. 
International public health organisations and associations around the world, such as the WHO, 
UN and others, have recommended a coordinated action to brings together multiple sectors and 
stakeholders engaged in human, terrestrial and aquatic animal and plant health, food and feed 
production and the environment to communicate and work together in the design and 
implementation of programmes, policies, legislation and research to attain better public health 




quinolones (Fair & Tor, 
2014) 
Virus Haemophilus influenzae ampicillin-resistant MEDIUM  
Bacteria Streptococcus group A 





Fungal Aspergillus fumigatus azole-resistant  Watch list 
Bacteria Mycoplasma genitalium n/a  Watch list 




Therefore the WHO recommendations, the IAGG report and the O’Neill report, have 
established 10 fronts on which to tackle AMR, as part of “One health response to antimicrobial 
resistance” are as follow: (1) public awareness; (2) sanitation and hygiene; (3) antibiotics in 
agriculture and the environment; (4) vaccines and alternative; (5) surveillance; (6) rapid 
diagnostics; (7) human capital; (8) new drug discovery; (9) global innovation found; and finally 
(10) International coalition for action (O’Neill., 2016). 
 
(1) Public awareness involves creating global campaigns or events, such as the World 
Antimicrobial Awareness Week, that aims to raise awareness of antimicrobial 
resistance worldwide and encourage best practices among the general public, health 
workers and policy makers to slow the development and spread of drug-resistant 
infections (WHO, 2020). The improvement of AMR awareness is targeting the concept  
that patients and farmers do not demand, and clinicians and veterinarians do not 
prescribe, antibiotics when they are not needed (O’Neill., 2016). 
 
(2) Sanitation and hygiene, the lack of hygiene and poor sanitation increases the risk of 
infection and therefore the use of antibiotics which will lead to drug resistance. The less 
people get infected, the less they need to use medicines such as antibiotics, and the less 
drug resistance arises (O’Neill, 2016). This step involves expanding access to clean 
water and sanitation in the developing world; reducing infections in health and care 
settings, including limiting superbugs in hospitals; and proper hand washing for 





(3) Reducing antibiotics in agriculture and the environment, is aimed at reducing the over-
use of antibiotics in livestock and fish farming which will later be released into the 
environment or ingested by human. It is well understood that antibiotics are required in 
agriculture and aquaculture, for maintaining animal welfare and food security. 
However, much of their global use is not for treating sick animals, but rather to prevent 
infections or simply to promote growth (O’Neill, 2016). Antibiotics reach the 
environment in many ways, including through sewage systems and run-off from food-
producing units such as farms, or through effluent from factories on AMR nearby water 
systems (O’Neill, 2016). This step involves regulations to set minimum standards for 
the treatment and release of manufacturing waste; and manufacturers to drive higher 
standards through their supply chains to take responsibility and correct any unnecessary 
environmental pollution (O’Neill, 2016; Wellington et al., 2013). 
 
(4) Vaccines and alternative can prevent infections and therefore reduce the use of 
antimicrobials which will slow the rise of drug resistance. This step involves the 
development of existing vaccine to use against AMR, the development of new vaccines 
against AMR and founding for early-stage research (O’Neill, 2016).  
 
(5) Surveillance ; this front include the Global Antimicrobial Resistance and Use 
Surveillance System (GLASS) which provides a standardized approach to the 
collection, analysis, interpretation and sharing of data by countries, territories and areas, 
and monitors the status of existing and new national surveillance systems, with an 





(6) Rapid diagnostics can change the way we are currently using antimicrobials in both 
humans and animals. Using data and testing technologies effective in informing the 
doctor’s judgement to prescribe will improve the diagnostic and reducing unnecessary 
use of antibiotics, which will slow AMR and so making existing drugs last longer 
(O’Neill., 2016; WHO, 2020). 
 
(7) Investing in human capital to improve the numbers, pay and recognition of people 
working in infectious disease to make the work attractive again and increase the 
candidates to work in AMR by improving career paths and rewards in these fields. From 
nurses and pharmacists in hospitals trained to improve stewardship, to microbiologists 
and laboratory scientists doing surveillance, diagnostic testing and R&D in academia, 
governments, public sector organisations or companies focusing on AMR-related 
specialties (O’Neill., 2016; WHO, 2020). 
 
(8) New drug discovery is essential to counter AMR. The number of effective antimicrobial 
drugs to defeat infections that have become resistant to existing medicines must be 
dramatically increased. In addition, to increase this number, the investment in new drug 
discovery must improve as well as improving investment for existing ones (O’Neill., 
2016). In addition, harmonised regulations and clinical trial networks can play an 
important role in this area to lower drug development costs and increase the investment 
(O’Neill., 2016; Wellington et al., 2013). 
 
(9) and (10) Establish a global innovation fund for early-stage and non-commercial 
research, and build a global coalition for real action – via the G20 and the UN (O’Neill, 




any one region as we live in a connected world where people, animal, food and 
microbes regularly travel around the globe (O’Neill, 2016; WHO, 2020).  
 
New drug discovery 
The marked increase in AMR together with the lack of innovation and effort in the discovery 
of new antibiotics drugs could result in humanity going back to “the dark ages of science and 
medicine” in a world without antibiotics (O’Neill, 2016; WHO, 2020). This could potentially 
result in a world where a simple infection would be fatal and a world where any attempt to save 
a life could be more life threatening than the disease itself. To counter this, there is a renewed 
interest globally in drug discovery, which is being spearheaded by the discovery of new natural 
product (NPs) including secondary metabolites. Secondary metabolites, including antibiotics, 
are widely believed to have been originally produced by bacteria as part of their chemical 
diversity, to allow them to compete and to survive against other bacteria in a competitive 
environment. As previously mentioned, NPs of microbial origin, are among many of our 
common antibiotics but have to date mainly been isolated from bacteria and fungi from 
terrestrial environments. To expand this repertoire scientists are now looking for NPs and 
secondary metabolites from as yet under or unexplored environment and ecosystems. This has 
led scientists to explore other more extreme environments, such as marine environments (with 
extremes in pressure), Antarctic environments (extreme cold temperature) and volcanic 







1.2 Marine Genetic Resources (MGR) 
 
1.2.1 Marine biodiscovery pipeline 
 
Marine environments cover >70% of the earth’s surface, and contain 95% of the biosphere, 
including millions of phylogenetically divergent microorganisms, and therefore represent an 
abundant source of biological and chemical diversity (Romano et al., 2018; Jensen et al., 1996; 
Hughes et al., 2010) which makes marine natural products a “treasure of the oceans”, offering 
molecules with potential novel bioactivities and chemical biodiversity. The marine 
environment consists of ecosystems which possess a large variety of different environmental 
conditions. These involve ecosystems with variations in temperature, oxygen levels, nutrient 
availability, salinity and pressure, which has resulted in marine microorganisms which have 
evolved both phenotypically and genetically to survive in these extreme environments. This 
has resulted in many of these microorganisms producing enzymes and small bioactive 
molecules with potential use in a variety of different biotechnological applications (Reen et al., 
2015). In addition, marine environments have peculiar geochemical features when compared 
with other land-based ecosystems, which is often reflected in the chemistry and properties of 
marine NPs produced by microorganisms inhabiting these marine ecosystems (Romano et al., 
2018; Gribble et al., 2015). 
The marine biodiscovery pipeline, from sample collection to drug lead is schematically 
depicted in Figure 3. It detailed all the step for marine drug biodiscovery  starting with the 
collection of the sample at the source, either from existing partner collections (e.g. universities, 
culture collection, etc.) or most often, from an underexplored or new marine ecosystem (Jaspars 
et al., 2016a). These samples, such as, an entire organism, tissue, or microbial culture are then 




confirm their activity (Firsova et al., 2017). When the source is of  microbial origin and 
confirmed to be active, a medium to large-scale culture is then extracted by a chemical liquid-
liquid extraction using organic solvents followed by a second confirmatory screen for 
bioactivity and or a screen for secondary metabolites on the crude extracts. When crude extracts 
are confirmed to be active or potentially novel, lastly these lead extracts follow the pipeline 
onto fractionation, purification, and chemical structural elucidation which ultimately confirms 




Figure 3: A typical Marine biodiscovery pipeline as envisaged by EU funded project 
Pharmasea. (Source: http://www.ibp.cnr.it/research/donatella-de-pascale). The collaboration 
project brought researchers to some of the deepest and coldest places on the planet. Scientists 
from all around the globe worked together to collect and screen samples of mud and sediment 
from huge previously untapped oceanic trenches. The large-scale, four-year Pharmasea project 
was backed by more than €9.5 millions of EU funding and brought together 24 partners from 








1.2.2 Marine natural products (MNPs) as a source of new bioactive secondary 
metabolites 
 
As detailed previously, marine natural products are often termed “a treasure of the oceans”, 
offering novel bioactivities and chemical biodiversity (Romano et al., 2018; Jensen et al., 1996; 
Hughes et al., 2010). In particular it is well established that, microbes which are associated 
with marine sponges are exposed to highly competitive environments both physiologically and 
nutritionally which is likely to promote the production of novel secondary metabolites (Antoraz 
et al., 2015; Tang Xi et al., 2015; Lui et al., 20017; Jackson et al., 2018). In our case, this study 
focused on samples obtained from marine sponges, including deep sea sample and shallow 
water samples from Lissodendoryx diversichela (Porcupine Bank) and from Halicona simulans 
(Galway Bay) respectively (Figure 4).  
 
Figure 4: Origin of samples. 
Porcupine banc - image credit available at https://en.wikipedia.org/wiki/Porcupine_Bank ; Galway bay/ Ireland 
map: Image adapted from Politics of Ireland - Wikipedia ; Lissodendoryx diversichela - Image credit: Crossman 
et al., 2013. Available at Norwich Research Park Science (nrp.ac.uk); Halicona stimulans- Image credit: 
(Johnston, 1842); Picton, B.E. & Morrow, C.C. (2016). Haliclona simulans (Johnston, 1842).  Encyclopedia of 





Both sponges (Lissodendoryx diversichela and Halicona simulans) harbour their own unique 
bacterial communities and are classified as low microbial abundance (LMA) sponges on the 
basis of these microbial communities (Kennedy et al., 2014; Giles et al., 2013; Marra 2019). 
These microbial communities are not only diverse but also  appear to possess real  potential as 
a source for the discovery of new medically relevant biological active agents (Kennedy et al., 
2008) and play an important role in sponge biology (Kennedy et al., 2009) which make them 
relevant for this study. Secondary metabolites are generally produced by enzymes encoded by 
co-localized genes, forming biosynthetic gene clusters (BGCs) (Romano et al., 2018). Recent 
advances in genome sequencing have revealed that microbes often harbour various “cryptic” 
BGCs, which are not associated with currently chemically characterized molecules but are 
thought to be “silent” (not expressed) under standard laboratory conditions (Romano et al., 
2018). Indeed, researchers have found that different growth conditions such as nutrients, 
culturing methods, and culturing parameters, together with other factors can affect the 
metabolic capacity and secondary metabolite biosynthetic potential of many microorganism. 
For example, Streptomyces coelicolor was initially known to encode BGCs for the production 
of 13 different classes of SMs, but the subsequent analysis of the newly sequenced genome 
revealed the presence of 16 additional BGCs which likely produce molecules with novel 
structures conditions (Romano et al., 2018; Bentley et al., 2002).  
 
Overall, microbial diversity within marine ecosystems appears even greater than previously 
imagined, and has been described as “the tip of the microbial NP iceberg” (Romano et al., 
2018). But despite the undoubted potential that marine microrganisms offer, problems continue 




the phenomenon which is often referred to as “uncultivable microbes” (Romano et al., 2018). 
Indeed, only a tiny fraction of the marine microbial diversity present in the oceans can be 
suitably cultured in laboratory. In addition even if these microorganism can be cultivated under 
laboratory conditions, it does not always result in the synthesis of many of the secondary 
metabolites encoded within the biosynthetic gene clusters (BGCs) present in their genomes. 
This was initially highlighted by Williamson et al., 2006, who reported on the inconsistency 
between the number of biosynthetic gene clusters (BGCs) identified using bioinformatics 
approaches as potentially producing secondary metabolites and the actual number of 
chemically characterized secondary metabolites produced by any given microorganism. 
Therefore it is clear that the conventional approach of cultivating marine microorganisms under 
laboratory conditions must be complemented with alternative approaches in order to explore a 
larger portion of this potential microbial diversity. A number of approaches have been 
undertaken in an attempt to induce expression from these “silent” or “cryptic” BGCs   which 
are present in the genome of theses marine microorganisms, but which are not expressed under 
typical laboratory conditions. Specific culture conditions are required to induce expression of 
these silent BGCs to unlock the chemical diversity that marine diversity can provide, leading 
to the discovery of novel bioactive molecules (Williamson et al., 2006). This has led to the 
development of both cultivation-dependent and independent methods to help unlock the 
potential of these “silent” BGCs (Romano et al., 2018). One of the methods that is typically 
used to awaken cryptic microbial biosynthetic pathways, is the One Strain MAny Compounds 
(OSMAC) approach, which is underpinned by the fact that one single microbial strain can 
produce different compounds when grown under different conditions, using different 
parameters of fermentation including nutrient source (e.g. salts, C-, N-, P-, S-sources), 





1.2.3 Marine sponges 
 
Marine sponges (phylum: Porifera), are one of the oldest extant metazoans having branched 
off from other metazoans at least 650 million years ago (Rajendran, 2019; Kamalakkannan, 
2015; Li et al., 1998). They are sessile filter feeding organisms, which display an impressive 
capacity to pump thousands of litres of seawater per kilogram of sponge bodyweight per day. 
Once the water has entered the sponge the microorganisms present in the seawater are either 
phagocytosed or are retained either as commensals or symbionts in the sponge mesophyll 
tissues. In this way sponges typically harbour dense microbial communities of up to 38% of 
their biomass (Vacelet 1975). This association between sponges and their microbiota appears 
to be unique and selective, with sponge symbionts possessing the ability to produce secondary 
metabolites, many of which have been shown to be chemically diverse bioactive compounds 
(Naughton et al., 2017; Faulkner, 2002; Laport et al., 2009; Hertiani et al., 2010; Turk et al., 
2013). For example, 283 novel compounds were reported from the phylum Porifera in 2014 
alone (Naughton et al., 2017; Blunt et al., 2014). It is believed that these metabolites may be 
part of a sophisticated armory of defence chemicals that help protect the sponge; who do not 
have complex immune systems, from predation by fish and other invertebrates. These 
metabolites may not only deter predators but may also help prevent growth on their surfaces 
by competitive bacterial species (Naughton et al., 2017). Most of the novel compounds that are 
produced by sponges are from a diverse number of structural classes, including steroids, 
terpenes, polyketides and peptides. (Kamalakkannan, 2015).  
The chemical diversity of these bioactive compounds is immense, ranging from nucleosides, 
cyclic peptides and fatty acids to amino acid derivatives, and to terpenoids, macrolides, 
porphyrins, aliphatic cyclic peroxides and sterols (Naughton et al., 2017; Kamalakkannan, 




immunomodulatory, neurosuppressive  ,and anti-viral properties (Naughton et al., 2017; Sagar 
et al., 2010; Villa and Gerwick, 2010; Frota et al., 2012; Mehbub et al., 2014; Kamalakkannan, 
2015). In the last number of years there has been mounting evidence suggesting that microbial-
symbionts of sponge species are in fact the true producers of these bioactive molecules 
(Naughton et al., 2017; Donadio et al., 2007; Piel, 2009). Marine sponges and their associated 
microbes, together with seaweeds, soft and  hard  corals,  gorgonians,  and cnidarians continue 
to be important rich sources of structurally novel bioactive secondary metabolites, with 
potential biopharmaceutical applications  (Rajendran, 2019; Kamalakkannan, 2015). 
Members of the Streptomyces genus, which will be discussed later in this review, are known to 
be among the most prodigious producers of antibiotics and bioactive secondary metabolites.  
By focusing on marine Streptomyces samples taken from sponges in marine environments our 
hope in this study was to identify novel bioactive secondary metabolites.   
 
 
1.2.4 Marine Streptomyces 
 
Streptomyces is a genus of gram positive bacteria from the Actinomycetaceae family, the 
Actinomycetales order and the Actinobacteria phylum (Waksman et al., 1943; Watve et al., 
2001). They resembles fungi due to their filamentous form and display specific morphological 
differentiation which involves the formation of a layer of hyphae that can differentiate into a 
chain of spores (Figure 5). They inhabit a variety of different habitats, mostly terrestrial such 
as soil but they have also been isolated from different marine environments such as in fish, 
molluscs, sponges, seaweeds and mangroves, seawater and sediments. Streptomyces species  
exhibit an unusual, developmentally complex life cycle, an extreme chemical diversity and are 




tumor, anti-hypertensive, anti-suppressant and anti-insecticidal activities; as well as being 
potent producers of antibiotics; which makes them of significant industrial and commercial 
importance (Jones et al., 2017). They are also known to produce enzyme inhibitors and 
pigments, as well as having biodegradation potential by producing biopolymer degradative 
enzymes (Malik et al., 2020); while  marine Streptomyces are often used as probiotics in marine 
aquaculture applications (Mazón‐Suástegui et al., 2020ab ; Tan et al., 2016; Das et al., 2010). 
 
Figure 5: Scientific classification and illustrations of Streptomyces species 
Picture credits below. Picture of Slide culture of Streptomyces on microscope obtained from the 
CDC Public Health Image Library, Image credit: CDC/Dr. David Berd (PHIL #2983), 1972. Available 
at https://phil.cdc.gov/Details.aspx?pid=2983. Picture of Streptomyces coelicolor on a plate (petri dish): 
Mervyn Bibb and Andrew Davis (John Innes Centre), Norwich Research Park (NRP-68); Available at  
http://images.norwichresearchpark.ac.uk/imagedetails.aspx?imgid=68. Picture of Streptomyces 
ipomoea on an electron micrograph: Individual spores of a spiral spore chain of Streptomyces ipomoea, 
are approximately 1 µm in diameter and 1-2 µm long. Image credit: Amanda Lawrence and C. A. Clark 
(Clark et al. 1981). Morphology of spore-bearing structures in Streptomyces ipomoea. Canadian Journal 






They have linear genomes which have a high GC content, often over 70% (Lee, et al. 2020; 
Hopwood, et al. 2006; Lee et al. 2019), which make them quite difficult to annotate and 
highlights the necessity to obtain high quality genome sequences when attempting to annotate 
their genomes (Madigan et al., 2005; Hwang et al. 2019; Lee, et al. 2020). Indeed since 
Streptomycetes have linear chromosome, it is often difficult to confirm the completeness of the 
assembled chromosome and one of the major obstacles in obtaining high quality genomic 
information from Streptomycetes is the low fidelity of sequencing techniques when dealing 
with high G C genomes and frequently repetitive sequences such as terminal inverted repeats 
(Harrison et al.2014; Lee, et al. 2020).  Good quality whole genome sequence together with 
genome assembly and annotation are essential when attempting to predict the presence of 
secondary metabolite biosynthetic gene clusters (smBGCs). As of late 2019, of the 1,614 
Streptomyces genomes that had been deposited in the NCBI Assembly database only 189 and 
35 assemblies were designated as complete genome level and chromosome level, respectively. 
In addition more than 86% of the assemblies were draft-quality genome sequences, which 
contained fragmented multiple contigs or ambiguous sequences (Lee et al., 2020).  
Several complete genome sequences of various Streptomyces species organisms, such as, 
Streptomyces coelicolor M145, as well as Streptomyces rochei 7434AN4, and others has been 
published and studied in an attempt to elucidate metabolic and regulatory networks, to elucidate 
complex smBGC regulation, to increase the production of commercially important compounds 
and to facilitate the discovery of novel and or new secondary metabolites (Paradkar et al., 2003;  
Lee, et al. 2020; Nindita. Et al, 2019). In addition the genomes of other Streptomyces strains, 
including Streptomyces sp. GS93–23, Streptomyces sp. 3211–3, and Streptomyces sp. S3–4, 
have also been published in studies contributing to the ecology and evolution of disease-




discovery, they are also used as soil inoculants in agriculture where they are known to function 
in promoting plant growth and in protecting plants from disease (Heinsch et al., 2019). 
 
Approximately two thirds of all known natural antibiotics have been isolated from 
actinomycetes, with around 75% of these from the Streptomyces genus (Franco-Correa et 
al. 2010). It is also known that Streptomyces has the capacity to produce around a total of about 
7600 bioactive compounds, making this genus the major antibiotic producer used for drug 
discovery and production in the pharmaceutical industry (Olanrewaju & Babalola, 2019). Thus 
given the aforementioned AMR crisis and the urgent need for new drug discovery; and 
knowing that the marine ecosystem is a huge potential source of novel isolates and new 
bioactive compounds coupled with the previous track record of Streptomyces as a potent  
source of antibiotics; there is a renewed interest in marine Streptomyces. A number of research 
groups are currently focusing on the genus and investigating their abilities to produce novel 
bioactive compounds (Cheng et al., 2020). Furthermore, recent advances in genome mining 
have shown that marine Streptomyces isolates possess a large number of unexplored silent 
secondary metabolite biosynthetic gene clusters (smBGCs) which makes them an invaluable 
natural source of new drug discovery (Xu et al., 2019; Lee, et al. 2020). 
Indeed, not only are marine Streptomyces drawing more and more attention as a promising 
source of new natural products, but they also represent a valuable pool of genes for 
combinatorial biosynthesis of secondary metabolites. Genome sequencing and metabolic 
profiling of a number of diverse marine Streptomyces isolates has already resulted in reports 
that they produce new secondary metabolites and to the identification of the gene clusters 
necessary for their biosynthesis, which overall facilitates the discovery of new secondary 




clusters involved in the biosynthesis of 18 different types of secondary metabolites which were 
predicted using AntiSMASH analysis and led to the identification of several new biologically 
active compounds including lagunapyrones D and E metabolites (Paulus et al, 2017). Another 
example is the discovery of a new metabolite, namely, dentigerumycin E, and its putative PKS-
NRPS biosynthetic gene cluster, produced by Streptomyces sp strain JB5 when co-cultured 
with  Bacillus sp strain GN1 (Shin et al., 2018). In addition, other marine Streptomyces have 
also displayed the potential to produce novel bioactive secondary metabolites, such as, 
Streptomyces sp. DUT11 which has the potential to produce novel lassopeptides and 
lantibiotics due to its production of tunicamycin I, V, and VII metabolites and biosynthetic 
gene clusters sharing similarities with tunicamycin and nonactin have also been identified in 
the genome of this strain (Xiao-Na Xu et al., 2018). Also Streptomyces sp. IOPU isolated from 
the marine sponge  Iotrochoto purpurea  which produced ten diverse bioactive compounds, 
namely, hexahydro‐menaquinone MK‐9, borrelidin, ferulic acid, N‐acetylanthranilic acid, 
uracil, uridine, thymidine, sitosteryl‐3β‐D‐glucoside, linoleic acid and methyl linoleate, have 
been reported and have been investigated as antioxidant and antimicrobial agents (Abd‐Ellatif  
et al., 2019).  
 
 
1.3 “Omics” and bioinformatics methods for biodiscovery of marine 
microbial natural products. 
 
Up until recently, computational based bioinformatic analysis of large data sets using machine 
learning programs was traditionally the preserve of researchers who were computer literate 




computational data analysis using languages such as R and Python, required some level of 
fluency in writing instructions together with familiarity of relevant functions and packages; as 
well as some degree of programming skills to perform any integrative omics study such as data 
processing, integration, modelling and processing the large quantities of available data. 
However, thanks to the advances in genomics technology, increases in  computational speed, 
memory storage capability to store big and large data, advances in analytical techniques and to 
the multitude of recent available resources to generate high-throughput data, such as using tools 
or software or programs like AntiSMASH, GNPS, Cytoscape, KNIME, Galaxy, Ugene, 
FinchTV, Antibase, ChemSpider, MZmine2, BLAST, GenBank, MG-RAST;  genome mining 
has become the preserve of a larger cohort of scientists. These advances, together with a 
growing number of tutorials and courses available at workshops, webinars, or on public online 
platforms such as YouTube, have allowed a much greater participation by scientists in   the 
analysis of bacterial genomic datasets. This so called “omics revolution”, has made the analysis 
of large genomic datasets much more accessible to biologists and while still challenging, quite 
complex computational analyses is becoming much easier with time.  
What is “omics”? Omics refers to the branches of sciences which regroup various discipline in 
biology that ends in the suffix – omic (Figure 6a). It combines genomics (including cognitive 
genomics, comparative genomics, functional genomics, metagenomics, neurogenomics, 
pangenomics and personal genomics), epigenomics, transcriptomics (including 
metatranscriptomics), lipidomics, proteomics (including immunoproteomics, nutriproteomics, 
and proteogenomics), metabolomics (including metabolomics and metabonomics) and 
ionomics. It is used to analyse the whole makeup of a given biological structure or function, to 
characterise, quantify, explore roles and relationships, at different levels, including at the gene  





Figure 6: Integrated Omics approaches general descriptions (a) and applications (b). 
Representation of different omics branches being used individually or in an integrated manner in science (a); applications and explanation of bioinformatics 
‘‘omics’’ in marine biology (b) from a gene level to a metabolite level.  (a) Image Source: Chaudhary et al., 2019. (b) Figure b adapted from both Akbar et al., 




In marine biotechnology research,  “-omics” based methodologies are typically used to 
investigate and ultimately exploit different marine bacterial species at different scales, from 
genomics with whole genome sequencing (WGS) to the elucidation of the genes and BGCs of  
microorganisms, while also providing a reference baseline for other omics based approaches. 
These include both transcriptomics and proteomics which are used to understand gene 
regulation and to investigate the functional properties of the microorganism; together with  
metabolomics, which is used to gain a fuller understanding of  the phenotypic effects of gene 
expression with respect to metabolites and metabolic pathways involved in both primary and 
secondary metabolism (Ambrosino et al., 2019) (Figure 6b). In addition other omics based 
approaches can also be employed in marine science, including metagenomics which is typically 
used to gain a better understanding of the microbial populations associated with different 
marine ecosystems such as marine sponges as well as metatransriptomics to identify the genes 
being expressed and which are likely to be functional within these microbial populations 
(Kennedy et al., 2010). Researchers in this area has been greatly enhanced by access to the 
recently established Marine Metagenomics Portal (MMP) whose aim is to provide high-quality 
curated and accessible microbial metagenomics resources (https://mmp.sfb.uit.no/). 
These multi-level (multi-omics) approaches, based on molecular and bioinformatic 
investigations at the genomic, transcriptomic, proteomic, and metabolomic levels are important 
in the discovery of marine natural products with novel bioactivities and to explore the key 
molecular processes involved in their production. Indeed, omics approaches, accompanied by 
the associated bioinformatic resources and computational tools for molecular analyses and 
modelling, have boosted the rapid advancement in biotechnology in general as well as in the 







The capacity for an organism to produce bioactive secondary metabolites is embedded within 
its own genome with the presence of specific genes and BGCs involved in the biosynthesis of 
the metabolites. Therefore an analysis of the genomes of these organisms is often the first step 
in uncovering their potential in the marine drug discovery pipeline.  
Genomics based studies typically involves sequencing marine bacterial genomes, using Next 
Generation Sequencing (NGS) and or Whole Genome Sequencing (WGS) based techniques 
following by the use of various  computational based tools. These typically involve homology-
based searches which are often conducted with BLAST (Basic Local Alignment Search Tool); 
resulting in the identification of the genetics basis of desirable traits, and knowledge of the 
genes responsible for a given phenotype; as well as allowing for phylogenetic analysis to 
establish the evolutionary relationships together with identifying potential Biosynthetic Gene 
Clusters (BGCs) including the discovery of silent biosynthetic gene clusters. In this respect 
bioinformatics tools such as AntiSMASH (antibiotics and Secondary Metabolites Analysis 
SHell) have been particularly useful (Blin et al., 2019).  AntiSMASH is used to identify 
smBGCs within a genome and relies on the highly conserved sequences within the smBGCs to 
map their location. (Lee et al, 2020). AntiSMASH achieves this by employing a sequence 
alignment-based profile in a Hidden Markov Model (HMM) of genes that are specific for 
certain types of smBGCs (Lee et al, 2020; Blin et al., 2019).  For example, AntiSMASH 
identifies smBGCs based on the highly conserved core biosynthetic enzymes and evaluates the 
results using a set of manually curated BGC cluster rules, followed by the discarding of false 





The most recent updated version of AntiSMASH (version 5), can predict up to 52 different 
types of smBGCs and can provide rapid gene annotation when bacterial genome data sets are 
submitted in FASTA format (Lee et al, 2020). 
 
In this respect genomics has proven very useful for the characterization of marine species that 
are important in the production of secondary metabolites of interest for industrial, 
pharmaceutical, and green biotechnology applications (Kumar et al., 2018). 
 
1.3.1.1 Secondary metabolites Biosynthetic Gene Clusters sm(BGC). 
 
Secondary metabolites are produced from the multi enzyme complexes encoded by  secondary 
metabolite biosynthetic gene clusters (smBGCs), which generally contain whole pathways that 
facilitate precursor biosynthesis, assembly, modification, resistance, and regulation of their 
product (Lee et al, 2020). The expression of these clusters is controlled by complex regulatory 
networks governed by both biotic and abiotic stresses which are typically found in the 
bacteria’s natural habitat (Lee et al, 2020). 
 
BGCs are classified based on their product as; saccharides, terpenoids, ribosomally synthesized 
and post-translationally modified peptides (RiPPs), non-ribosomal peptide synthetases 
(NRPS), and polyketide synthases (PKS) (Naughton et al., 2017). NRPS, PKS and Hybrid 
NRPS-PKS BGCs (Figure 7), are gaining more and more attention due to the large number  of 
clinically relevant bioactive natural products that have been discovered from Non-ribosomal 
peptides and polyketides molecules which were are synthesized in a modular fashion by large 




2013).  These multi-enzyme complexes, which consist of functional units known as modules, 
which contain at least three essential domains; (i) a catalytic domain responsible for selection 
of a specific monomer (ii) a carrier protein domain which facilitates attachment of the monomer 
after thioesterification and (iii) a second catalytic domain which functions in chain elongation 
(Naughton et al., 2017; Fischbach and Walsh, 2006), (Figure 7).  
 
Figure 7: Representative biosynthetic pathways of (A) PK: 6-deoxyerythronolide B (6-





Catalytic domains: AT, acyltransferase; KS, ketosynthase; KR, ketoreductase; DH, dehydratase; ER, 
enoylreductase; TE, thioesterase; A, adenylation; C, condensation; T, thiolation; E, epimerase; MT, 
methyltransferase; Re, reductase (Li et al,. 2018). 
 
In a typical NRPS module, illustrated in Figure 7B, these domains are represented by a 
condensation domain (C), an adenylation domain (A) and a peptidyl carrier protein (PCP) 
domain (Naughton et al., 2017). Analysis of the amino acids which line the binding pocket of 
the A domain, facilitates prediction of the specific monomer incorporated at this site, which 
allows the prediction of the amino acid backbone structure of the resulting peptide (Naughton 
et al., 2017; Finking et al,. 2004).   
In a typical PKS module, illustrated in Figure 7A,  the domain are as follow, a ketosynthase 
(KS) domain, an acyltransferase (AT) domain and an acyl carrier protein (ACP) domain 
(Naughton et al., 2017). However, there are 3 types of PKSs, classified by the organization of 
their catalytic domains (Naughton et al., 2017; Shen, 2003). These 3 types of PKSs are further 
detailed and illustrated in Figure 8. Type I PKS consist of multi-domain polyproteins which 
can be classified as either modular biosynthetic complexes, consisting of a series of enzymatic 
domains for each chain extension and modification step; or iterative, wherein a single set of 
enzymatic domains are reused several times during polyketide biosynthesis (Naughton et al., 
2017). Type II PKS differ from Type I PKS, by the separate and discrete proteins which form 
the putative multienzyme complexes (Naughton et al., 2017; Shen, 2003). Lastly Type III PKS, 
consist of a simple homodimeric architecture and function essentially as condensing enzymes 
(Austin et al, 2003). In addition, tailoring domains such as heterocyclization and epimerisation 
(E) domains (in the case of NRPS modules) or β-ketoreductase (KR) and dehydrogenase (DH) 
domains (as in the case of PKS modules) which contribute to the overall structural diversity of 
the resulting final products, may be associated with each of these module (Naughton et al., 




functional similarities shared between NRPS and PKS gene clusters, which offers an even 




Figure 8: Domain organization of the different type of PKSs. (Source: Lim et al,. 2016). 
Putative domains are represented by circles, in modular type I PKSs, functional domains are organized 
into several modules, with each module being responsible for a single decarboxylative condensation 
step in polyketide formation (Lim et al. 2016). For iterative type I PKSs, the functional domains are 
clustered in a single module, and each domain is used repeatedly during polyketide synthesis (Lim et 
al. 2016). Type II PKSs are dissociable multi-enzyme complexes, with each protein bearing a single 
and independent catalytic domain that is used iteratively during polyketide formation (Lim et al. 2016). 
Reactions by type III PKSs are also iterative but do not require an ACP for the attachment of the growing 
polyketide chain (Lim et al, 2016). AT: Acyltransferase; ACP: Acyl carrier protein; KS: Ketosynthase; 









The metabolome of an organism, refers to the complete set of small-molecule metabolites that 
can be found within the organism and it directly correlates with gene expression and associated 
metabolite production, typically representing the phenotypical responses of the organism to a 
vast range of physiological and environmental stimuli (Yan et al., 2015; Ambrosino et al., 
2019; Bundy et al., 2005). Any disturbance or perturbation to a microbial system, will typically 
cause changes in the metabolite profile of that system (Yan et al., 2015). Metabolomics is the 
study of the whole repertoire of molecules in microbial cells, which represents a significant 
and speedily evolving part of the new systems biology area (Chandra Mohana et al.2018).  
Relative to different omics fields, metabolomics remains a comparatively young discipline but 
has become a “key field” in the study of marine biodiversity, particularly due not only to the 
extreme variability in chemical and physical conditions that the marine environment presents 
(Ambrosino et al., 2019; Romano et al., 2017), but also due to the ongoing advances being 
made in metabolomics technologies that are leading to the generation of more accurate data. 
Indeed, instrumentation has become much quicker, more sensitive with increased reliability 
and automation resulting in the reduction of errors in the measurement of constituents, while 
also allowing for the application of increased statistical analyses for data validation (Chandra 
Mohana et al.2018). In addition, metabolomics provides data that is typically, more precise, 
germane and quantitative than genomics, transcriptomics or proteomics; by accurately 
quantifying the spectrum of biochemical changes, allowing the mapping of changes to various 
metabolic pathways within bacterial cells (Chandra Mohana et al.2018). While genome mining 
approaches aid in the prediction and identification of biosynthetic gene clusters from genes that 
are likely to produce molecules, metabolomic approaches aid in the analysis of the chemical 




cell and linking metabolite production to genes within gene clusters or operons. Thus 
metabolomics approaches complement genomics, as a way to confirm the predictions that the 
genomics based approaches can offer, with respect to the metabolites that are produced from 
the different microbial gene clusters (Chandra Mohana et al., 2018; Patti et al., 2012). 
Metabolomic approaches in research are based on the direct profiling of molecules via Mass 
spectrometry (MS) techniques (Ambrosino et al., 2019; Fuhrer et al., 2011; Zampieri et al., 
2016). It involves chemical based techniques and analysis, such as in most of cases, (1) 
chemical extraction of molecule, (2) MS based techniques, (3) manual dereplications strategies, 
and (4) Nuclear magnetic resonance (NMR), to allow the chemically extraction, analysis, 
identification and characterisation of the metabolites being targeted. These approaches also 
involve the use of bioinformatic based skills , by employing  bioinformatics resources such as 
ChemSpider, GNPS, MZmine 2, Cytoscape, AntiSMACH, Jupiter notebook among  others, to 
visualize the metabolome together with the chemical diversity and the metabolite clusters on a 
(5) molecular network and or a (6) bioactivity map. 
 
1.3.2.1 (1) Chemical extraction 
 
In the field of marine natural products biodiscovery, there are several methods that can be 
employed to chemically extracts molecules or compounds, however, the most commonly 
used method is  Liquid–liquid extraction (LLE), also known as partitioning. It is a useful 
method for separating compounds within a mixture, based on their relative solubilities in 
two different immiscible liquids, usually water (polar) and an organic solvent (non-polar). 
In marine natural products discovery, samples containing potential bioactive compounds, 
which are often from bacterial  isolates from samples obtained from different marine 




solvent such as ethyl acetate, methanol or dichloromethane, thereby producing crude 
extracts from 2 separate phases: the aqueous phase and organic phase. Potential bioactive 
compounds can be present in either of these phases. In general most of compounds tend to 
be in the organic phase which later facilitates the LC-MS analysis. However, some 
compounds may also be present in the aqueous phase, which can complicate the LC-MS 
analysis as the aqueous phase contain a lot of waste which make more background noise in  
the LC-MS.  
 
1.3.2.2 (2) MS- based techniques 
 
In untargeted metabolomics approaches, biological samples are most often processed, 
through an initial liquid chromatography (LC) or gas chromatography (GC) phase and 
subsequently subjected to MS analysis, leading to the detection of thousands of metabolites 
in a single eluate (Cox et al., 2014). There is a lot of different MS based techniques that 
can be used in metabolomics, but in general they fall into five categories: Gas 
Chromatography – Mass Spectrometry (GC- MS), Liquid Chromatography - Mass 
Spectrometry (LC - MS), Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR) 
and Integrated Applications (IA) (Cox et al., 2014). However, the most widely used 
technique is LC-MS. LC-MS Liquid Chromatography - Mass Spectrometry is an analytical 
technique that combines the physical separation capabilities of liquid chromatography with 
the mass analysis capabilities of mass spectrometry. LC-MS is a technique that has become 
routine with the development of electrospray ionisation (ESI) providing a simple and robust 
interface (Pitt, 2009) and has been used frequently in natural product discovery programs 
(Floros et al., 2016). Pitt, 2009, reported that LC-MS can not only provide superior 




reproducible assays when combined with stable isotope dilution. Another advantage of LC-
MS assays is the capacity to multiplex several analytes within a single analytical run with 
minimal incremental cost, which gives the potential to simplify laboratory set up and 
provide additional useful information including metabolite profiles, which are very useful 
in metabolomics (Pitt, 2009). Indeed, it can detect hundreds of compounds in a single run 
due to fast scanning speeds, thereby demonstrating a high degree of multiplexing 
possibilities (Pitt,. 2009). Modern mass spectrometers are highly sensitive and with the 
advances in technologies, the sensitivity of MS continues to improve (Pitt, 2009) and LC-
MS have now reached an unparalleled sensitivity (Dunn et al., 2005) making them one of 
the cornerstones in marine natural product discovery. The goal of such metabolomics based 
efforts is typically to allow the identification of both known and unknown molecules in 
complex backgrounds (Floros et al., 2016).  
 Cox and co workers have previously described the commonly employed liquid 
chromatographic methods used in metabolomic analysis: normal-phase, reverse-phase, and 
hydrophilic interaction liquid chromatography (Cox et al., 2014). Normal-phase liquid 
chromatography (NPLC) readily separates highly non-polar metabolites (e.g. fatty acids, 
sterols, triacylglycerols, etc.) while reverse-phase liquid chromatography liquid 
chromatography (RPLC) is better suited for the separation of metabolites of medium to low 
polarity (e.g. alkaloids, flavonoids, glycosylated steroids, phenolic acids, etc.) (Cox et al., 
2014). Hydrophilic interaction liquid chromatography (HILIC) can be used to separate a 
broad range of metabolites depending upon the bonded-phase of chromatographic media 
used (e.g. amino bonded, cationic boned, zwitterionic bonded, etc.) (Cox et al., 2014; Dunn 
et al., 2005; Lu W et al., 2008, Zhou B et al., 2012). Ultra-high performance liquid 
chromatography (UPLC) employs a short column with a small diameter particle size 




expense of separation resolving power (Cox et al., 2014; Dunn et al., 2005, Zhou et al., 
2012); while capillary liquid chromatography incorporates much longer capillary columns, 
which significantly increase the resolution of chromatographic separation but necessitate 
increased analysis time (Cox et al., 2014; Dunn et al., 2005). Multidimensional liquid 
chromatography (MDLC) combines two or more of the aforementioned chromatographic 
modes to enhance metabolite separation (Cox et al., 2014; Lu et al., 2008; Zhou  et al., 
2012). 
In LC-MS, the series of metabolites produced following chromatography are subsequently 
exposed to an ion source which will dissociates them into ionic derivatives required for 
mass analysis (Cox et al., 2014). The ionization sources can include atmospheric pressure 
chemical ionization (APCI), atmospheric pressure photoionization (APPI), fast atom 
bombardment (FAB) and electrospray ionization (ESI). However, in metabolomics studies, 
ESI is by far the most common ionization source employed, due to its ability to ionize both 
polar and semi-polar compounds within a wide molecular weight range (Cox et al., 2014; 
Zhou et al., 2012). Mass spectrometers can be categorized as fourier transform ion 
cyclotron resonance (FTICR), ion trap (IT), orbitrap, quadrupole and time-of-flight 
(QTOF). Hybrid/tandem mass spectrometers are constructed by using two or more of the 
previously described mass analyzers in the same LC-MS system (Cox et al., 2014).  For 
metabolomics studies, IT and QTOF are most commonly used, due to their ability to 
provide the accurate high mass resolution of MS/MS analysis (Cox et al., 2014). In the 
study that will be described later in this thesis, High Resolution LC-MS/MS analysis was 
performed with a Bruker MAXIS II QTOF instrument which runs in tandem with HPLC 





The flexible nature of LC-MS technologies coupled with the extreme diversity of 
metabolite chemo-physical properties or concentration, within a sample, can result in the 
introduction of a clear source of variation in the metabolomics data that is obtained (Cox 
et al., 2014). Furthermore, the ability to customize parameters to separate, detect and target 
a wide range of diverse molecules at low concentrations (e.g. pg mL−1), makes LC-MS an 
ideal tool for metabolomic analysis (Cox et al., 2014; Shen et al., 2005; Kaddurah-Daouk  
et al., 2008). For example, Shen and co workers have reported the detection of over 5000 
metabolites from a single experiment utilizing a capillary-RPLC-IT-TOF-MS/MS platform 
in a study on Shewanella oneidensis (Shen et al., 2005).  
 
1.3.2.3 (3) Manual dereplication strategies 
 
Manual dereplication strategies, including manual annotation of peak ions, are employed 
on metabolites from the LC-MS data to assess the possibilities of identification of the 
detected metabolites, following specific criteria and libraries. Part of this criteria is  
deduction of the possible molecular weights and molecular formulas using Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma); and by 
comparison with the relevant natural product library databases. The absence of any “hits” 
following searches on these libraries databases will deduce the presence of potential new 
metabolites, which would later need to be confirmed by NMR.   
Metabolomics based approaches for natural product discovery, including manual 
dereplication, depends on the aforementioned natural product libraries which enable rapid 
characterization of known metabolites (Chandra Mohana et al., 2018). Libraries such as 
Chemspider, Antibase, The Dictionary of Natural Products, Reaxys and others, provide 




formula, molecular weight, monoisotopic mass and pharmacological activity 
(The_Royal_Society_of_Chemistry, 2015). In addition, the open-access platforms sharing 
of raw, processed, or liquid chromatography with tandem mass spectrometry data; such as 
the global natural products social molecular networking (GNPS) is very useful in the 
identification of the metabolites and their related metabolic pathways (Ambrosino et al., 
2019; Wang et al., 2016). One of the often-perceived hurdles involved in natural product 
drug discovery is the chance of redundancy and many dereplication procedure have been 
established to deal with this potential drawback (Chandra Mohana et al., 2018). The 
structural information on metabolites, obtained at an early stage, provided by NMR and 
high-resolution MS-based platform, followed by its comparison with literature, can lead to 
identification without the need for laborious isolation processes, if structures have been 
previously reported (Chandra Mohana et al. 2018).  
 
1.3.2.4 (4) Nuclear magnetic resonance (NMR).   
 
NMR spectroscopy is a traditional powerful analytical tool that is essential for the structure 
elucidation of natural products (Mohamed et al., 2020; Kim et al., 2011; Kim et al., 2010; 
Mahrous et al., 2015). It is also a very useful technique for the structural elucidation of 
novel and/or unexpected compounds (i.e. identifiable by NMR but not LC-MS) including 
those with identical masses and/or different isotopomer distributions (Mohamed et al., 
2020; Robinette et al., 2012; Tawfike et al., 2013). Unlike MS-based techniques, NMR is 
less biased as the results do not rely on the type of ionization condition or the preferences 
of the instruments that are used (Mohamed et al., 2020; Cai et al., 2007). NMR also allows 
the detection of both primary and secondary metabolites, simultaneously (Mohamed et al., 





1.3.2.5 (5) Molecular networks 
 
The data obtained from chemical analysis using MS-based techniques, including raw 
spectrum files, are typically then processed by bioinformatics tool such as GNPS. GNPS is 
a web-based mass spectrometry ecosystem that aims to be an open-access knowledge base 
for community-wide organization and facilitates the sharing of raw, processed, or annotated 
fragmentation mass spectrometry data (MS/MS). Thus it aids in identification and 
discovery throughout the entire life cycle of data; from initial data acquisition/analysis to 
post publication (Wang et al., 2016). GNPS will analyse the chemical diversity and clusters 
compounds with similar structural features together, which translate into similar 
fragmentation patterns and into groups of molecular families (Hamed et al., 2020). The 
resulting visualisation, followed by specific annotations can then be performed by 
metabolome mining using Cytoscape (https://cytoscape.org/), an open source software 
platform for visualizing complex networks and integrating these with any type of attribute 
data; allowing the final version of the molecular network which will allow complete 
visualization of the chemical diversity of the metabolome. An example of such as molecular 
is in illustrated in Figure 13 in Chapter 2, which consists of nodes which correspond to 
parent ions and are linked into groups with edges which represent a cosine similarity score 
and provides effective and rapid dereplication of large and complex MS/MS datasets 
(Hamed et al., 2020).  Molecular networks have and continue to be successfully 
implemented in natural product research to accelerate targeted isolation of potentially new 
metabolites (Hamed et al., 2020. Ding et al., 2018, Yang et al., 2013, Li et al., 2018). The 




specifically when employed in the study of the metabolome and chemical diversity of the 
Streptomyces B226SN104, SM3 and SM9 isolates. 
 
1.3.2.6 (6) Bioactivity mappings 
 
A second method for molecular networking, called Feature-based Molecular Networking 
(FBMN) is also available in the GNPS online platform, where a feature detection and alignment 
tool (MZmine, OpenMS, XCMS, etc.) is used to pre-process the LC-MS/MS data 
(Buedenbender et al,. 2020). This pre-processing involves filtering data for noise, duplication 
of peaks and isomers which all together allow relative quantification within the FBMN and 
furthermore makes it possible to integrate biological activity data into FBMN in a 
complementary workflow termed “bioactive molecular networking” (BMN) (Buedenbender et 
al,. 2020). BMN correlate the features of chromatographic profiles of a fractionated extract 
derived through for example MZmine, ( http://mzmine.github.io/)  with the bioactivity levels 
of the respective sample (extracts) leading to the calculation of a bioactivity score for each 
molecule in the network. The bioactivity score is based on the statistical Pearson correlation 
coefficients between chemical features and observed bioactivity and can be mapped out on the 
molecular network to predict potential bioactive compounds or chemical families and 
subsequently guide their targeted isolation (Buedenbender et al,. 2020). Bioactivity mapping 
will also be further detailed in the thesis, where the BMN concept was employed in an attempt 
to map the antimicrobial components in the Streptomyces SM9 metabolome. 
It is important to note that bioinformatics analysis relies not only on the quality and accuracy 
of the chemical analysis and results, including the spectrometry data; but also on the 
metabolome annotation component of the metabolome mining, as an accurate annotation is 




for metabolomic interpretation, such as, high-throughput metabolite profiling and annotation, 
are highly challenging tasks, with fast evolving metabolomics datasets (Ambrosino et al., 2019; 
Rawlings et al., 2017; Chaleckis, et al., 2019). 
The importance of the use of chemical analysis (LC-MS/NMR) coupled with bioinformatics 
involving genomics and metabolomics in marine drug discovery is reflected in the increased 
number of scientific papers being published in the area. Amongst these numerous papers, 
characterization of a 7-prenylisatin antibiotic from Streptomyces Species MBT28, which is 
effective against Bacillus subtilis is typical (Wu et al., 2015).  The used of NMR-based 
metabolomics together with a proteomics based approach facilitated the identification of a gene 
cluster which was subsequently shown to encode an indole prenyltransferase enzyme that 
catalyzed the conversion of tryptophan into 7-prenylisatin (Chandra Mohana et al.2018; Wu et 
al., 2015). Another example, from the same research group is the reported identification of 
novel C-glycosylpyranonaphthoquinones in Streptomyces sp. MBT76, utilising a combined 
NMR based metabolomics approach coupled to genome mining (Chandra Mohana et al.2018; 
Wu et al., 2017). This led to the discovery that these C-glycosylpyranonaphthoquinones were 
produced as a result of the activation of the qin gene cluster involving a type II PKS pathway 
and that these molecules were effective against Gram-positive bacteria, which ultimately 
provided valuable insights into the pyranonaphthoquinone group of antibiotics (Chandra 
Mohana et al.2018; Wu et al., 2017). Finally another example is the report by Cheng and co 
workers who isolated 64 actinomycetes from 12 different marine sponge species and subjected 
them to metabolomic analysis using high-resolution LC-MS and NMR for dereplication 
purposes (Cheng et al., 2015). This LC-MS/NMR based detection allowed the prioritization of 
two isolates which exhibiting distinct chemical profiles belonging to the 
genera Streptomyces (SBT348) and Micromonospora (SBT687); as well as, both possessing 





In this study, we aimed to contribute to the global fight against AMR by employing a large 
scale based OSMAC approach, involving changes in both temperature and nutrient source 
parameters, together with new  marine “omics” based methods, to study  and characterize new 
marine Streptomyces isolates from sponges. In addition, specific bioactivity towards clinical 
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activities which are also important and of biomedical interest. This study employed a multi-
fields perspectives, to investigate on the production of secondary metabolites, of potential new 
metabolites and of potential new activity (Figure 9). We investigated and described potential 
novel biosynthetic pathways that may encode for any potential new bioactivities, using 
molecular networks and bioactivity mappings. With this study, we hope to increase the 








Figure 9:  Design of OSMAC based approach developed in this study. (Adapted from 
Antoraz et al., 2015).  
The One Strain MAny Compounds approach using genomics analysis, nutrient sources and 
temperatures changes in parameters of growth conditions. Bioactivity screening and 
metabolomic analysis additional steps has been added to the original OSMAC approach to 
enhance further the production and the selection of potential bioactive novel metabolites 
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2 Chapter 2: Utilization of OSMAC, Genomic mining, LC-MS 
and Metabolomic analysis to detect and identify potential new 
bioactive metabolites in marine Streptomyces strains, from 







Microbes associated with marine sponges are exposed to highly competitive environments both 
physiologically and nutritionally which is likely to promote the production of novel secondary 
metabolites. This study focuses on the OSMAC (One Strain MAny Metabolites) approach from 
a number of bacterial strains that were originally isolated from marine sponges, including one 
from a deep sea sponge, for the production and identification of potential new bioactive 
metabolites. Six Streptomyces strains were functionally characterized by screening for anti-
bacterial and anti-fungal activities and were genetically characterized. Full genome sequence 
were generated for each strain using Illumina technology and approximately 159 potential 
secondary metabolism biosynthetic gene clusters in total were identified using the AntiSMASH 
program and genome mining approaches. In addition, two of these strains, B226SN104 and 
SM3, which displayed the highest number of gene clusters of interest, were subjected to 
different growth conditions using the OSMAC approach to determine the optimal nutrient 
media and the optimal temperature for the production of potential novel secondary metabolites. 




ethyl-acetate. Crude extracts containing the potential secondary metabolites from both aqueous 
and organic phases were analyzed using LC-MS, molecular networking and manual de-
replication for the chemical prediction of the molecules involved. This resulted in the 
identification a high number of interesting metabolites and a potential new metabolite, 
produced in specific fermentation conditions which highlight the good candidacy of these 
strains for the study of potential “silent” gene clusters. To our knowledge this is the first 
OSMAC study tested on a large scale nutrient sources (seven media per strain tested) while 
simultaneously comparing the two most used optimum temperature for marine bacteria (i.e. 
28ºC and 30ºC). For ours strains, OSMAC revealed that the best condition of fermentation -to 
produce potential new metabolites from these marine bacterial strains was 28ºC as the optimum 
temperature, and mannitol with peptone as the optimum nutrient sources. 
 
Keywords: OSMAC, secondary metabolites, potential new metabolite, marine bacterial strain, 


















The One Strain MAny Metabolites (OSMAC) principal involves growing a microbial strain 
under a variety of different environmental conditions, which typically results in the production 
of many different types of metabolites; ultimately leading to the potential discovery of new 
bioactive metabolites such as for example antibiotics (Figure 10) (Antoraz et al. 2015; Romano 
et al., 2018; Pan et al., 2019). It is highly efficient in inducing chemical diversity through the 
provision of variations in cultivation parameters (Fan et al., 2019). Factors such as nutrient 
content, growth temperature, pH and culture aeration, are all known to alter the physiology of 
microbial strains and thereby alter their secondary metabolism profiles (Ying et al., 2018). 
Parameters such as changes in nutrient sources, involving the modification of both carbon and 
nitrogen sources in the culture media are known to be particularly useful in altering the 
metabolite production profile in bacterial strains (Sproule et al., 2019). Other parameters 
include signals that can activate regulatory systems to trigger antibiotic production (Antoraz et 
al. 2015; Pan et al., 2019), while other parameters, including the use of antibiotics and 
hormones which can also boost the production of secondary metabolites (Antoraz et al. 2015). 
Finally, the use of co-culture approaches with the strain of interest being cultured with another 
fungal or bacterial strain to stimulate interspecies interactions can also result in the induction 
of the secondary metabolites (Fdhila et al., 2003; Wang et al., 2014; Antoraz et al. 2015). 
Changes in these parameters tends to promote, induce or stimulate the production of bioactive 
secondary metabolites and potentially new metabolites (Reen et al., 2015; Pan et al., 2019). 
Following use of the OSMAC strategy, the culture media is  typically extracted generating  
crude extracts from the organic and-or aqueous phases.  Bioassay guided approaches are then 
employed on these crude extracts for the chemical detection of metabolites that are produced, 
and  together with dereplication strategies, result in the identification of these  metabolite with 




existing metabolites (Weller  et al.,  2012). For a unifying review of bioassay-guided 
fractionation, effect-directed analysis and related techniques, see Weller et al., 2012.  
In marine environments, bacteria are exposed to quite unique environmental conditions such 
as temperature, pressure, dissolved oxygen and low nutrient availability, which often results in   
the production of structurally diverse and biologically important metabolites (Petersen et al., 
2020). Marine Streptomyces species have in particular being shown to produce a wide variety 
of different bioactive metabolites, which are rich in biological activity. For example marine 
Streptomyces derived metabolites have been reported to exhibit anticancer, antifungal, 
cytotoxic and antibacterial activity (Niu et al., 2011; Zotchev, 2012; Song et al., 2014; Jackson 
et al., 2018).  
 
 




Nutrient sources are known to regulate secondary metabolism in Streptomyces strains (Martin 
et al., 2011) with for example antibiotic SBR-22 production in the marine sediment isolate 
Streptomyces psammoticus BT-408 being  reported to be regulated by different nitrogen 
sources (Sujatha et al., 2005) . In addition Surugamide A production in the marine sponge 
isolate Streptomyces sp. SM17 is also known to be regulated by different carbon sources (Saha 
et al., 2005; Almeida et al., 2019).  Thus in this study we employed the OSMAC approach to 
investigate the effect of seven different culture conditions with differing carbon and nitrogen 
nutrient sources, on secondary metabolite production in two marine Streptomyces strains; 
namely Streptomyces sp. SM3 isolated from the sponge Haliclona simulans (Kennedy et al., 
2009) and Streptomyces sp. B226SN104 isolated from the deep sea sponge Stelletta normani 
(Borchert et al., 2016). 
 
In addition while a number of studies have reported the effect of temperature on secondary 
metabolite production in marine bacteria, such as Pseudoalteromonas, Pseudomonas, Serratia 
and Vibrio species; with the optimal temperature being either 28°C or 30°C, within the 
temperature range from 25°C to 40°C (Wietz et al., 2011; Darabpour et al. 2012); there is little 
information on the effect of temperature on secondary metabolite production in marine 
Streptomyces species. Thus given that there is some evidence that secondary metabolite 
production may be affected by temperature in terrestrial Streptomyces strains, with Jadomycin 
B production in Streptomyces venezuelae ISP5230 being reported to increases following a 42°C 
heat shock (Doull et al., 1994), and that temperature may regulate validamycin A production 
in Streptomyces hydroscopicus; we decided to also investigate the potential effect of 
temperature on secondary metabolite production when both SM3 and B226SN104 were grown 
on the aforementioned different media at two commonly used temperature conditions for the 




Results and Discussion 
 
2.1 Genomics and microbiological activity of the Streptomyces spp isolates 
 
2.1.1 Secondary metabolite gene clusters of the Streptomyces spp isolates. 
 
The isolation and characterization of 18 marine sponge derived Streptomyces strains, which 
displayed a range of antimicrobial and antifungal activities against a number of clinical 
pathogens has previously been reported (Kennedy et al., 2009; Jackson et al., 2018).  The 
genomes of five of these strains namely Streptomyces sp SM3, SM6, SM9 and B226SN104 
which displayed the best range of bioactivities were subsequently sequenced and together with 
genome sequence data available for another marine sponge derived Streptomyces strain namely 
SM14 (Almeida et al., 2019ª), the six genomes were analysed for the presence of potential 
secondary metabolite gene clusters (Figure 11).  
 
Values were automatically converted from the normal distribution of the number of gene clusters to the 
standard normal distribution by “standardizing” with the use of z-scores. The z-score – (indicated by 
colour scale) is positive if the value lies above the mean, and negative if it lies below the mean. The 
Figure 11: Heat map of the predicted secondary metabolite gene clusters in the genomes 




dendrogram was generated automatically according to the default parameters (“predicted clusters”) 
which shows two distinct clusters, representing the genomes which contain the lowest number of gene 
clusters in one group cluster, and those which contain the higher number of gene clusters in the other 
group cluster defined by two sub-group clusters. Normal distribution values of the total number of gene 
clusters identified among the six genomes isolates were manually added on the top of the heat map. 
 
 
Among these six Streptomyces genomes, a total of 159 secondary metabolite gene clusters were 
predicted to be present, including a total of 29 PKS, 24 Terpene, 22 NRPS, 11 Siderophore and 
11 PKS-NRPS hybrids. Following this analysis, two isolates namely B226SN104 and SM3 
appeared to have the highest number of predicted gene clusters in their genomes. Thus having 
identified these two strains as possessing the most promising genomes for the potential 
production of secondary metabolites, we selected them for analysis using the OSMAC 
approach, to monitor production of secondary metabolites following growth in different culture 
conditions including different parameters such as nutrient sources and temperatures. The 
culture conditions were chosen taking into account well established media for the culture of 
marine Actinobacteria strains (Goodfellow et al., 2010)  general media for culturing 
Streptomyces strains (Romano et al., 2018; Almeida et al., 2019b) together with media known 
to induce sporulation and antibiotics production in  Streptomyces (Tian et al. 2013) (Table 2).  
 
Media Composition 
M19 Mannitol 2%, Peptone  2% (Goodfellow et al., 2010). 
M400 Glucose 1%, Meat extract 0.3%, Peptone 0.3%, Starch 2%, Yeast extract 
0.5%, CaCO3 0.3% (Goodfellow et al., 2010). 
MMM Glucose 1%, Tryptone 0.5%, Starch 0.5%, CaCO3 0.1% (Goodfellow et 
al., 2010). 




SGG Glucose 1%, Glycerol 1%, Corn steep solid  0.25%, Peptone 0.5%, Starch 
1%, Yeast extract 0.2%, CaCO3 0.3%, NaCl  0.1%. (Goodfellow et al., 
2010). 
SM Soymeal  2%, Mannitol  2%, pH=7 (Tian et al. 2013; Almeida et al., 
2019b] 
SYP Starch 1%, Yeast extract 0.4%, Peptone 0.2% (Romano et al., 2018; 
Almeida et al., 2019b) 
M410 Glucose 1%, Glycerol 1%, Casaminoacid  1.5%, Oatmeal 0.5%, Peptone 
1%, Yeast extract 0.5%, CaCO3 0.1% (Goodfellow et al., 2010). 
Table 2: Composition of the different media used for the fermentation of the 
Streptomyces sp SM3 and Streptomyces sp B226SN104 strains. 
 
 
2.1.2 Biological activities of B226SN104 and SM3 isolates 
 
To confirm that both isolates were producing bioactivity when cultured under these particular 
growth conditions, the isolates were screened for antimicrobial activities against relevant 
clinical pathogens species when grown in M410 media. When grown on this medium the deep 
sea isolate B226SN104 displayed bioactivity against C. glabrata (CBS138) while the shallow 
water isolate SM3 displayed bioactivity against P. aeruginosa (PAO1) and B. subtilis (IE32), 




Isolate ID Bioactivities Against Relevant pathogenic 
species 
B226SN104 Anti-fungal activity C. glabrata (CBS138) 
SM3 Anti-bacterial activity P. aeruginosa (PAO1) 
  B. subtilis(IE32) 
Table 3: bioactivity table of the deep sea isolate B226SN104 and the shallow water isolate 
SM3 both tested by well diffusion assay against the relevant pathogenic species: 
Staphylococcus aureus (NCIMB 9518), Pseudomonas aeruginosa (PAO1), Bacillus subtilis 





2.2 Metabolomics and chemical analysis 
 
2.2.1 Temperatures involvement in the production of secondary metabolites from both 
B226SN104 and SM3 isolates. 
 
We then employed metabolomics analysis through molecular networking on the crude organic 
and aqueous extracts of SM3 cultures that had been fermented in the seven different culture 
media namely- M19, M400, MMM, OM, SGG, SM and SYP (Table 2) at both 28°C and 30°C; 
to examine the SM3 metabolome and to visualize the chemical diversity of the metabolites 
produced by the strain growing under these different conditions, by comparing   the mass 







Figure 12: Molecular network of SM3 fermented at 28°C and 30°C (a). Venn diagram of the specific and shared detected compounds, including potential new compounds, 
for SM3 (b) and B226SN104 strain (c) fermented at 28°C and 30°C respectively. 
The node (molecular network) and metabolite (venn diagram) originated from media/temperature controls were excluded from the network and venn diagrams to enable 




Molecular network analysis was performed using the MS/MS based Global Natural Product 
Molecular Networking GNPS online platform, which employs rapid and automated mass 
spectral mining of large number of samples by using high-resolution mass spectrometry parent 
ion fragmentation data (MS/MS); with parent ions being connected based on the chemical 
architecture of the metabolite ( Watrous et al., 2012; Fan et al., 2019; Oppong-Danquah et al., 
2018). In addition it has also been reported that  molecular networks can  be used to link  known 
and unknown compounds belonging to the same molecular family within the  network and 
deliver more in-depth information on the chemical inventory of the  producing organism (Fan 
et al., 2019 and Oppong-Danquah et al., 2018). Molecular networks   can also be used to 
compare and/or optimize the culture conditions, and the extraction methods from both organic 
and aqueous phases for bacterial natural products (Fan et al, 2019). 
 
Figure 12a represents the metabolites detected by GNPS-Cytoscape in all the samples 
fermented at 28°C and 30°C respectively, with the blue and yellow nodes corresponding to the 
metabolites, with the edges corresponding to the relatedness of the individual nodes within a 
cluster based on the cosine score. The cosine score determines the relationship between 
individual nodes to each other which is indicated by the visual thickness of the edge between 
related nodes in the network. The higher the cosine score, the thicker the edge will be and 
therefore the more related the individual nodes are to each other (Wang et al., 2016). It is clear 
that temperature is an important parameter with respect to the production of metabolites in 
SM3, with different metabolites being produced when the strain is grown in the same growth 
medium, but at different temperatures Figure 12a. These metabolites are visible as single blue 
or yellow colours on the nodes in the network, which demonstrates that if fermented in the 
same media but at different temperatures, different metabolites are produced.  In contrast multi-




indicating that they are produced when SM3 is cultured at both at 28°C and 30°C (Figure 12a). 
When focusing on the specific groups of metabolites observed when SM3 is grown at 28°C, 
one group composed of seven metabolites that are strongly related to each other; based on the 
edges thickness visible on the network, is clearly evident. The presence of this group of 
metabolites, both single and multi-coloured, with high cosine scores, suggests that these 
molecules or “metabolite cluster” may potentially have been produced through the same 
synthetic route and thus may originate from the same gene cluster and be regulated at least to 
some extent by temperature, particularly given that they are only produced when SM3 is grown 
at 28°C and not 30°C.  
Further analysis involving the total manual de-replication of metabolites detected from all the 
organic and aqueous phase extracts when SM3 was cultured in all 7 culture media at both 
temperatures indicated that only 9.1% (15 of 165 metabolites) could be detected in extracts 
from SM3 when the culture was grown at both 28°C and 30°C. In contrast 102 (61.8%) and 53 
(32.1%) metabolites were only present in extracts of SM3 grown at 28°C or at 30°C 
respectively (Figure 12b). Manual de-replication revealed that the production of metabolites 
such as Vitexin and Soyasaponin I only occurs at 28°C, while the production of other 
metabolites such as Notoamide J and Puerarin in SM3 only occurs at 30°C (Figure 12b).  
When a similar analysis was performed on the manually de-replicated metabolites detected in 
all organic phase extracts produced by the B226SN104 strain at both temperatures, it appeared 
that 4.3% (7 of 161 metabolites) were produced at both temperatures, while 55.3% (89 of 161 
metabolites) and 40.4% (65 of 161 metabolites) were only produced at 28°C and 30°C 
respectively (Fig 12c). Thus as with SM3 it also appears that production of some specific 
metabolites only occurs in B226SN104 at certain temperatures with Putrebactin and 
Concanamycin B only being produced at 28°C, and Coproporphyrin III, Pyranonigrin D and 




focusing on potential new metabolites  (Fig 12b and 12c), and  comparing the number of new 
metabolites detected in both strains at  28°C and 30°C; it appears that growth at 28°C resulted 
in an increase in the production of potential new metabolites.  For example, in B226SN104 
extracts, 51 and 30 potential new metabolites were detected when cultured specifically at 28°C 
and 30°C respectively compare to 3 when cultured at both temperatures.  Expressed as a 
percentage of total potential new metabolites, these numbers correspond to:  21.8% (in the 
28°C culturing condition), 9.7% (in the 30°C condition) and only 1.2% (cultured at both 
temperatures), respectively. 
 
Temperature has previously been reported to effect metabolite production in different 
microorganisms. In fungi for example temperature is known to regulate aflatoxin production 
in Aspergillus flavus (Lind et al., 2016), terpene T-2 toxin production in Fusarium species 
(Nazari et al., 2016) as well as Trypacidin and Endocrocin production in A. 
fumigatus (Hagiwara et al., 2017). Temperature also affects metabolite production in marine 
microorganisms. For example, the optimal temperature for antimicrobial metabolite production 
with anti-MRSA (Methicillin Resistant Staphylococcus aureus) activity in Pseudoalteromonas 
pricida PG02 has been reported to be 28°C (Darabpour et al. 2012), while optimal prodigiosin 
production in Serratia marceans occurs at 30°C (Thomson et al., 2000) and antibiotic 
production in Vibrio coralliticus strains LMG10953 and LMG20984, was also found to be 
optimal at 30°C (Wietz et al. 2011). In addition, the optimal production of secondary 
metabolites with antibacterial, antifungal and antioxidant activities in the deep sea sediment 
isolate Streptomyces sparsus VSM-30 has been reported to occur at 30°C (Managamuri et al., 
2017). While valinomycin production in the cold desert isolate Streptomyces lavendulae is 
regulated at lower temperatures with optimal production at 10°C, with lower levels being 




upregulation of the valinomycin biosynthetic genes at 10°C (Sharma et al., 2017).  Temperature 
has also been shown to regulate validomycin production in Streptomyces hygroscopicus, with 
higher levels being produced at 37°C rather than at 30°C, which is the normal temperature for 
growth and sporulation. A SARP-family regulatory gene has been shown to be involved in the 
thermo-regulation of validamycin production in this strain (Wu et al., 2012). Thus it is perhaps 
not surprising that different metabolites were observed in both SM3 and in B226SN104 when 
both were cultured at different temperatures (Figure 12a, 12b, and 12c). 
 
2.2.2 Nutrient source media involvement in the production of secondary metabolites 
from both B226SN104 and SM3 isolates 
 
It is also important to consider that the observed effect of temperature on metabolite production 
in both strains is also likely to be influenced by the nutrient media in which the strain is being 
cultured at the given temperature. Indeed the specific conditions for the production of each 
metabolite differed by strain and/or media and/or temperature. For example, some metabolites 
were detected under a particular set of conditions, such as Cyclo (L-leucyl-L-propyl), Vitexin, 
Puerarin, Putrebactin, Furaquinocin H, Mannioside A, Coproporphyrin III, Serinolamide A, 
among others, which were only detected at a specific temperature when SM3 and/or 
B226SN104 are cultured in a specific nutrient media condition (Table 4). In contrast other 
metabolites were detected following growth of one strain in one specific condition regardless 
of the culture temperature, such as for example Furaquinocin D which was detected in SM3  
following growth of  the strain in OM media specifically, at both temperatures 28°C and 30°C. 
Other metabolites, however, such as Gibbestatin B were detected under all the media tested 
(M19, M400, MMM, OM, SGG, SYP and SM) and at both temperatures tested (28°C and 















Compound name Reported Biological activity 
Additional reported information 




433.1132 C21H20O10 Vitexin 
Anti-oxidant, Anti-cancer, Anti-inflammatory and Anti-hyperalgesic activity 
with also neuroprotective capacity (He, et al. 2016). 
n/a 
SM3 28ºC SM Organic 943.5263 C48H78O18 Soyasaponin I Potent and Specific Sialyltransferase inhibitor (Wu et al. 2001). n/a 
SM3 




663.4520 C34H48O13 Sarmentoside B Cardiac toxicity (Callow et al.  1952). 
Sterol glycoside  
(Callow et al.  1952). 
SM3 




Antileukemic and anti-vancomycin-resistant enterocci (VRE) (Rhee, 2002). 
Inhibitor of aflatoxin production (Yan et al. 2004). 
n/a 
SM3 





387.1811 C23H22N4O2 Fiscalin B 
Antitumor activity against non-small cell lung cancer (NCI-H460) and 
colorectal adenocarcinoma (HCT-15) cell lines, neuroprotection capacity 
(Long et al. 2019).Inhibit the binding of radiolabeled substance P ligand to 
the human neurokinin (NK-1) receptor (Wong et al. 1993).  
Quinazolinone Alkaloids 










C20H34O8 Botcinolide Weak antifungal activity against Magnaporthe grisea (Tani et al. 2006). 
n/a 






C22H26O6 Gibbestatin B Inhibits the GA-induced expression of α-amylase (Hayashi et al. 2000). n/a 
SM3 28ºC - 30 ºC 
OM organic 
387.1804 C22H26O6 Furaquinocin D 
cytocidal activities against HeLa S3 and B16 melanoma cells in vitro (Ishibashi 
et al. 1991). 
PKS-Hybrid (Kumano et al. 2010) 
SM3 30 ºC MMM water 836.403 C38H57N7O14 Formestin B n/a n/a 
SM3 
30 ºC M400, OM, 
SGG, SYP 
water 
384.1923 C21H25N3O4 Notoamide J 
Potential biosynthetic precursor and cytotoxicity against HeLa cells with an 
IC50 value of more than 50 μg/mL (Tsukamoto et al. 2008)]. Potential Pivotal 
Intermediate in the Biosynthesis of Several Prenylated Indole Alkaloids and 
anti-cancer activity (Ding et al. 2010; Finefield et al. 2010). 
Prenylated indole alkaloid (sukamoto 
et al. 2008). 
SM3 
30 ºC SM organic 
417.1185 C21H20O9 Puerarin 
Vasodilatation, cardioprotection, neuroprotection, antioxidant, anticancer, 
anti-inflammation, alleviating pain, promoting bone formation, inhibiting 
alcohol intake, and attenuating insulin resistance (Zhou et al. 2013). 
 
Isoflavone C- glycoside  
(Zhou et al. 2013). 
B226SN104 
28ºC M400, SYP organic 
852.5100 C45H73NO14 Concanamycin B 
Specific inhibitor of the vacuolar type H(+)-ATPase, inhibit PTH-stimulated 
osteoclastic pit formation, suppress the acidification of vacuolar organelles 
by V-ATPase in the osteoclasts (Woo et al. 1996.; Lee et al. 2000). 
n/a 
B226SN104 28ºC M400 organic 373.2092 C16H28N4O6 Putrebactin Iron ion binding (Codd et al. 2018) Siderophore (Ledyard et al. 1997) 
B226SN104 




Potential muscle relaxant, antibiotic and anticancer, active in prokaryote and 
eukaryote (Milne et al. 1998). 
n/a 


















C24H19N3O3 Benzomalvin E 
Indoleamine 2,3-dioxygenase inhibitor, leads to apoptosis and 




30 ºC SYP organic 
419.1709 C22H26O8 Furaquinocin H 
cytocidal activities against HeLa S3 and B16 melanoma cells in vitro (Ishibashi 
et al. 1991) 
Polyketide-isoprenoid hybrid 
(meroterpenoid) (Kumano et al. 
2010) 
B226SN104 
30 ºC M400 organic 
235.0516 C11H9NO5 Pyranonigrin D n/a 
Potential PKS-NRPS hybrid (as 
Pyranonigrin E is pks-nrps hybrid 
(Awakawa et al. 2013) 
B226SN104 30 ºC OM organic 739.4265 C39H62O13 Mannioside A In vivo anti-inflammatory effect (Tapondjou  et al. 2008) n/a 
B226SN104 
30 ºC M19 organic 
384.8468 C23H45NO3 Serinolamide A 
Cannabinomimetic agents, 
 moderate agonist effect and selectivity for the CB
1
cannabinoid receptor. 
(Gutiérrez et al. 2011)  
Probable PKS (Gutiérrez et al. 2011) 
B226SN104 
30 ºC M400 water 
655.2770 C36H38N4O8 Coproporphyrin III 
bound zinc in excess over other metals 
antibacterial activity (Cleary et al. 2018) 
Siderophore (Cleary et al. 2018) 
B226SN104 30 ºC SM water 415.1250 C19H18N4O7 Futalosine Cytotoxic activity (Schneemann et al. 2010) Nucleoside (Schneemann et al. 2010) 
B226SN104 
30 ºC OM organic 
505.1775 C18H32O16 Globotriose 
Oral therapeutic agent with in vivo and in vitro effect, 
inhibit and reverse the binding and agglutination of a P-fimbriated strain of 
E. coli and is a feasible alternative therapy for urinary tract infections (Leach 
et al. 2005). 
n/a 
Table 4: Some compounds produced by SM3 and B226SN104 in different conditions following the OSMAC approach. 
All compounds were identified by LC-MS, manual de-replication, Chemspider, Antibase, GNPS and Cytoscape. For some samples, different 
[M+H] 











Another example of the combined effect of temperature and culture media is the production of 
Vitexin which was only detected in extracts from SM3  following growth in SM media at 28°C, 
while Serinolamide A was only detected when B226SN104 was grown in M19 media at 30°C 
(Table 4). 
 
Based on the most promising number of potential new metabolites obtained from the manual 
de-replication in SM3, both aqueous and organic phase extracts from six of the seven media in 
which the strain had been grown were selected for further metabolomics analysis through the 
establishment of a Molecular Network (Figure 13a). It is clear that nutrient source plays an 
importance role in metabolite production in SM3, with some metabolites appearing to only be 
produced in specific media (single colour node), such as Cyclo (L-leucyl-L-propyl) which is 
only detected in the M19 extracts; while other metabolites appear to be produced in a variety 
of different media (multi-colour node), such as Sarmentoside B which was detected by GNPS 
and Cytoscape in extracts from five different media namely M19, MMM, OM, SGG and SYP. 
 
Thus it is likely that SM3 contains a number of potential “silent” or “cryptic” gene clusters 
encoding for the production of specific secondary metabolites that are only produced under a 
specific set of nutrient conditions or at a specific temperature. For example Cyclo (L-leucyl-L-
propyl) is only produced when the strain is fermented in M19 media, but is not produced in 
any of the other media tested when fermented at the same temperature. Furthermore, it may be 
interesting to investigate if the metabolite cluster involving the 7 metabolites with high cosine 
scores, that appear to be only produced in SM3 when grown in the M19 media (Figure 13a) are 




Results obtained using: Chemspider, Antibase, Reaxys, GNPS and Cytoscape. The nodes corresponds to the compounds detected by GNPS and Cytoscape. The 
edges corresponds to the individual node relatedness within a cluster based on the cosine score. This value determines the relationships between individual 
nodes to each other which is indicated by the visual thickness of the edge between related nodes in the network. The chemical structure pictures were generated 
from both the GNPS and Chemspider software.
Figure 13: Molecular network of SM3 fermented in six media (a). Enlarged sub-network view of the compounds Sarmentoside B in the 






Figure 13b represents the sub-network of Sarmentoside B metabolites that were identified, in 
a number of different culture media (namely M19, MMM, OM, SGG and SYP) but not when 
SM3 was grown in M400 media. Sarmentoside B is a sterol glycoside, which has previously 
been reported to display cardiac toxicity activity (Callow et al. 1952). While in contrast, Cyclo 
(L-leucyl-L-propyl) was only produced when SM3 was grown on M19 growth media which 
contains conditions mannitol and peptones as nutrient sources (Figure 13c).  
 
While a number of metabolites were identified that could be linked to the metabolomic network 
others metabolites that were identified, such as Furaquinocin D, Fiscalin B, Vitexin and 
Soyasaponin I, could not be linked to the metabolomic network (Figure 13d).  Of these 
Soyasaponin I and Vitexin were only detected when SM3 was grown in SM media, while 
Furaquinocin D was only detected when SM3 was grown in OM media (Figure 13d). 
Soyasaponin I is a potent and specific sialyltransferase inhibitor (Wu et al. 2001); while Vitexin 
is a metabolite which has been reported to have  anti-oxidant, anti-cancer, anti-inflammatory 
and anti-hyperalgesic activity, while also possessing  neuroprotective capacity (He et al. 2016). 
Furaquinocin D is known to be synthesised by a hybrid-PKS and to possess cytocidal activities 
(Ishibashi et al. 1991; Kumano et al. 2010), while Fiscalin B has been reported to possess 










2.3 Potential new metabolites detected from SM3 and B226SN104 crude extracts 
Figure 14 represents a Venn diagram indicating the numbers of metabolites produced when 
SM3 was grown on 4 different growth media, namely M 19, Medium 400, Oatmeal and MMM 
media. The four media were selected from the results of the molecular network analysis on 
SM3 with the manual de-replication results together as the more promising media for the 
production of potential new compounds fermented at 28°C. Growth of SM3 in M19 media 
resulted in the detection of the highest numbers of metabolites suggesting that a combination 
of mannitol-peptone in the growth medium promoted production of these metabolites (Figure 
14a). In total 32 metabolites were identified in the M19 extracts, including 27 metabolites that 
were only present following growth in M19 (Fig 14a). In addition, a total of 19 potential new 
metabolites were detected in M19 extracts from SM3, while only 6, 6 and 7 potential new 
metabolites were detected in extracts following growth in OM, MMM and M400 respectively, 
indicating that of the 4 growth media analyzed, M19 appears to be optimal, for the production 





Figure 14: Venn diagram of the specific and shared compounds (a), including potential 
new compounds (b), produced by SM3, detected in the four most promising media in 
both aqueous and organic phase. 
 
Based on the most promising number of potential new metabolites obtained from the manual 
de-replication in the deep sea isolate B226SN104, aqueous and organic phase extracts from the 
strain grown on four different growth media were analyzed.  Growth of B226SN104 in M19, 
oatmeal (OM), MMM and SGG resulted in the detection of a total of 106 metabolites, including 
77 metabolites which were only produced following growth in one specific media (Figure 15). 
Growth of B226SN104 on M19 media (56 metabolites) and the SMG media (48 metabolites) 
resulted in the highest numbers of metabolites being produced. Thus these two media appear 
better than OM and MMM growth media as nutrient sources to promote the production of 
secondary metabolites in B226SN104 (Fig 15a). In addition, when specifically focusing on the 
production of potential new metabolites, a total of 31 and 28 potential new metabolites were 
detected in M19 and SGG extracts respectively, while only 8 and 6 potential new metabolites 




metabolites by B226SN104, both M19 and SGG were again better than MMM and OM for 
production of potential new metabolites produced by the strain (Fig 15b). 
 
 
Figure 15: Venn diagram of the specific and shared compounds (a), including potential 
new compounds (b), produced by B226SN104 strain, detected in the four most 
promising media in organic phase. 
 
The most interesting metabolites detected during this OSMAC approach experiment from both 
SM3 and B226SN104 crude extracts with their culturing conditions are listed in Table 4, 
together with the potential new metabolites detected from SM3 crude extracts fermented at 
28°C in seven media listed in Table 4. Both tables, (Table 4 and Table 5), highlight the fact 
that the production of many of the metabolites detected is regulated differently in each strain, 
and that subtle changes in nutrient source or in temperature, even if a change of only 2 degree 
(28-30°C) can result in not only marked change in the metabolites been produced and in the 
metabolites not been produced, but also to changes in the resulting bioactivity being targeted. 




metabolites were only detected in SM3 extracts following growth in SM media at 28oC degree; 
whereas, when cultured in the exact same media at 2 degree higher (30°C), these metabolites 
where not only not detected but another metabolite, not detected in 28°C extract, Puerarin, was 
detected. Furthermore, this tables highlight the possibility that each strain has the capacity to 
produces not only metabolites that are already know and which have established bioactivities, 













 Molecular formula 
Libraries identification: 
ChemSpider ID, 
AntiBase ID, PubChem 












































28ºC M19 organic 4.1 425.3114 C21H44O8 no hit 
 

















































28ºC M19 water 0.6 625.1592 C21H24N10O13 no hit 
 









28ºC M400 water 1.1 585.3158 C20H48N4O16 no hit 
 

















28ºC M400 water 1.6 513.3761 C25H48N6O5 no hit 
 
28ºC M19 water 1.8 627.3282 C22H51N4O16 no hit 
 


























28ºC MMM water 2.1 397.2086 C12H23N13O3 no hit 
 
28ºC OM water 3.0 821.4400 C36H48N22O2 no hit 
 














7.8 403.2336 C21H30N4O4 no hit 
 
28ºC M19 water 7.9 403.2317 C17H26N10O2 no hit 
 
28ºC OM water 9.1 683.5551 C35H70N8O5 no hit 
 
30 ºC M400 organic 0.8 582.3246 C27H40N11O4 no hit n/a 
30 ºC SYP organic 2.8 821.4384 C37H64N4O16 no hit n/a 





30 ºC M400 organic 8.2 665.5816 C40H76N2O5 no hit 
 
30 ºC MMM water 1.9 814.4551 C37H63N7O13 no hit 
 
30 ºC MMM water 2.6 920.4609 C43H65N7O15 no hit 
 





30 ºC M19 water 3.2 403.2327 C21H30N4O4  no hit 
 





30 ºC M19 water 4.3 421.2238 C9H24N16O4 no hit 
 
30 ºC M19 water 4.5 465.2767 C28H36N2O4 no hit 
 








30 ºC M19 water 6.9 750.4056 C52H51N3O2 no hit 
 
30 ºC SYP water 7.6 424.282 C23H39NO6 no hit 
 
30 ºC SM 
SYP 
water 8.1 465.2778 
465.2778 
C33H36O2 no hit 
 





 OM water 8.1 465.2765 C11H29N17O4 no hit 
 
Table 5: Potential new compounds detected from LC-MS analysis of the crude extracts samples from SM3 
Crude extracts fermented at 28 °C and 30 °C in seven media (M19, M400, MMM, OM, SGG, SM and SYP) from both aqueous and organic 
phases-. n/a= picture of the chromatogram not available. The metabolites originated from media/temperature controls were excluded from the 





The remaining total metabolites from both SM3 and B226SN104 crude extracts, detected in all 
tested temperatures and media tested, including potential new metabolites are in the 
supplementary figures 1 to 8 and supplementary tables 1 to 8. It is important to note that the 
term “potential new metabolite” is only “potential” as the metabolites were compared to a 
selection of different libraries, only structural characterisation by NMR can ultimately 
definitely confirm the novelty of those potentially new metabolites.   
 
Overall, a total of 472 metabolites were detected by LC-MS analysis and manual de-replication, 
including 192 potential new metabolites (Table 4), which allowed us to observe the complexity 
of chemical diversity in both marine strains. It is well established that the production of 
secondary metabolites in Streptomyces species is regulated at least to some extent by 
temperature and by nutrient sources including relative concentration of specific nutrient such 
as a single or combined carbon and phosphorous source or by different carbon and nitrogen 
sources, (Martin et al., 2011). Thus it is clear that different nutrient sources in both SM3 and 
B226SN104 affect metabolite production in both SM3 and B226SN104. 
 
This study therefore reveals that the production of secondary metabolites in these two marine 
Streptomyces strains is likely to be complex and that both strains possess the potential to 
produce both existing and novel bioactive secondary metabolites. In addition to revealing the 
likely complexity of the regulation of these metabolites in both strains, it is also indicates that 
OSMAC based approaches can be useful in not only inducing production of metabolites in new 
isolates but also has merit in being used to re-culture existing isolates that have already been 
cultures, but not under specific sets of physiological conditions, thereby opening up the 
possibility that these strains may produce different metabolites and some with potential 




regimes; suggesting that OSMAC could represent a new way to explore the production of 
bioactive metabolites. Thus such an approach could help elucidate the full metabolic potential 
of strains that have already been isolated in many different laboratories, but that are likely to 
possess the potential to produce more and different types of metabolites, by subjecting these 
strains to different sets of physiological parameters.  Such an approach would of course be both 
strain dependant, and parameter dependant, as certain changes could result in either a higher or 
reduced number of metabolites being produced. However not withstanding this, these 
approaches involving existing strain collections could  reduce the need to re-collect new 
samples, thereby saving time and expenses such as expedition costs,  and also reduce barriers 
that may exist in the future in sample collection in certain oceanic regions.  However, it should 
also be considered that finding new physiological parameters that induce the production of 




The growth of our two marine Streptomyces strains SM3 and B226SN104 employing an 
OSMAC based approach, involving seven different culture media and two temperatures 
conditions, resulted in a complex metabolome being observed in each strain, with a total of 472 
metabolites being identified, with 192 of these being potentially new metabolites. Some 
metabolites were detected in all samples, regardless of the temperature or the media used for 
the fermentations; while other metabolites was only detected under specific culture conditions. 
This reveals, the complexity of the chemical diversity of these two marine strains and 
demonstrates both   nutrient source and temperature as important parameters to monitor in 
studying the production of secondary metabolites and for the discovery of potential new 





The complexity of the metabolomes in each strain and the selective production of some 
metabolites, suggests the presence of  cryptic or silent gene clusters in these strains that are 
specifically activated under different culture regime-temperature conditions. 
 
 
Material and Methods 
 
 Origin of strains 
The bacterial strains were obtained from the marine sponge Haliclona simulans (class 
Demospongiae, order Haplosclerida, family Chalinidae) for the shallow water strains, at a 
depth of 15 m in Galway bay (Ireland); and Inflatella pellicula (class Demospongiae; order 
Poecilosclerida; suborder Myxillina; family Coelosphaeridae) for the deep sea sample on the 
Porcupine bank at a depth of 2900 m (North Atlantic Ocean). These strains were obtained 
previously, I did not participate their collection. 
 DNA extraction 
Genomic DNA from both B226SN104 and SM3 was isolated using the phenol-chloroform-
isoamyl alcohol extraction method (Wilson, 2001). Isolates were grown overnight (~16 h) in 5 
mL liquid cultures. Cells were pelleted by centrifugation (6000 g), supernatants were decanted 
and discarded. Cell pellets were resuspended in 467 μL TE buffer. 30 μL of 10% SDS and 3 
μL of 20 mg/mL Proteinase K (Fermentas, Sankt Leon-Rot, Germany) was added to each tube 
and incubated for 1 h at 37 °C. An equal volume of phenol/chloroform (phenol-chloroform-
isoamyl alcohol mixture ratio 25:24:1, Sigma Aldrich, Arklow, Ireland) was added and mixed 
well. Tubes were centrifuged, at ~18,042 g for 10 min (Eppendorf Centrifuge, 5417r, 
Eppendorf UK Ltd., Stevenage, UK). The upper phase of each Eppendorf tube was aspirated 




pH 5.2 was added to each tube and mixed well. 600 μL of isopropanol (Sigma Aldrich, Arklow, 
Ireland) was added, mixed well, and incubated at room temperature for 15 min. Tubes were 
then centrifuged at ~18,042 g for 20 min. Supernatants were removed and discarded. DNA 
pellets were washed with cold (4 °C) 70% EtOH. Tubes were centrifuged at ~18,042 g for 10 
min. Ethanol was removed and discarded and DNA pellets were allowed to air-dry. DNA was 
re-suspended in 1 mL TE buffer. 1 μL of RNase A was added to the tubes, which were then 
incubated at 37 °C for 30 min. DNA was again purified by phenol extraction. DNA was 
analysed by gel electrophoresis and quantified using a spectrophotometer (NanoDrop ND-
1000, Thermo Scientific, Gloucester, UK). The DNA solutions were stored at −20 °C. 
 Whole genome sequencing 
 Whole genome sequencing was performed by Macrogen (Seoul, South 1334 Korea), mate pair 
libraries were prepared using the Nextera XT DNA Library Preparation Kit (Illumina, San 
Diego, CA, USA) according to the manufacturer’s instructions. All libraries were sequenced 
in 250 bp paired read runs on the Illumina MiSeq platform. Reads were trimmed for quality 
with Sickle (https://github.com/najoshi/sickle) and Scythe 
(https://github.com/vsbuffalo/scythe). 
 Genomic and bioinformatics methods 
Genomes were assembled by Dr. Eduardo Almeida using SPAdes, version 3.1.1 and 
comparative genomic methods were carried out on the following six genomes: B226SN104, 
SM3, SM6, SM9, SM14 and SM19. Potential bioactive gene clusters were identified by 
searching the genomes with antiSMASH version 3 and parsed with R methods, R is a free 
software environment for statistical computing and graphics (https://www.r-project.org/). 
Identified gene clusters were counted and graphed using Heatmap and R. Values were 




standard normal distribution by “standardizing” with the use of z-scores. The dendrogram was 
generated automatically according to the default parameters (“predicted clusters”). The most 
promising genomes among all the isolates are observed by the blue colours on the map (scale 
colour from white-pink to blue). Normal distribution values of the total number of gene clusters 
identified among the six genomes isolates were manually added on the top of the heat map. 
 Production of secondary metabolites by fermentation 
The production of secondary metabolites was performed following the OSMAC approach with 
fermentation of the strains in different nutrient-sources media and different temperature 
conditions. The composition of the fermentation media is provided in Table 2. The 
Streptomyces samples were first streaked on a plate and incubated at 28 °C for 3 days to allow 
for sporulation, then a single colony of each strain was individually selected to be cultivated in 
250mL Erlenmeyer flasks, containing 50 mL of rich media M410. They were incubated for 7 
days at 28°C, in a rotary shaker incubator at 200 rpm. 1mL of each culture media was 
inoculated to  250mL flasks containing 49 mL of each respective media (OM/ MMM/ SGG/ 
M400/ M19/ SYP/ SM) and incubated for 14 days at 28 °C, 200rpm. In addition, 1 mL of the 
culture M410 media was used for the analysis of anti-microbial activity. The fermented culture 
samples were centrifuged at 4 °C, max speed for 10-15 min. The pellet was freeze-dried at-
80°C and the cell free supernatant (50 mL) stored at -80 °C or used immediately for extraction. 
Identical methods were employed for growth of the strains at 30 °C. See Table 2 for exact 
details about the media used for fermentation. Control media of each media were cultured in 
the same conditions than the isolates. Due to the high number of samples, no replicates were 






 Antimicrobial activities screening - Well diffusion assays 
The isolated strains were screened for antimicrobial activity using the well diffusion assay 
method against different test strains such as Staphylococcus aureus (NCIMB 9518), 
Pseudomonas aeruginosa (PAO1), Bacillus subtilis (IE32), Escherichia coli (NCIMB 12210), 
Candida glabrata (CBS138), and Candida albicans (Sc5314). YPD (Yeast Extract-Peptone-
Dextrose) and LB (Luria-Bertani) agar plates were prepared and streaked with a single strain 
of each test strains at an OD=0.1, then wells were manually made in each plate by using sterile 
tips. A volume of 75uL of the cell free supernatant from the M410-strain cultures broth at day 
7 of fermentation, were poured into each well. Plates were then incubated overnight at 37 °C 
for the bacterial plates and 28 °C for the fungal plates. Both anti-bacterial and anti-fungal 
activities, were deduced by observation of growth inhibition around the well. To confirm the 
validity of the results, in parallel, negative controls were performed by replacing the volume of 
75 µL of culture by 75 µL of sterile water and the results were validated by the absence of 
growth inhibition surrounding the wells. 
 
 Liquid Liquid Extraction (LLE) 
Cell-free supernatants (50 mL) were chemically extracted using Liquid Liquid Extraction 
(LLE) with ethyl-acetate as solvent. The solvent was added to the filtrate in the ratio of 1:1(v/v), 
shaken vigorously and left to stand for 5 min to obtain the organic and aqueous phases. The 
organic phase was separated from the aqueous phase using a separating funnel. Both layers 
were concentrated by evaporating to dryness at 45 °C in a GeneVac to generate dry crude 
extracts. 




LC-MS was conducted on all the crude extracts on a Bruker MAXIS II QTOF. The Bruker 
MAXIS II QTOF was run in tandem with an Agilent 1260 HPLC using a Phenomenex Kinetex 
2.6 mM XB-C18, 100 x 2.1 mm column. All samples were run at a concentration of 0.5 mg/ml 
using a gradient of 95 % Water / 5 % Acetonitrile – 100 % Acetonitrile.  
 Manual de-replication 
Manual de-replication of the metabolites from the LC-MS data was obtained by deduction of 
the possible molecular weights and molecular formulas predicted from the Bruker software 
using Data Analysis based on two criteria: mass error (ppm) and isotope pattern matching 
(mSigma). For the interpretation of the MS data a number of different libraries were used, such 
as Chemspider, Antibase, Reaxys and The dictionary of Natural Products. The potential new 
metabolites were deduced by the absence of any hits following searched on these databases. A 
second manual de-replication of the identified metabolites was obtained by matching the LC-
MS raw data with the spectral data from the Molecular Network. 
 Metabolomic analysis and Visualisation of Molecular Network 
The raw data generated from the LC-MS was converted into mzXLM file format by using the 
downloaded zip file GNPS_Vendor_Conversion obtained through the DataAnalysis software 
from the online portal of Global Natural Products Social Molecular Networking GNPS 
(https://gnps.ucsd.edu). All mzXLM files were larger than 20MB so they were uploaded to 
ProteoSAFe (http://proteomics.ucsd.edu/ProteoSAFe/) using FileZilla as an ftp client.  When 
all the files were uploaded to ProteoSAFe they became available within the GNPS system. 
Separately, a metadata table composed of attributes (metadata) describing the samples 
properties was created by following the GNPS requirements workflow, in a text file format, 
and then used as an input to the molecular networking of GNPS. Molecular networking was 




Networking. The data were filtered by removing all MS/MS peaks within ±17 Da of the 
precursor m/z. The MS/MS spectra were window filtered by choosing only the top 6 peaks in 
the ±50 Da window throughout the spectrum. The data was then clustered with MS-Cluster 
with a parent mass tolerance of 0.02 Da and an MS/MS fragment ion tolerance of 0.02 Da to 
create consensus spectra.  Consensus spectra that contained less than 2 spectra were discarded. 
A network was then created, where edges were filtered to have a cosine score of above 0.7 and 
more than 6 matched peaks. Further edges between two nodes were retained in the network 
only if each of the nodes appeared in each other's respective top 10 most similar nodes. The 
spectra in the network were then searched against GNPS spectral libraries. The library spectra 
were filtered in the same manner as the input data. All matches that were kept between network 
spectra and library spectra were required to have a score above 0.7 and at least 6 matched peaks. 
The molecular network was visualized using Cytoscape version 3.7.1 and displayed using the 
settings “Organic layout” with “sample 2” style. The node (metabolite) originated from media 
controls were excluded from the network to enable visualization of only the metabolites 
potentially produced by our isolates in these specific parameters. To visualize each different 
media from all samples, regardless of the organics and water phases, color-codes was 
established manually for each media via the group columns from “pie” in “chart” in the Node 
window. 
 Colour-code 
 A colour code was applied to all the different media used for production of secondary 
metabolites to facilitate ease of visual representation. The same colour code was used for both 
Figures 3 and 6 as follows:  M19 red, M400 blue, MMM yellow, OM green, SGG purple, SM 
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3 Chapter 3: Genome mining, together with metabolomic and 
molecular networking approaches to elucidate metabolite 





Microbes associated with marine sponges are exposed to highly competitive environments both 
physiologically and nutritionally which is likely to promote the production of novel secondary 
metabolites. This study focuses on the detection and identification of potential bioactive 
compounds from the Streptomyces isolate SM9, which following functional screening for anti-
bacterial and anti-fungal activities displayed bioactivity against Candida glabrata (CBS138) 
and Candida albicans (Sc5314). Following genome scanning of SM9, approximately 56 
potential biosynthetic gene clusters were identified. In addition the OSMAC (One Strain MAny 
Compounds) approach was employed on the strain to determine the optimal media for the 
production of secondary metabolites including production of potential new compounds. Cell 
free supernatants were chemically extracted and crude extracts containing potential secondary 
metabolites from both aqueous and organic phases were analyzed for their metabolome content. 
LC-MS, GNPS and Cytoscape were employed in the chemical prediction of the molecules 
involved, the molecular network and the visualization of the secondary metabolites within the 
chemical diversity of the strain respectively. This resulted in the identification of 140 
metabolites including a number of interesting compounds such as Bisucaberin B, Maculosin, 
Bpagaome, glu-ala-pro-pro, Desferrioxamine B, pro-thr-ala-ile, Desferrioxamine E, 
Concanamycin B, Lipoamicoumacin B, Probestin, Bhimamycin B, Surugamide A, Fiscalin B, 




The gene clusters encoding some of the metabolites such as Deferrioxamine B, Deferrioxamine 
E, Antimycin A1, Surugamide A were located on the SM9 genome by linking metabolomics 
analysis and genome mining. In addition siderophore and NRPS sub-networks were also 
identified. Taken together, these results indicate that SM9 is a good producer of potential new 






In marine environments, bacteria are exposed to quite unique environmental conditions such 
as high pressure, low temperature, dissolved oxygen and nutrient availability, which often 
result in  the production of structurally diverse and biologically important metabolites (Petersen 
et al., 2020). Marine Streptomyces species have in particular being shown to produce a wide 
variety of different bioactive metabolites, which are rich in biological activity. For example 
marine Streptomyces derived metabolites have been reported to exhibit anticancer, antifungal, 
cytotoxic and antibacterial activity (Niu et al., 2011; Zotchev, 2012; Song et al., 2014; Jackson 
et al., 2018).  
The One Strain MAny Metabolites (OSMAC) principal involves growing one strain under a 
variety of different environmental conditions, which typically results in the production of many 
different types of metabolites. This may ultimately lead to the potential discovery of new 
bioactive metabolites such as for example antibiotics (Antoraz et al. 2015; Romano et al., 2018; 
Pan et al., 2019). Parameters such as changes in nutrient sources, involving the modification 
of both carbon and nitrogen sources in the culture media are known to be particularly useful in 
altering the metabolite production profile in bacterial strains and in promoting or stimulating 




2015; Pan et al., 2019). In addition, nutrient sources are known to regulate secondary 
metabolism in Streptomyces strains (Martin et al., 2011) with for example antibiotic SBR-22 
production in the marine sediment isolate Streptomyces psammoticus BT-408 being reported 
to be regulated by different nutrient sources. 
In the previous chapter, the One Strain MAny Metabolites (OSMAC) approach was employed 
on the two isolates Streptomyces sp. SM3 and Streptomyces sp. B226SN104, by monitoring 
changes in both temperatures and nutrient sources parameters. In this study, a similar OSMAC 
approach from the previous experiment was employed to investigate the effect the same seven 
different culture conditions with differing carbon and nitrogen nutrient sources, namely M19, 
M400, MMM, OM, SGG, SM and SYP; on secondary metabolite production in the marine 
Streptomyces sp. SM9 which had previously been shown to possess anti-fungal activities, and 
which had been isolated from the sponge Haliclona simulans (Kennedy et al., 2009).  
The effect of culturing SM9 in fermentations involving the aforementioned different nutrient 
media sources was investigated, for the production of bioactive metabolites from a 
microbiology, bioinformatics, genomics, metabolomics and chemical perspective. The overall 
aim was to link specific fermentation conditions to the production of specific metabolites; to 
link metabolites to Biosynthetic gene clusters (BGCs) on the SM9 genome; and to therefore 
link potential metabolite production to these clusters, and to culture regimes. 
 
Results and Discussion 
 
We had previously reported on the isolation and characterization of 18 marine sponge derived 
Streptomyces strains, which displayed a range of antimicrobial and antifungal activities against 
a number of clinical pathogens (Kennedy et al., 2009; Jackson et al., 2018) as well as a large 
scale study employing an OSMAC approach on two of these marine Streptomyces strains, 




metabolites and potential new compounds which was reported in Chapter 1. In this study we 
reproduced a similar set of fermentation conditions to those used in Chapter 1 by growing SM9 
at 28°C on the seven nutrient source media (M19, M400, MMM, OM, SGG, SM and SYP) 
previously used for the production of metabolites in Streptomyces SM3 and Streptomyces 
B226SN104 [Chapter 1] .  
 
3.1 Bioactivity and detection of metabolites 
 
3.1.1 Bioactivity screening 
 
During this fermentation process, to confirm that SM9 isolate was producing bioactivity when 
cultured under  these  growth conditions, the isolate was screened for antimicrobial activity 
against strains of relevant clinical pathogens,  when grown in M410 media both in the presence 
and absence of synthetic sea salt (Instant Ocean) (+/- sw). When grown on this medium the 
shallow water isolate SM9 displayed bioactivity against both C. glabrata (CBS138) and C. 
albicans (Sc5314), in well diffusion assays (Table 6).  No difference in bioactivity was 
observed when SM9 was grown in M410 media with or without salt presence when tested 
against C. glabrata (CBS138), but interestingly, when tested against C. albicans (Sc5314), 
there was a visible increase in bioactivity when SM9 was grown in M410 without salt presence 
compared to when SM9 was grown in M410 in the presence of salt (Table1). This could be due 
to the fact that SM9 was originally isolated from a marine sponge in an environment with 
natural salt, and that the removal of salt from the culture media, may have induced osmotic 
stress, resulting in an increase in bioactivity. Although this increase was only visible when 





+sw = with synthetic sea salt(Instant Ocean); sw = without artificial salt. Controls were fermented in 





3.1.2 Detection of metabolites – chemical results 
 
Figure 16 represents the total manually de-replicated metabolites detected from all the organic 
and aqueous phase extracts following analysis by LC-MS and manual de-replication, when 
SM9 was cultured at 28°C, in seven different growth media, namely M19, M400, MMM, OM, 
SGG, SM and SYP. 
Table 6: Bioactivity of the shallow water isolate SM9 tested by well diffusion assays 
against the relevant pathogenic species: Staphylococcus aureus (NCIMB 9518), 
Pseudomonas aeruginosa (PAO1), Bacillus subtilis (IE32), Escherichia coli (NCIMB 
12210), Candida glabrata (CBS138), and Candida albicans (Sc5314). 
Isolate 
ID 
Bioactivities Against relevant 
pathogenic species 
Picture 
SM9 Anti-fungal activities C. glabrata (CBS138).  
C. albicans (Sc5314). 
 
Controls No anti-fungal 
activity 
C. glabrata (CBS138).  






Picture of the metabolites were generated with Chemspider. 
 
Following growth liquid liquid extractions (LLE) were then performed to obtain  both aqueous 
and organic phase extracts from the SM9 cultures, and LC-MS analysis was then performed on 
all the crude extracts followed by manual de-replications strategies, using the following 
libraries: Chemspider, Antibase, Reaxys and The Dictionary of natural products, in an attempt 
to identity the detected metabolites. 
When comparing the two phase extracts quantitatively, the results indicated that from all the 
detected metabolites from the SM9 crude extracts, only a small portion (11 of 140 compounds) 
were detected in both organic and aqueous phase extracts, corresponding to 7.86% of the total 
Figure 16: Venn diagram of the specific and shared metabolites, including potential new 
metabolites, produced by SM9 strain, fermented in 7 media at 28°C, detected chemically in 




detected metabolites. These included the following metabolites: Surugamide A, Antimycin A1, 
Desferrioxamine B and Desferrioxamine E (Figure 16). While in contrast, 50.71 % and 41.43% 
of the total detected metabolites were present in only either the organic phase or the aqueous 
phases respectively. A total of 71 compounds were detected only in the organic phase extracts, 
representing 50.71 % of the total metabolites that were detected, and included Maculosin and 
Bisucaberin B (Figure 16). In addition 58 compounds were only detected in the aqueous phase 
extracts, representing 41.43% of the total detected metabolites, and included the metabolites 
Lipoamicoumacin B and glu-ala-pro-pro (Figure 16). Thus more metabolite were detected from 
the organic phase extracts than from the aqueous phases extracts. But nevertheless, the aqueous 
phase extracts also contain interesting metabolites.  
Furthermore, when focusing specifically on the production of potential new metabolites: 28 
potential new metabolites were detected only in the organic phase crude extracts when 
compared to 29 being detected only in  the aqueous phase extracts; while 3 were detected in 
both of the two  phase extracts. This highlights the fact that despite the difficulties in analysing 
and detecting metabolites from the aqueous phases extracts, as these aqueous phases extract 
also typically contain impurities and ionic analytes (Sargent, 2013), there is still a good 
possibility of identifying  potential new metabolites  from  aqueous phase extracts.  
From these results, it is clear that the organic phase extracts contained the highest number of 
total detected metabolites (Figure 16) so our attention subsequently focused on the organic 
phase crude extracts for a more in-depth analysis of the metabolites produced in the different 
nutrient sources media. Figure 17a shows a Venn diagram representing both the specific and 
shared compounds produced by the SM9 isolate when it was fermented in the 6 media at 28°C]. 
The six media chosen from the 7 originally tested for this analysis, were chosen based on their 






The Venn diagram was produced by using the website from http://www.interactivenn.net/ - 
(Heberle et al. 2015). The histogram was produced from the Jvenn website 
(http://jvenn.toulouse.inra.fr/app/example.html) - (Bardou et al. 2014).  The four media 
(Medium 19; Medium 400; Oatmeal and Media SYP) were selected from the results of the 
histogram in Figure 17b as the more promising media for the production of potential new 
metabolites when SM9 is fermented at 28°C. 
 
 
Extracts from SM9 grown in SYP resulted in the production of the highest number of secondary 
metabolites, followed by M400, M19 and SM when comparing production from all six growth 
media.  (Figure 17a). In all 25 metabolites were detected in SYP extracts, with 24 and 22 
metabolites being  detected in M400 and M19 extracts respectively; while 20, 14 and 15 
Figure 17: Venn diagram of the specific and shared metabolites produced by SM9 strain in six 
fermentation media from the organic phase crude extract samples (a), including their potential new 
metabolites (b). Venn diagram of the specific and shared potential new metabolites produced by SM9 




metabolites were detected in SM, SGG and OM extracts respectively (Figure 17a). This 
suggests that the nutrient regimes in  the SYP, M400 and M19growth media were optimal for 
metabolite production in SM9, further demonstrating the importance of nutrient source 
combination in regulating metabolite production in Streptomyces species. These results are in 
accordance with other studies focusing on the effect of nutrients on the production of secondary 
metabolites in marine bacteria (Romano et al., 2018)), including the earliest study of Okazaki, 
et al. (1975) who reported the production of an antibiotic produced by the marine actinomycete 
Chainia purpurogena, where production was dependent on the addition of an extract from the 
seaweed Laminaria (Okazaki et al., 1975). In addition, Sujathat et al. (2005) assessed the effect 
of 6 inorganic single nitrogen sources and 13 single amino acids, as single nitrogen sources, on 
the production of the antibiotic SBR-22 in the marine Streptomyces psammoticus BT-408 strain 
(Sujathat et al., 2005; Romano et al., 2018). They reported that optimization of medium and 
cultural conditions resulted in 1.82-fold increase in antibiotic yield, as well as, that Glucose 
and ammonium nitrate were found to be best carbon and nitrogen sources respectively for 
antibiotic production (Sujathat et al., 2005). Fan and co workers also investigated the impact 
of culture regime on chemical diversity by comparison of liquid and solid culture-derived 
fungal extract to confirm that the chemical composition and other characteristics including 
nutrient source (carbon source) of the growth media had significant effect on metabolite 
production of the fungi derived from F. vesiculosus (Fan et al., 2019). 
Furthermore, from figure 17a, it is also clear that OM and SYP extracts followed by M19 and 
M400 extracts were those in which most of the specific metabolite produced by SM9 isolate 
were detected, representing 15, 10 followed by 7 and 7 specific unique metabolites 
respectively.  For example in OM extract, 15 metabolites were detected. Among those 15 
metabolites, 3 metabolites were also detected in SYP extract, 1 and 1 of them was also detected 




metabolites as they are detected in several extracts from different culturing parameters; while 
the remaining 10 of the 15 metabolites produced were only detected in OM extract specifically, 
following specific OM culturing parameters making those 10 metabolites unique to OM 
culturing condition. Therefore, culturing SM9 in the OM media promoted the production of 15 
metabolites, including 10 which were specifically dependent on the OM culturing parameters 
when compared to the others media tested and analyzed. Similarly, 15 of 25 metabolites that 
were produced were dependant on the SYP culturing parameters; while 7 of the 22 and 7 of the 
24 metabolites produced were dependant on the M19 and M400 culturing parameters 
respectively (Figure 17a). It is clear that SYP extracts contained the highest number of both 
detected metabolites and potentially specific metabolites, with 25 metabolites being identified 
following growth in SYP, including 15 specific metabolites which appeared to only be 
produced in this growth media containing starch -yeast extract-peptone (SYP). Although, 
growth in OM, M19 and M400 did also result in the production of specific metabolites; with 
SM9 producing 10, 7 and 7 specific metabolites respectively, following growth in these media 
(Figure 17a). The use of an OSMAC based approach is regarded as an essential method for 
activating silent BGCs and to enhance the overall chemical diversity of microorganisms (Fan 
et al,. 2019). The presence of these specific 15,10,7 and 7 metabolites could suggests the 
potential activation of silent BCGs encoding these metabolites; due to varying culture 
parameters, although this would require further investigation to be confirmed.  
When focusing our attention on the production of potential new metabolites, a total of 11, 10, 
7 and 7 potential new compounds were detected in SYP, M400, M19 and OM extracts 
respectively; while only 3 and 2 potential new compounds were detected in SGG and SM media 
extracts (Figure 17b). This difference indicates that SYP, M400, M19 and OM appear to be the 
four most promising media for production of potential new metabolites by SM9 (Figure 17b). 




among these 4 most promising extracts, namely SYP, M400, M19 and OM we can see that for 
each extract, some of the potential new metabolites are specific to the culturing parameters 
while other potential new metabolites are shared between the extracts and therefore not specific 
to the culturing parameters (Figure 17c).  For example, in the SYP extract: 8 of the 11 potential 
new metabolites were specifically detected only from that extract, while the remaining 3 
potential new compounds were detected not only in SYP but also in M400 (for 2 of them) and 
in OM extracts (for 1 of them) (Figure 17c). The same was true for the OM, M400 and M19 
extracts, where, only 5 of 7, 5 of 10 and 5 of 7 potential new metabolites were specifically 
detected in these specific culturing parameters respectively (Figure 17c). 
Overall, when looking at the production of potential new metabolite detected in specific SM9 
extracts, the most promising nutrient source was SYP, followed by M19 and OM which also 
gave good overall levels of metabolite production.  
 
 
3.1.3 Detection of metabolites – metabolomic results 
 
We then employed metabolomics analysis through molecular networking on the crude organic 
and aqueous extracts of the SM9 cultures that had been fermented in the six different culture 
media namely- M19, M400, OM, SGG, SM and SYP at 28°C; to examine the SM9 metabolome 
and to visualize the chemical diversity of the metabolites produced by the strain growing under 
these different conditions, by comparing the mass spectrometry profiles present in the extracts 
(Figure 18a). As with our previous study  (Chapter 1) the Molecular networks analysis was 
performed using the MS/MS based Global Natural Product Molecular Networking GNPS 
online platform, which employs rapid and automated mass spectral mining of large number of 




with parent ions being connected based on the chemical architecture of the metabolite (Watrous 
et al., 2012; Fan et al., 2019; Oppong-Danquah et al., 2018). The six media for the network 
analysis were selected based on the most promising number of potential new metabolites 
obtained following   manual de-replication. The metabolome of SM9 is presented in Figure 
18a, with each single coloured node corresponding to a metabolite detected in one specific 
media extract, while multi-coloured nodes correspond to metabolites detected in several media 
extracts. This allows us to observe which of the metabolites is present only in one media extract 
(specific) and which of the metabolite are present in a number media extract (shared). The 
edges between nodes correspond to the relatedness of the individual nodes within a cluster 
based on the cosine score. The cosine score determines the relationship between individual 
nodes to each other which is indicated by the visual thickness of the edge between related nodes 
in the network. The higher the cosine score, the thicker the edge will be and therefore the more 





Results obtained using Chemspider, Antibase, GNPS and Cytoscape. Color code per extracts: pink= M19, blue=M400, purple= SGG, green= OM, grey= SM 
and black=SYP extracts. Picture of metabolites obtained from Chemspider. The nodes corresponds to the compounds detected by GNPS and Cytoscape. The 
edges corresponds to the individual node relatedness within a cluster based on the cosine score. This value determines the relationships between individual 
nodes to each other which is indicated by the visual thickness of the edge between related nodes in the network. 
Figure 18: Molecular Network of SM9 fermented in 6 media (a). Enlarged view of the isolated metabolites Concanamycin B and 
Maculosin in the network (b). Enlarged sub-network view of the metabolites Antimycin A1 and Surugamide A in their respective 




Globally, 36 metabolite clusters, from different size (from a cluster of 2 metabolites to cluster 
of 32 metabolites) were detected through molecular networking (Figure 18a). In addition, we 
can see that some metabolites produced by SM9 in only one specific media interact with other 
metabolites that can be produced following growth in a variety of different media. This is 
illustrated in Figure 18a, where within some clusters there are nodes highlighted by one colour 
only linked to other multi-coloured nodes, suggesting that those specific metabolites have the 
ability to interact with the shared metabolites. It is clear from Figure 18 that  nutrient source is 
an important parameter in the culture conditions during fermentation and that the production 
of secondary metabolites is regulated at least to some extent  by the nutrient sources present in 
the fermentation media. Figure 18 also highlights the complexity of this nutrient source 
regulations and suggest activation of different BGCs, encoding the metabolites that were 
observed under specific culture regime, as opposed to metabolites observed under several 
different culture regimes. This result is in accordance with Fan et al. (2019) study, which also 
suggested BGCs activation through metabolomics analysis, using molecular network and an 
OSMAC approach, when comparing liquid and solid culture regimes of fungi associated with 
the brown alga Fucus vesiculosus (Fan et al,. 2019). 
In the SM9 metabolome, some metabolites were isolated that had been identified in the 
metabolite clusters present in the molecular network. Figure 18b shows the identification of 
Concanamycin B and Maculosin isolated from the metabolite clusters in the molecular network 
and which were also identified following the manual de-replication using ChemSpider and 
Antibase libraries. Concanamycin B was detected in extracts from SYP, and M400 by 
metabolomics analysis via GNPS and Cytoscape (Fig 18a) while manually detected only in 
SYP media extracts by chemical analysis via LC-MS and manual de-replication (Table 7). 
Concanamycin B is a polyketide macrolide (Sharom et al., 1995; Kinashi et al., 1984) which 




in vitro, and  is also known to  display antifungal and larvicidal properties (Woo et al., 1996; 
Kinashi et al., 1984; Sharom et al., 1995; Yilla et al., 1993) . It has also been reported to possess 
immunosuppressant properties in the induction of cytotoxic T cells (Lee et al., 2000). In 
parallel, Maculosin was detected in 4 media following metabolomics analysis (e.g. M400, M19, 
SYP and SGG) (Figure 18a) and detected in 4 media (e.g. M19, M400, MMM and SYP) by 
chemical analysis and manual de-replication (Table 7). MMM extracts were not analysed by 
metabolomics analysis. Maculosin [a diketopiperazine cyclo(-L-Pro-L-Tyr-)], was  previously 
isolated from the fungus Alternaria alternata and has been reported to possess phytotoxicity 
activity against spotted knapweed  (Stierle et al., 1988). 
In the metabolome of SM9, some metabolites were isolated that had been identified in the 
metabolite clusters present in the molecular network. Figure 18b show the identification of 
Concanamycin B and Maculosin isolated from the metabolite clusters in the molecular network 
and which were also identified following the manual de-replication using ChemSpider and 
Antibase libraries. Concanamycin B was  detected in extracts from  SYP, and M400) by 
metabolomics analysis via GNPS and Cytoscape (Fig 18a) while manually detected only in 
SYP media extracts by chemical analysis via LC-MS and manual de-replication (Table 7). 
Concanamycin B is a polyketide macrolide (Sharom et al., 1995; Kinashi et al., 1984) which 
is an antibiotic and an inhibitor of vacuolar-type H+-ATPase, which suppress bone resorption 
in vitro, and  is also known to  display antifungal and larvicidal properties (Woo et al., 1996; 
Kinashi et al., 1984; Sharom et al., 1995; Yilla et al., 1993) . It has also been reported to possess 
immunosuppressant properties in the induction of cytotoxic T cells (Lee et al., 2000). In 
parallel, Maculosin was detected in 4 media following metabolomics analysis (e.g. M400, M19, 
SYP and SGG) (Figure 18a) and detected in 4 media (e.g. M19, M400, MMM and SYP) by 
chemical analysis and manual de-replication (Table 7). MMM extracts were not analysed by 




isolated from the fungus Alternaria alternata and which possess phytotoxicity activity against 

















Compound name Reported Biological activity 
Additional reported information 










Organic 1.5 261.1238 C14H16N2O3 Maculosin Phytotoxicity activity (knapweed and 
hypocotyls) (Stierle et al., 1998). 
 
 
Cyclic peptide (Meenaa et al., 2019). 
SYP Organic 1.6 455.2134 C20H30N4O8 Bpagaome n/a n/a 

















Known to binds iron and aluminium. (Used in 
iron overdose, hemochromatosis). (Moeschlin et 
al.1963; Mobarra et al. 2016). 


















Antibiotic agent, antibacterial activity against 
mycobacteria, weak antimicrobial against 
Gram+, anti-fungal activity, anti-tumor activity 
(Kalinovskaya et al. 2011; Ishida et al,.2011; Li 
et al,.2018). 
Siderophore (Kalinovskaya, et al. 





SYP Organic 3.3 852.5073 C45H73NO14 Concanamycin B Antibiotic and inhibitor of vacuolar-type H+-
ATPase, suppress bone resorption in vitro, shows 
antifungal and larvicidal properties (Woo et al. 
1996, 1982; Kinashi ., et al. 1984; Sharom et al. 
1995; Yilla M., et al. 1993). 
Immunosuppressants that inhibit the induction of 
cytotoxic T cells (Lee ., et al.2000). Inhibits the 
expression of MHC class II molecules on Colo 
205 cells, abrogates the enhancement of the 
MHC class II expression and suppresses the 
antigen presentation by MHC class II molecules 
(Ito ., et al. 1995).   
Polyketide Macrolide or Macrolide 
antibiotic 
(Sharom et al. 1995; Kinashi ., et 
al. 1984). 
SYP Water 3.3 716.4078 C37H56N4O10 Lipoamicoumacin 
B 
n/a NRPS-PKS hybrid (Li, et al. 
2015). 
 
M19,SGG Organic 3.4 503.2844 C26H38N4O6 Probestin Aminopeptidase N (APN) inhibitors, inhibits the 
angiogenic activity and tumor growth (Pathuri  et 
al. 2013). 
n/a 
SM Organic 3.7 271.0601 C15H10O5 Bhimamycin B Moderate activity against Bacillus subtilis and 
Escherichia coli (Fotso ., et al. 2003). 
Pocess the rare naphtho[2,3-c]furan-4,9-dione 
chromophore responsible of antioxidant and 
weak antiplasmodial activities (Bezabih  et al. 
2001; Fotso ., et al. 2003). 
 
Isofuranonaphthoquinone (Fotso., 










4.9 912.6273 C48H81N9O8 Surugamide A cathepsin B inhibitory cyclic peptides 
Inhibitory activity against bovine cathepsin B, a 
cysteine protease implicated in invasion of 
metastatic tumor cells (Ninomiya et al. 2016). 





Organic 5.0 387.1811 C23H22N4O2 Fiscalin-B Substance P inhibitor, neuroprotective and 




quinazolinone derivatives of the 
marine-derived alkaloids 





Organic  387.1803 C22H26O6 Gibbestatin B Inhibits the GA-induced expression of alpha-





6.8 549.282 C28H40N2O9 Antimycin A1 Potential anti-cancer agent (Liu et al. 2016).  
 
Synthesis route: Hybrid PKs-
NRPS (Liu et al. 2016; Seipke et 
al. 2011). 
Table 7: Some interesting identified metabolites produced by SM9 in different media conditions following the OSMAC approach 
All compounds were identified by LC-MS, and manual de-replication, using Chemspider, Antibase, Reaxys, The Dictionary of Natural Products libraries. For 






Some of the other metabolites observed in  the molecular network could be grouped into a 
metabolite cluster, and  form a sub-network, this can be seen in  Figure 18c and 18d, which 
represent the sub-network of the Antimycin A1 and Surugamide A metabolites that were 
detected in the crude extracts following both chemical and metabolomics analysis. Antimycin 
A1, which is part of a cluster of 4 metabolites, was detected in both SM and M400 extracts 
following  metabolomics analysis (figure 18c) and was only detected in SM extract from 
chemical analysis via LC-MS and manual de-replication (table 7). It is a potential anti-cancer 
agent (Liu et al., 2016) which is synthetized by PKS-NRPS hybrid route (Liu et al., 2016; 
Seipke et al., 2011). Surugamide A was detected in M19, M400, OM, SGG and SYP extracts 
following metabolomics analysis using GNPS and Cytoscape, and was also detected in SGG, 
OM and SYP extracts following chemical analysis using LC-MS and manual de-replication 
(Table 7). Surugamide A, was detected in a cluster of 3 metabolites, and has been previously 
reported to be produced by other marine sponge derived Streptomyces species such as 
Streptomyces sp. SM17 [Almeida et al., 2019]. The surugamides and their derivatives have 
been shown to possess a number of bioactivities, with the surugamides A–E and the 
surugamides G–J being shown to possess anticancer activity by inhibiting bovine cathepsin B, 
a cysteine protease reported to be involved in the invasion of metastatic tumour cells ( 
Ninomiya et al., 2016); while another derivative, namely acyl-surugamide A, has been shown 
to possess anti-fungal activity. Surugamide A production in Streptomyces SM17 has also 
previously been reported to be regulated by different carbon sources being present in the 
growth medium. High levels were reported following growth in YD media containing yeast 
extract, malt extract and dextrin sugars) with surugamide A production being  repressed in TSB 
media, suggesting that carbon catabolite repression (CCR) may influence the production of 
surugamides in SM17  (Almeida et al., 2019). The high cosine score which is visible by the 




synthetized by the same biosynthetic route. As this cluster contains one module which has been 
identified as a PKS-NRPS Hybrid involved in: Antimycin A1 synthesis, this suggest that this 
metabolite cluster may be related to a PKS-NRPS hybrid region cluster.  Also, the metabolite 
cluster presented in figure 18d containing 3 metabolites may also be related to a NRPS cluster 
as it also contain a metabolite which has been  identified  as likely to be  synthetized from a 
NRPS route (e.g: Surugamide A - 912.629). On the other hand, compared to the cluster in 
figure 18c, the cluster in figure 18d has a low cosine score and therefore may not contain only 
NRPS metabolites , which mean that in addition to contain NRPS metabolite, it may also 
contain other metabolite which are not all synthetized via NRPS route). Indeed, the edges 
between metabolites 912.629 and 884.598, as well as between metabolites 884.598 and 
898.614 are not very thick, representing a low cosine score and therefore could also suggest a 
different biosynthetic route. Thus a more thorough investigation on the 884.598 and or 898.614 
metabolites would need to be undertaken to confirm the exact biosynthetic route used to 
synthetized of this cluster.  
During the manual de-replication, the chemical tools chemspider, antibase, reaxys, and the 
dictionary of natural product, were employed to identify the metabolites that were produced. 
Then following bioinformatic and metabolomic analysis, we attempted to link those 
metabolites that had been identified to the molecular network. However, a number of  
metabolites which were identified, that were present in the chemical extracts could not be  not 
linked to the metabolomic network (Figure 18e).  Of these Bisucaberin B, is a siderophore with 
a ferric ion chelating activity (Fujita et al., 2013); also known to be produced by marine 
microorganisms such as by the marine bacterium Tenacibaculum mesophilum) (Fujita et al., 
2013; Chen et al., 2019); was only detected when SM9 was grown on the M19, M400 and SGG 
media, while the val-ser-pro-pro metabolite was only detected when SM9 was grown on the 




The largest metabolite cluster of the SM9 metabolome is presented in Figure 19. It represents 
the sub-network of the following metabolites Desferioxamine B, Desferioxamine E, pro-thr-
ala-ile and glu-ala-pro, that were detected and identified following both chemical and 
metabolomics analysis, following growth of SM9 in a number of different culture media. 
Desferrioxamine B and Desferrioxamine E were both detected in 2 extracts, namely SM and  
SGG) by manual de-replication (Table 7) and subsequently detected in additional extracts by 
metabolomics analysis using GNPS and Cytoscape tools, namely M19, M400, SGG, SM and 
M19, M400, SGG, SM and SYP extracts respectively. The related chemical chromatograms of 
Desferrioxamine B and Desferrioxamine E in SGG extracts can be seen in Figure 19. Glu-ala-
pro-pro and Pro-thr-ala-ile were also detected and identified by both chemical and 
metabolomics analysis, and their relative chromatograms can also be seen of Figure 19. 
Results obtained using Chemspider, Antibase, GNPS and Cytoscape. Metabolite picture obtained from 
Chemspider. Color code per extracts: pink= M19, blue=M400, purple= SGG extracts, grey= SM and 
black=SYP extracts. 
 
Figure 19: Enlarged sub-network view of the Desferrioxamine B, Desferrioxamine E, glu-
ala-pro-pro and pro-thr-ala-ile metabolites in the metabolite cluster, all together with 




Desferrioxamine B is a siderophore which is known to bind iron and aluminium (Sven 
Moeschlin et al., 1964; Mobarra et al., 2016; Neubauer et al., 2000), while Desferrioxamine E 
is also a siderophore, that is known to be an antibiotic agent and to possess anti-bacterial, anti-
fungal and anti-tumor activity (Kalinovskaya et al., 2011; Ishida et al., 2011; Yan Li et al., 
2018). In addition, both siderophores have previously been reported to be produced by marine 
microorganisms (Chen et al., 2019) including the very well studied marine 
actinomycete Salinispora tropica CNB-440 (Ejje N et al., 2013; Chen et al., 2019). 
Desferrioxamine B has also been reported to be produced by Streptomyces pilosus (Schupp et 
al., 1988) and by Streptomyces coelicolor M145 (Barona-Gomez et al., 2004). 
 
3.2 Identification of the secondary metabolite regions responsible of the 
biosynthesis of the Antimycin A1, Desferrioxamine B, Desferrioxamine E and 
Surugamide A detected metabolites from SM9 extracts.  
 
Genome sequencing was performed by Macrogen (Seoul, South Korea), using the PacBio RSII 
sequencing platform. The PacBio raw reads were processed and quality filtered using the 
BamTools toolkit v2.4.1 (subread length >1000, subread quality >0.75) (Barnett et al., 2011). 
The genome assemblies were performed using the Canu v1.7 software (Koren et al., 2017), 
followed by assembly polishing using Quiver v2.1.0 (Pacific Biosciences Inc). The assembly 
coverage check was performed using the BBMap program v37.90 (Almeida et al., 2019). 
Genome assembly statistics were calculated using the QUAST v4.6.3 program (Gurevich et 
al., 2013). Genome annotation was performed using the Prokka v1.12 program for this study’s 
analysis (Seemann, 2014), and with the NCBI Prokaryotic Genome Annotation Pipeline for 
data submission to the GenBank database (Tatusova et al., 2016; Benson et al., 2018).  
Following assembly using APAdes, the SM9 genome was initially analyzed using AntiSMASH 




AntiSMASH version 5.0.0. The updated version of AntiSMASH identified 56 potential 
biosynthetic gene clusters (BGCs) compared to 16 potential BGCs identified by the previous 
AntiSMASH version (data not shown). This could be explained by the fact that the new updated 
version of AntiSMASH offers more detailed predictions when compared to the previous 
version, including for example, new gene cluster classes; new refinement of cluster detection 
rules; improved type II PKS predictions; a new ‘region’ concept instead of the original ‘cluster’ 
previous concept which better distinguish the different biological options that lead to BGCs, 
together with many other features and updates (Blin et al., 2019). 
The 56 potential BGCs that were identified included 19 NRPS, 21 PKS, 9 terpene, 3 
siderophore, 2 bacteriocin, 1 ectoine and 1 LAP (Linear azol(in)e-containing peptides (LAPs)). 
In addition, Ectoine, Carotenoid, Hopene, Vazabitide A, Desferrioxamine B, Geosmin, 
Rhizomide A / B/ C, Surugamide A/D, Albaflavenone, Micromonolactam, Antimycin, and 
Frontalamides gene regions were identified based on the similarities  with most similar know 
cluster analyzed with AntiSMASH (Table 8). This high number of BCGs and these region 
clusters highlight the high potential of SM9 to be a big producer of secondary metabolites. 
Also, the identification of these regions suggest that some of our metabolites detected by LC-
MS could be synthetized via the activation of these regions clusters, such as antimycin A1, 









Region Type From To Most similar known cluster Similarities 
25.1 T1PKS 1 5,481 Frontalamides nrps-t1pks 28% 
103.1 ectoine 1 6,485 Ectoine other 100 
110.1 terpene 1 2,296 Carotenoid terpene 18 
127.1 terpene 2,425 13,344 Geosmin terpene 100 
151.1 bacteriocin 1 3,324 - 
182.1 siderophore 1 1,726 - 
193.1 terpene 1 2,261 - 
227.1 terpene 1 1,156 Hopene terpene 15 
241.1 T1PKS 1 2,949 - 
349.1 T1PKS 1 6,092 - 
360.1 NRPS 1 2,723 Vazabitide A NRPS 4 
369.1 terpene 1 2,923 Hopene terpene 15 
478.1 NRPS 1 7,124 - 
507.1 terpene 1 1,185 - 
517.1 terpene 1 7,758 Phosphoglycans saccharide 6 
541.1 terpene 1 1,213 Geosmin terpene 100 
630.1 T1PKS 1 4,508 Micromonolactam t1pks 100 
637.1 T3PKS 1 13,805 Herboxidiene t1pks+t3pks 9 
664.1 T1PKS 1 3,458 - 
684.1 T1PKS 1 3,301 Micromonolactam t1pks 100 
715.1 NRPS 1 2,118 Lipopeptide 8D1-1/ 
8D1-2 
NRPS 6 
736.1 T1PKS 1 6,136 Micromonolactam t1pks 100 
741.1 NRPS 1 6,637 - 
744.1 bacteriocin 1 4,012 - 
759.1 siderophore 14,655 22,222 Desferrioxamine B other 100 
790.1 NRPS 1 12,075 Dechlorocuracomycin NRPS 8 
799.1 terpene 3,815 23,987 Albaflavenone terpene 100 
860.1 NRPS 1 6,866 - 
882.1 LAP 1 2,741 - 
909.1 T1PKS 1 4,877 Micromonolactam t1pks 100 
924.1 T1PKS 1 3,213 Micromonolactam t1pks 100 
949.1 T1PKS 1 5,842 Stambomycin t1pks-
saccharide 
36 
965.1 NRPS 1 3,167 Pyridomycin nrps-t1pks  
967.1 T1PKS 1 3,280 Micromonolactam t1pks 100 
976.1 NRPS 1 3,764 - 
1014.1 T2PKS 1 8,750 Fredericamycin t2pks 36 
1023.1 T1PKS 1 5,654 JBIR-100 t1pks 33 
1026.1 NRPS 1 8,054 Surugamide A / D NRPS 33 
1039.1 NRPS 1 1,968 Rhizomide A / B/ C NRPS 100 
1041.1 NRPS 1 7,380 Surugamide A / D NRPS 19 
1042.1 T1PKS 1 3,596 Micromonolactam t1pks 100 
1044.1 NRPS 1 2,805 - 
1045.1 NRPS 1 8,504 - 
1047.1 T1PKS 1 2,259 Micromonolactam t1pks 100 
1049.1 NRPS 1 2,519 - 
1050.1 NRPS 1 2,503 - 




1072.1 NRPS 1 9,945 Decholorocuracomycin NRPS 8 
1076.1 T1PKS 1 7,145 Cremimycin t1pks 17 
1081.1 NRPS 1 4,036 - 
1083.1 T1PKS 1 4,482 Micromonolactam t1pks 100 
1084.1 T1PKS 1 5,032 Micromonolactam t1pks 100 
1085.1 T1PKS 1 9,695 Micromonolactam t1pks 100 
1086.1 NRPS 1 10,354 - 
1137.1 siderophore 1 7,144 - 
1193.1 NRPS 1 11,400 Antimycin nrps-t1pks 20 
Table 8: Secondary metabolite region clusters of SM9, identified by AntiSMASH 
version 5.0.0. Region: the region number; Type: the product types as detected by 
antiSMASH; From, To: the location of the region (in nucleotides); Most similar known 
cluster: the closest compound from the MiBIG database, along with its type (e.g. 
t1pks+t3pks); Similarity: a percentage of genes within the closest known compound that have 
a significant BLAST hit to genes within the current region (Blin et al., 2019). 
 (Result were reloaded from AntiSMASH- version 3.0.5 to version 5.0.0. from the assesion number: 
NEUA01000302.1). 
 
3.2.1 Genomic results – Identification of the secondary metabolite regions responsible 
of the biosynthesis of the Antimycin A1 
 
Using the KnowClusterBlast from AntiSMASH, it is clear that the SM9 genome contains a 
NRPS region [1193.1] which has 20% similarities with the antimycin gene cluster at the 
nucleotide level (Figure 20). More precisely, “similarity” on AntiSMASH documentations are 
visible in this link Understanding the output - antiSMASH Documentation 
(secondarymetabolites.org) and are referred as “a percentage of genes within the closest known 






From Figures 20a and 20b, all the genes required to synthetize an Antimycin metabolite are 
present in this region cluster, such as core biosynthetic genes and regulatory gene (Figure 20a). 
Furthermore, the Antimycin metabolite that SM9 isolate is likely to produce from this region 
cluster is one Antimycin without Phenylacetate-CoA oxygenase, Phenylacetate-CoA 
oxygenase subunit Paal and PaaA and a CoA-ligase compared to the Antimycin produced by 
Figure 20: Detail of NRPS region 1193.1 identified by AntiSMASH version 5.0.0 (a). 
KnownClusterBlast of the region cluster showing similarities and differences with the 




the reference BGC0000958 (from Streptomyces sp. S4) Antimycin gene cluster (Figure 20b). 
(The missing genes are not considered as necessary to Antimycin biosynthesis). This 
corroborates the chemical results previously obtained, where the Antimycin A1 metabolite was 
detected following LC-MS analysis in SM9 extracts.  
This was also confirmed following BlastP analysis on this NRPS region, where we could see 
that both the ctg1193_1 and ctg1193_2 genes share 100% of query cover and 99% identities 
with the AntC and AntB genes respectively, while the ctg1193_3 gene shares 100% query 
cover, and appears to encode an RNA polymerase sigma factor (Figure 21).  Thus this results 
suggest that the ctg1193_1 gene is likely to encode for antC, that the ctg1193_2 gene encodes 
for antB and that the ctg1193_3 gene encodes for the σAntA sigma factor. It has previously been 
reported that σAntA may represent a new sub-family of ECF σfactors that to date have only been 




Figure 21: Gene legend (a) from the NRPS region 1193.1 identified by AntiSMASH version 5.0.0, with the Blastp identifications 




Thus it is clear when considering the chemical, metabolomic and genomics data that the 1193 
region gene cluster in SM9 is likely to encode for genes involved in the synthesis of Antimycin 
A1. In addition, it is also suggesting that the weak percentage of similarities (only 20%) with 
the referenced BGC0000958 Antimycin region cluster is due to the absence of Phenylacetate-
CoA componments in our Antimycin A1. This is more suggested when looking at the specific 
definition of similarity by AntiSMASH similarity is “a percentage of genes within the closest 
known compound that have a significant BLAST hit to genes within the current region” 
[available at this link: Understanding the output - antiSMASH Documentation 
(secondarymetabolites.org)]. Therefore the percentage of gene that have a hit with the 
referenced BGC0000958 antimycin,  is lower, as the hit were only for 3 genes (antB, antC and 
σAntA sigma factor) out of the 15 total genes of the referenced BGC0000958 which were 




3.2.2 Genomic results – Identification of the secondary metabolite regions responsible 
of the biosynthesis of the Desferrioxamine B and Desferrioxamine E 
 
Following analysis using AntiSMASH it was possible to identify the region on the SM9 
genome (Siderophore region 759.1); which encodes the potential production of both 
Desferrioxamine B and Desferrioxamine E.  
When focusing on Desferrioxamine B, the siderophore region 759.1 displayed  100% similarity 
with the Desferrioxamine B region cluster from the referenced BGC0000941 cluster (from 
Streptomyces griseus subsp. griseus NBRC 13350) using the KnownClusterBalst analysis 




necessary for  the synthesis synthetize of  Desferrioxamine B  (Figure 22a). The ctg759_21 
gene in SM9 is most closely related to desaB gene, showing 74% identity with the referenced 
BGC0001453 (from Streptomyces argillaceus) (Figure 22c). In addition, the ctg759_19, 
ctg759_21, ctg759_22 and ctg759_23 genes displayed 55%, 81%, 74%, 65% and 65% identity 
with desaF, desaA, desaB, desaC and desaD with the reference strain BCG0001453 
respectively (Figure 22c). Thus it is clear that the Desferrioxamine B metabolite present in the 
crude extract from SM9 is likely to have been synthetized from the ctg759_21 gene in the 






Figure 22: Detail of the Siderophore region 759.1 identified by AntiSMASH version 5.0.0 (a). 
KnownClusterBlast of the region cluster showing similarities with referenced desferrioxamine B and 
desferrioxamine E gene clusters (b). Details of the similarities and differences with the following 





Regarding Desferrioxamine E, the siderophore region 759.1 on the SM9 genome displayed 
75% similarity with the Desferrioxamine E region cluster from the reference BGC0001572, 
using KnownClusterBlast analysis (Figure 22b). It also appears to possess the necessary core 
and additional biosynthetic genes to synthetize Desferrioxamine E (Figure 22a), as confirmed 
by detection of the compound in the LC-MS analysis (Table 8).  
A notable difference between the reference clusters (both BGC001453 and 
BCG001572) and SM9 can be seen in the desaE gene, encoding an ABC transporter substrate-
binding protein (Figure 22c) or encoding an MSF transporter DfoS (Figure 22d). In the 
reference BGC001453, desaE is observed at the 3’ end of the cluster and is 1049 nt in length, 
whereas desaE appears to be absent in SM9, instead containing an open reading frame 
(ctg759_24; Figure 22c) of 649nt in length at the 5’ end of the cluster. Similarly, In the 
reference BCG001572, which represent specifically the Desferrioxamine E gene cluster 
(Figure 22d), the gene AWD37884.1 which could be the desferrioxamine E gene have also a 
bigger size, size of 1226nt and like in SM9 query, it is located at the 5’ end of the cluster.  
BLASTp analysis found similarities between ctg759_24 and DUF4429 domain-containing 
proteins in other Streptomyces species (see supplementary figures 11); however, the function 
of this domain is unknown. Both SM9 and the reference BCG001572 are capable of producing 
Desferrioxamine E; therefore suggesting either that ctg759_24 encodes a protein of similar 
function to DesaE or of a modified form of DesaE, such as for exemple a smaller DesaE.  
Taken together, this confirms the chemical results from the SM9 extracts where 
Desferrioxamine B and Desferrioxamine E metabolites were both detected from SM9, and 
suggests the likelihood that the Siderophore region 759.1 in the SM9 genome, encodes for the 





3.2.3 Genomic results – Identification of the secondary metabolite regions 
responsible of the biosynthesis of the Surugamide A 
 
Following AntiSMASH analysis it was also possible to link Surugamide A biosynthesis to the 
NRPS region 1026.1 on the SM9 genome, with the NRPS Region 1026.1 sharing 33% 
similarity with the surugamide A/D region BGC0001792 following KnownClusterBlast 
analysis (Figure 23b). While this is a somewhat low overall percentage similarity nonetheless 
it is clear that the region possess all the essential genes necessary to encode for the production 
of a Surugamide metabolite (core synthetic gene and transport related gene including core 
NRPS gene and MFS transporters) (Figure 23b). Indeed, it is a small percentage but as we see 
in the figure 23a and 23b, the Surugamide synthetized by SM9 genome will be mostly a 
Surugamide without ABC transporters and ATP binding cassettes, TetR/AcrR family 
transcriptional regulator, compared to the reference Surugamide A synthetized through the 








Figure 23: Detail of the NRPS region 1026.1 identified by AntiSMASH version 5.0.0 (a) 
KnownClusterBlast of the region cluster showing similarities (b) and differences (c) with the 




In addition, from our chemical data, Surugamide A was only detected in SGG, OM and SYP 
extracts suggesting that this transcription of this NRPS region 1026.1 may be regulated by 
different nutrient regimes and may only be activated under specific conditions.  
As previously mentioned surugamide A production in another marine Streptomyces strain 
SM17 has previously been reported to be differentially regulated by nutrient sources, with 
production being increased in growth media containing yeast extract, malt extract and dextrin 
sugars; and repressed in TSB media, suggesting some degree of control being mediated by 





Streptomyces strain SM9 which displayed anti-fungal activities against C. glabrata (CBS138) 
and C. albicans (Sc5314), was used to produce secondary metabolites following growth on 7 
different nutrient sources using the OSMAC approach.  The metabolites that were produced 
were extracted using LLE (Liquid liquid extraction) to obtain crude extracts.  Additional 
chemical analysis (LC-MS and manual de-replication) was then performed to monitor 
metabolite production with both already known metabolites and potential new metabolites 
being detected using Chemspider, Reaxys, Antibase and the Dictionary of Natural Products 
libraries. 
Overall, a total of 140 metabolites were detected by LC-MS analysis followed by manual de-
replication using the aforementioned libraries from both organic and aqueous phases extracts 
from the 7 different growth media; including 60 potential new metabolites. Among the already 
known metabolites detected, the following were observed namely: we found Bisucaberin B, 




E, Concanamycin B, Lipoamicoumacin B, Probestin, Bhimamycin B, Surugamide A, Fiscalin 
B, Gibbestatin B and Antimycin A1 in these extracts. 
SM9 strain was selected as a promising strain for the anti-fungal activity, the production of 
secondary metabolites and the production of potential new metabolites. 
SM9 crude extracts were also analyzed by metabolomics tools to monitor their chemical 
diversity and the SM9 metabolome through molecular networking using GNPS and Cytoscape.  
In total 36 metabolite clusters of different sizes (from a cluster of 2 metabolites to a cluster of 
32 metabolites) were detected through molecular networking. Among those metabolites 
clusters termed as “sub-networks“ for the following metabolites were identified. These 
included Desferioxamine B, Desferioxamine E, glu-ala-pro-pro and pro-thr-ala-ile which were 
present in a cluster of 32 metabolites; together with Antimycin A1 which was present in a 
cluster of 4 metabolites and Surugamide A1 which was present in a cluster of 3 metabolites. In 
addition Concanamycin B and Maculosin which were not part of a sub-network were isolated 
in the molecular network. These metabolites were detected in only some of the specific media 
in which SM9 was grown.  For example, Antimycin A1 was only detected when SM9 was 
grown in SM and M400 media, while Surugamide A was detected in 5 of the growth media 
extracts (M19, M400, OM, SGG and SYP) which confirms the chemical data were some 
metabolites were only found in some extracts and not others. This demonstrates the importance 
of the nutrient source parameter in the culture conditions during growth of SM9 and that the 
production of secondary metabolites is regulated at least to some extent by the nutrient sources 
present in the growth media. This also highlights the complexity of this nutrient source 
regulation as those observed metabolic differences suggest activation of different BGCs 




Following genomic analysis, 56 secondary metabolite encoding regions were identified with 
AntiSMASH, including 19 NRPS, 21 PKS, 9 terpene, 3 siderophore, 2 bacteriocin, 1 LAP and 
1 ectoine encoding region within the SM9 genome. Among these, regions potentially encoding 
the following metabolites namely; Ectoine, Carotenoid, Hopene, Vazabitide A, 
Desferrioxamine B, Geosmin, Rhizomide A / B/ C, Surugamide A/D, Albaflavenone, 
Micromonolactam, Antimycin, and Frontalamides encoding metabolite were identified. 
By linking the metabolomics and genomic data for SM9 it was then possible to identify 
regions/clusters of genes on the genome that were likely to be responsible for the production 
of a) Desferrioxamine B and Desferrioxamine E which were linked to the Siderophore region 
759, b) Antimycin A1 which was linked to the NRPS region 1193 together with c) Surugamide 
A which was linked to the NRPS region 1026.1 on the SM9 genome.  
In addition, in the NRPS region 1193.1 responsible of the synthesis of the Antimycin A1, antC 
could also be linked to the ctg1193_1 gene, antB could be linked to ctg1193_2 and a gene which 
is likely to encode the AntA sigma factor was linked to ctg1193_3 using BlastP analysis (Figure 
20 and 21). Given that the AntA sigma factor has previously been shown to be involved in the 
biosynthesis of Antimycin A in Streptomyces albus(Seipke et al., 2014), this suggest that the 
ctg1193_3 gene from the region 1193.1, is likely to be involved in the biosynthesis of the 
detected Antimycin A1 in SM9 (Figure 20). In the siderophore region 759.1, potentially 
responsible for the synthesis of both Desferrioxamine B and Desferrioxamine E , the ctg 
759_21 gene could be  linked to desaB using AntiSMASH with 74% identity, while ctg759_19 
was linked to desaF (55% identity) and the ctg759_20 gene was linked to desaA (81% identity). 
In addition the ctg 759_22 gene was linked to desaC (65% identity), the ctg759_23 gene was 
linked to desaD (65% identity) and finally the ctg759_24 gene could be linked to desaE. This 




Desferrioxamine B and Desferrioxamine E, with the ctg759_21 being involved in the synthesis 
of Desferrioxamine B, and ctg759_24 with the synthesis of Desferrioxamine E (Figure 22). 
 Thus the detection of Antimycin A1, Desferrioxamine B, Desferrioxamine E and Surugamide 
A metabolites by chemical analysis using LC-MS and manual de-replication could be linked 
to metabolite clusters with bioinformatics and metabolomics analysis using molecular 
networking, GNPS and Cytoscape. Then together these could be linked to their respective gene 
cluster region by genomics analysis using AntiSMASH and genome mining. While the 
genomics data helped to corroborate the chemical data, it is clear that the metabolomics data 
helped both the genomics and chemical interpretations by giving a more in-depth perspective 
of the SM9 strain. In addition, both chemical analysis (LC-MS, manual de-replication) and 
genomic research analysis (genome mining, AntiSMASH,) can be very time-consuming, since 
chemical analysis requires analysis of a mixture of thousands of metabolites or more and 
genomics analysis require analysis of thousands of genes from several genomic regions, both 
fields can benefit from the use of metabolomics analysis. Indeed, metabolomics greatly 
increases the efficiency of this process by detecting most of the metabolites present in the 
mixture and helps in the identification of some of these metabolites  by comparing their 
chemical profile simultaneously in several libraries - allowing us to determine which 
metabolite is interesting to further investigation in fewer experiments such as by LC-MS and 
NMR, instead of  conducting experiments on thousands of metabolites and then attempting to 
identify metabolites one by one, and subsequently determining  the more interesting 
metabolites. From a genomics perspective, metabolomics also increases the efficiency, as it 
allows more time to be spent in connecting metabolites to the genomic regions clusters from 
which they are likely to be produced. It also can provide a visual hint as to which metabolite 
could potentially be synthetized from a “silent” gene cluster, allowing us to focus our next 




directly confirm this hypothesis or not. In both chemical and genomics fields, the use of 
metabolomics analysis, allows for less time-consuming experiments, and more focused in-
depth analysis of the potential of SM9 to produce secondary metabolites. 
 
Material and Methods 
 
 Origin of strains 
The bacterial strains SM9 was obtained from the marine sponge Haliclona simulans 
(class Demospongiae, order Haplosclerida, family Chalinidae), at a depth of 15 m in Galway 
bay (Ireland) (Kennedy et al., 2009).  
DNA extraction 
Genomic DNA from SM9 was isolated using the phenol-chloroform-isoamyl alcohol 
extraction method (Wilson, 2001). Isolate was grown overnight (~16 h) in 5 mL liquid cultures. 
Cells were pelleted by centrifugation (6000 g), supernatants were decanted and discarded. Cell 
pellets were resuspended in 467 μL TE buffer. 30 μL of 10% SDS and 3 μL of 20 mg/mL 
Proteinase K (Fermentas, Sankt Leon-Rot, Germany) was added to each tube and incubated for 
1 h at 37 °C. An equal volume of phenol/chloroform (phenol-chloroform-isoamyl alcohol 
mixture ratio 25:24:1, Sigma Aldrich, Arklow, Ireland) was added and mixed well. Tubes were 
centrifuged, at ~18,042 g for 10 min (Eppendorf Centrifuge, 5417r, Eppendorf UK Ltd., 
Stevenage, UK). The upper phase of each Eppendorf tube was aspirated to fresh 2 mL 
Eppendorf tubes, avoiding the interphase. Sodium acetate (NaOAc) 3M (100 µl) pH 5.2 was 
added to each tube and mixed well. 600 μL of isopropanol (Sigma Aldrich, Arklow, Ireland) 
was added, mixed well, and incubated at room temperature for 15 min. Tubes were then 




were washed with cold (4 °C) 70 % EtOH. Tubes were centrifuged at ~18,042 g for 10 min. 
Ethanol was removed and discarded and DNA pellets were allowed to air-dry. DNA was re-
suspended in 1 mL TE buffer. 1 μL of RNase A was added to the tubes, which were then 
incubated at 37 °C for 30 min. DNA was again purified by phenol extraction. DNA was 
analysed by gel electrophoresis and quantified using a spectrophotometer (NanoDrop ND-
1000, Thermo Scientific, Gloucester, UK). The DNA solutions were stored at −20 °C. 
 Whole genome sequencing 
For whole genome sequencing, it was performed by Macrogen (Seoul, South 1334 Korea), 
mate pair libraries were prepared using the Nextera XT DNA Library Preparation Kit (Illumina, 
San Diego, CA, USA) according to the manufacturer’s instructions. All libraries were 
sequenced in 250 bp paired read runs on the Illumina MiSeq platform. Reads were trimmed for 
quality with Sickle (https://github.com/najoshi/sickle) and Scythe 
(https://github.com/vsbuffalo/scythe). 
 
 Genomic and bioinformatics methods 
The SM9 genome was assembled by Dr. Eduardo Almeida by using SPAdes, version 3.1.1. 
The potential bioactive gene clusters were identified by searching the genomes with 
AntiSMASH version 3.0.5 and parsed with R methods, R is a free software environment for 
statistical computing and graphics (https://www.r-project.org/). Then, following advances in 
technologies in identify region clusters, the genome was later re-analysed with AntiSMASH 
new version 5.0.0, from the published assesion number: NEUA01000302.1, to be sure to have 




The region clusters involved in the synthesis of the following detected metabolites 
(Desferrioxamine B, Desferrioxamine E, Surugamide A1) were identified with genome 
minding methods using AntiSMASH version 5.0.0, Blastp and Blastn. 
 Production of secondary metabolites by fermentation 
The production of secondary metabolites was performed following the OSMAC approach used 
in chapter 1 (see chapter 1 material and methods) with fermentation of the strains in different 
nutrient-sources media and different temperature conditions. The composition of the 
fermentation media is provided in Table 2 of the chapter 1. The Streptomyces SM9 strain was 
first streaked on a plate and incubated at 28 °C for 3 days to allow for sporulation, then a single 
colony was selected to be cultivated in 250mL Erlenmeyer flasks, containing 50mL of rich 
media M410 with and without presence of synthetic sea salt (Instant Ocean). They were 
incubated for 7 days at 28°C, in a rotary shaker incubator at 200 rpm. 1mL of the culture media 
without salt, was inoculated to  250mL flasks containing 49mL of each respective media (OM/ 
MMM/ SGG/ M400/ M19/ SYP/ SM) and incubated for 14 days at 28°C, 200rpm. In addition, 
1 mL of each the culture M410 media (with and without salt) was used for the analysis of anti-
microbial activity. The fermented culture samples were centrifuged at 4°C, max speed for 10-
15min. The pellet was freeze-dried at-80°C and the cell free supernatant (50mL) stored at -
80°C or used immediately for extraction. Identical methods were employed for growth of the 
strains at 30°C. See table 2 for exact details about the media used for fermentation. 
 Antimicrobial activities screening - Well diffusion assays 
The isolated SM9 strain was screened for antimicrobial activity using the well diffusion assay 
method against different test strains such as Staphylococcus aureus (NCIMB 9518), 
Pseudomonas aeruginosa (PAO1), Bacillus subtilis (IE32), Escherichia coli (NCIMB 12210), 




Dextrose) and LB (Luria-Bertani) agar plates were prepared and streaked with a single strain 
of each test strains at an OD=0.1, then wells were manually made in each plate by using sterile 
tips. A volume of 75 µL of the cell free supernatant from the M410-strain cultures broth, at day 
7 of fermentation, were poured into each well. Plates were then incubated overnight at 37 °C 
for the bacterial plates and 28 °C for the fungal plates. Both anti-bacterial and anti-fungal 
activities, were deduced by observation of growth inhibition around the well. To confirm the 
validity of the results, in parallel, negative controls were performed by replacing the volume of 
75 µL of culture by 75 µL of sterile water and the results were validated by the absence of 
growth inhibition surrounding the wells. 
 Liquid Liquid Extraction (LLE) 
Cell-free supernatants (50 mL) were chemically extracted using Liquid Liquid Extraction 
(LLE) with ethyl-acetate as solvent. The solvent was added to the filtrate in the ratio of 1:1(v/v), 
shaken vigorously and left to stand for 5 min to obtain the organic and aqueous phases. The 
organic phase was separated from the aqueous phase using a separating funnel. Both layers 
were concentrated by evaporating to dryness at 45 °C in a GeneVac to generate dry crude 
extracts. 
 Liquid Chromatography - Mass Spectrometry (LC-MS) 
LC-MS analysis was performed at the University of Aberdeen, in the Marine Biodiscovery 
Centre, during my secondment. 
LC-MS was conducted on all the crude extracts on a Bruker MAXIS II QTOF. The Bruker 
MAXIS II QTOF was run in tandem with an Agilent 1260 HPLC using a Phenomenex Kinetex 
2.6 mM XB-C18, 100 x 2.1 mm column. All samples were run at a concentration of 0.5 mg/ml 




 Manual de-replication 
Manual de-replication was performed at the University of Aberdeen, in the Marine 
Biodiscovery Centre, during my secondment. 
Manual de-replication of the metabolites from the LC-MS data was obtain by deduction of the 
possible molecular weights and molecular formulas predicted from the Bruker software using 
Data Analysis based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). 
For the interpretation of the MS data a number of different libraries were used, such as 
Chemspider, Antibase, Reaxys and The Dictionary of Natural Products. The potential new 
metabolites were deduced by the absence of any hits following searched on these databases. A 
second manual de-replication of the identified metabolites was obtained by matching the LC-
MS raw data with the spectral data from the Molecular Network. 
 Venn diagrams and histogram 
The Venn diagram in Figure 17, was produced by using the website from 
(http://www.interactivenn.net/)- (Heberle et al., 2015). The histogram in Figure 17, was 
produced from the Jvenn website (http://jvenn.toulouse.inra.fr/app/example.html) - (Bardou et 
al., 2014).  
 Metabolomics analysis and Visualisation of Molecular Networking- 
The raw data generated from the LC-MS was converted into mzXLM file format by using the 
downloaded zip file GNPS_Vendor_Conversion obtained through the DataAnalysis software 
from the online portal of Global Natural Products Social Molecular Networking GNPS 
(https://gnps.ucsd.edu). All mzXLM files were larger than 20 MB so they were uploaded to 
ProteoSAFe (http://proteomics.ucsd.edu/ProteoSAFe/) using FileZilla as an ftp client.  When 




Separately, a metadata table composed of attributes (metadata) describing the samples 
properties was created by following the GNPS requirements workflow, in a text file format, 
and then used as an input to the molecular networking of GNPS. Molecular networking was 
performed using the online data analysis portal of Global Natural Products Social Molecular 
Networking. The data were filtered by removing all MS/MS peaks within ±17 Da of the 
precursor m/z. The MS/MS spectra were window filtered by choosing only the top 6 peaks in 
the ±50 Da window throughout the spectrum. The data was then clustered with MS-Cluster 
with a parent mass tolerance of 0.02 Da and an MS/MS fragment ion tolerance of 0.02 Da to 
create consensus spectra.  Consensus spectra that contained less than 2 spectra were discarded. 
A network was then created, where edges were filtered to have a cosine score of above 0.7 and 
more than 6 matched peaks. Further edges between two nodes were retained in the network 
only if each of the nodes appeared in each other's respective top 10 most similar nodes. The 
spectra in the network were then searched against GNPS spectral libraries. The library spectra 
were filtered in the same manner as the input data. All matches that were kept between network 
spectra and library spectra were required to have a score above 0.7 and at least 6 matched peaks. 
The molecular network was visualized using Cytoscape version 3.7.1 and displayed using the 
settings “Organic layout” with “sample 2” style. To visualize each different media from all 
samples, regardless of the organics and water phases, color-codes was established manually for 
each media via the group columns from “pie” in “chart” in the Node window. 
 Colour-code 
To help visualize the results, a colour code was applied to all the different media used for 
production of secondary metabolites. This colour code was use in both Figure 18 and Figure 
19. It is as follow: M19 red, M400 blue, MMM yellow, OM green, SGG purple, SM grey and 
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4 Chapter 4: Detection of bioactive secondary metabolites, from 




Microbes associated with marine sponges are exposed to highly competitive environments both 
physiologically and nutritionally which is likely to promote the production of novel secondary 
metabolites. This study focuses on the detection of potential bioactive secondary metabolites 
from a Streptomyces isolate SM9, using the two complementary methods of bioassays-guided 
dereplication and bioactive molecular networking, with the goal of discovering novel bioactive 
metabolites with potential biopharmaceutical utility.  SM9 was subjected to different growth 
conditions using the OSMAC (One Strain MAny Compounds) approach for the production of 
secondary metabolites. Cell free supernatants were chemically extracted using Liquid Liquid 
Extraction (LLE) with ethyl-acetate. Crude extracts containing the potential secondary 
metabolites from both aqueous and organic phases were then screened for anti-microbial 
activities. The antimicrobial screening of the crude extracts demonstrated that they  possessed 
secondary metabolites  with anti-fungal activity against C. glabrata CBS138; anti-
inflammatory activity against  LPS induced TNF-α production in Thp-1 cells, with an inhibition 
of 44-45%; and an anti-cancer activity against the human melanoma cell line A2058 allowing 
a percentage of 10-41% of cell survival. These activities varied depending on the culturing 
conditions; with ,  anti-cancer activity being observed following growth of  SM9 in SGG and 
SM media; a strong antifungal activity when  cultured in M19, M400, SGG, OM and SM 





 Bioinformatics and metabolomics analysis allowed the mapping of these bioactivities through 
the establishment of a bioactive molecular network and revealed the presence of approximately 
19 promising molecules from a total of 177, with high bioactive scores and low p_value. 
Bioactivity scores from 60% to 89% for potential anti-cancer activity against the human 
melanoma cell line A2058; 62% to 88% for potential anti-inflammatory activity against the 
LPS induced TNF-α production in Thp-1 cells; and 60% to 64% for potential anti-fungal 
activity against C. glabrata CBS138 were observed. Some promising molecules were matched 
to our previous LC-MS dataset, through their [M+H] + masses, such as, Desferrioxamine E, 
pro-thr-ala-ile, val-glu-pro-pro and val-ser-pro-pro metabolites.  Other molecules were also 
matched to potential new metabolites from our previous LC-MS dataset, through their [M+H] 
+ masses.  
 
Additional antioxidant activities (including radical scavenging activity) and antimicrobial 
activities against C. glabratra CBS138, S.aureus 6538p, A.baumannii AB13, B.metallica LMG 



















We have already described in chapter 1 and 2 how changes in fermentation parameters such as 
nutrient source media, following the OSMAC approach, results in  the production of bioactive 
secondary metabolites and potentially new metabolites ( Reen et al., 2015; Pan et al., 2019).  
In this chapter, we focused on the use of both bioassay guided and molecular networking 
approaches to further investigate the bioactivity profile of the SM9 isolate. This involved on 
the one hand employing bioactivity assays, together with refocusing our efforts on re analysing 
the chemical and molecular network data obtained from the crude extracts previously described 
in Chapter 2; with the overall aim of discovering both potential new and bioactive secondary 
metabolites being produced in this strain. 
In the context of bioassay guided dereplication, we investigated  the biological activities of our 
SM9 crude extracts by subjecting each sample to a diverse range of bioassays such as a)  anti-
fungal assays against C. glabrata CBS138 (a strain which had been previously used in several 
similar studies  (Xu et al., 2016 ; Roetzer et al., 2011), b)  anti-cancer assays against the human 
melanoma cell line A2058, which had previously been used in similar screens on extracts from 
Streptomyces sp. R(K44 Fang et al., 2020) and c)  anti-inflammatory assays measured in Thp-
1 cells which had previously been used in the isolation of Barettin from extracts of the marine 
sponge Geodia barrette (Lind et al., 2013). The overall aim was to not only identify the most 
promising extracts containing  high levels  of biological activity from the Streptomyces SM9 
crude extracts, but also by employing  dereplication strategies, together with the molecular 






Additional information: Chemical extraction LLE=Liquid liquid extraction; Evaluation of bioactivities 
1. Antifungal against C. glabrata CBS138; Anti-cancer against the human melanoma cell line A2058 
and anti-inflammatory assay measured in Thp-1 cells. Bioactive molecular networked updated consist 
of the correlation of the previous potential new metabolites masses detected in our previous study 
(chapter 2) with the masses of the bioactive molecular network. When the masses were matched, the 
value “no hit” was integrated into Cytoscape to allow direct visualization in  the network of molecules 
already known/suspected (from chapter 2 study) to be potential new metabolites (using metabolome 
mining and Cytoscape). 
 
In the context of bioactive molecular networking, we used both bioinformatics and 
metabolomics tools, such as such as MZmine2, the Jupyter notebook, the GNPS web platform, 
together with Cytoscape and metabolome “mining” to create the bioactive molecular networks. 
Since we did not know whether or not each activity was related to the other activities, a 
bioactive molecular network was generated for each of the individual bioactivities screened for 
in the SM9 crude extracts. A total of 3 bioactivity maps involving anti-fungal activity, anti-
cancer activity and anti-inflammatory activities were created following the process previously 
outlined by the Dorrestein group (Nothias et al, 2018). Following this the maps were 
Figure 24: Bioactive natural discovery workflow, involving a bioassay-guided dereplication 




subsequently employed together with the targeted selection of the most bioactive molecules of 
interest, to identify the most promising extract (Figure 24). 
Current approaches that are often employed in natural product discovery programs can be 
problematic given despite good bioassay results in the initial extract, the active compound(s) 
may not be isolated during the subsequent bioassay-guided purification (Nothias et al., 2018). 
To help overcome this the Dorrestein group introduced the concept of bioactive molecular 
networking to identify candidate active molecules directly from fractionated bioactive extracts. 
This is the approach that we chose to use, which typically involved a three step process (Figure 
24). The first step (I) involves processing LC-MS/MS spectral data with the MZmine2 toolbox. 
This step allows the detection and relative quantification of LC-MS/MS spectral features (ions) 
across the chromatographic extracts (Nothias et al, 2018). The second step (II) involves   
calculation of a bioactive score using the Pearson correlation between feature intensity across 
sample and the bioactivity level associated with each sample (Nothias et al, 2018). The score 
is calculated following the Jupyter notebook script using R language, which is available on the 
open source web application website http://jupyter.org/. The final step (III) involves two parts, 
with the first part (III.I), entailing an analysis of the MS/MS data on the GNPS web-platform 
using Cytoscape to visualize the corresponding molecular network. The objective of this step 
is to annotate molecules that are detected using both spectral library annotations and the 
network topology, and in particular those molecules with significant predicted bioactivity 
scores (Nothias et al, 2018). 
Finally, the last part (III.II) involves correlating and annotating the bioactive molecular 
networks with our previous data regarding potential new metabolites masses that match with  
our network, using metabolome mining and Cytoscape by manually incorporating the value 




metabolite masses, in our Cytoscape network. This allows the direct visualization of some of 
the potential new metabolites identified from Chapter 2, into this bioactive molecular network.  
For this workflow, adapted from Nothias et al, 2018., the data curation relies  on two 
complementary approaches; firstly a targeted approach, where prior knowledge can be used, 
thus we targeted a set of bioactive extracts (Nothias et al., 2018). Second an untargeted 
approach, by looking for consistent patterns of potential bioactive candidates within the 
network, such as individual molecule with a high bioactivity score and or cluster with high 
frequency of bioactive candidate (Nothias et al., 2018). This new concept of bioactive 
molecular networking (BMN) using molecular networking and dereplication tools (LC-
MS/MS) to detect candidate active molecules is gaining increased interest in the field of natural 
products chemistry as evidenced by  another recent study, by the Tasdemir group 
(Buedenbender et al., 2020). In this study  dereplication tools coupled with bioactive molecular 
networking (BMN) was used to identify cluster and individual compounds responsible for 
antimicrobial activity, involving the identification of  a galactolipids bioactive cluster, and the 
subsequent isolation and identification of  several bioactive compounds including 6 
monogalactosyldiacylglycerol derivatives that were active against Staphylococcus aureus from 
the alga Fucus vesiculosus   (Buedenbender et al., 2020). 
Having established the optimum media for SM9 to produce secondary metabolites, potential 
new metabolites and also bioactive metabolites, the strain was grown up under these conditions 








Results and Discussion 
 
4.1 Bioactive molecular network approach 
 
4.1.1 Bioactivities of crude extracts 
 
All the SM9 crude extract samples generated from the different culture conditions were 
screened for: anti-fungal activity (Table 9), anti-cancer activity (Table 10) and anti-
inflammatory activity (Table 11).  
 
Strain Media of fermentation Extract phases Result 
SM9 M19 aqueous phase A* 
organic phase A 
M400 
 
aqueous phase A * 
organic phase A 
MMM  aqueous phase I 
organic phase I 
OM aqueous phase A 
organic phase I 
SGG aqueous phase I 
organic phase A 
SM  aqueous phase I 
organic phase A 
SYP  aqueous phase I 
organic phase I 
Table 9: Table of the NCCLS assay (National Committee for Clinical Laboratory 
Standards, broth microdilution method) against C. glabrata CBS138. 























Extract phases Activity Activity 
average 
Units Result 
SM9_M19 1 A06 aqueous phase 82.3888916051435 82 PCT_SURVIVAL I 
1 A07 organic phase 71.3978389478316 71 PCT_SURVIVAL I 
SM9_M400 1 B06 aqueous phase 70.3613161883342 70 PCT_SURVIVAL I 
1 B07 organic phase 74.0918202708649 74 PCT_SURVIVAL I 
SM9_MMM 1 C06 aqueous phase 86.202513078766 86 PCT_SURVIVAL I 
1 C07 organic phase 72.9526230870777 73 PCT_SURVIVAL I 
SM9_OM 1 D06 aqueous phase 73.6713440571065 74 PCT_SURVIVAL I 
1 D07 organic phase 69.0901090304601 69 PCT_SURVIVAL I 
SM9_SGG 1 E06 aqueous phase 41.3289004058084 41 PCT_SURVIVAL A 
1 E07 organic phase 59.2089180071383 59 PCT_SURVIVAL U 
SM9_SM 1 F06 aqueous phase 59.8249645528773 60 PCT_SURVIVAL U 
1 F07 organic phase 10.4190094362685 10 PCT_SURVIVAL A 
SM9_SYP 1 G06 aqueous phase 81.9977509411822 82 PCT_SURVIVAL I 
1 G07 organic phase 74.0967095291644 74 PCT_SURVIVAL I 
Blank_M19 2 A09 aqueous phase 101.571235526351 102 PCT_SURVIVAL I 
2 A08 organic phase 102.901353965184 103 PCT_SURVIVAL I 
Blank_M400 2 B09 aqueous phase 94.7669643093718 95 PCT_SURVIVAL I 
2 B08 organic phase 96.3885429638854 96 PCT_SURVIVAL I 
Blank_MMM 2 C09 aqueous phase 98.699027582735 99 PCT_SURVIVAL I 
2 C08 organic phase 97.2470257809809 97 PCT_SURVIVAL I 
Blank_OM 2 D09 aqueous phase 94.4013142206089 94 PCT_SURVIVAL I 
2 D08 organic phase 97.0668503749238 97 PCT_SURVIVAL I 
Blank_SGG 2 E09 aqueous phase 95.1220158448372 95 PCT_SURVIVAL I 
2 E08 organic phase 103.553164992978 104 PCT_SURVIVAL I 
Blank_SM 2 F09 aqueous phase 97.4536975702817 97 PCT_SURVIVAL I 
2 F08 organic phase 102.143557404414 102 PCT_SURVIVAL I 
Blank_SYP 2 G09 aqueous phase 94.5125990302324 95 PCT_SURVIVAL I 
2 G08 organic phase 92.4511804138735 92 PCT_SURVIVAL I 
Table 10: Assay category: anti-cancers, assay name: A2058_MTT. 
 
Extracts were tested against the human melanoma cell line A2058 (ATCC-CRL-11147) at a 
concentration of 100 µg /mL. Extracts are considered to be active if the cell survival is less than 50 %.  

























Extract phases Activity Activity 
average 
Units Result 
SM9_M19 1 A06 aqueous phase -3.93736109764762 -4 PCT_INHIBITION I 
1 A07 organic phase 45.1785325947576 45 PCT_INHIBITION U 
SM9_M400 1 B06 aqueous phase 17.5064048803915 18 PCT_INHIBITION I 
1 B07 organic phase 4.13486115270618 4 PCT_INHIBITION I 
SM9_MMM 1 C06 aqueous phase 13.0792436461986 13 PCT_INHIBITION I 
1 C07 organic phase -8.45458235694718 -8 PCT_INHIBITION I 
SM9_OM 1 D06 aqueous phase -4.28812119543163 -4 PCT_INHIBITION I 
1 D07 organic phase -11.654083248896 -12 PCT_INHIBITION I 
SM9_SGG 1 E06 aqueous phase -28.8413280403128 -29 PCT_INHIBITION I 
1 E07 organic phase -7.95214221687819 -8 PCT_INHIBITION I 
SM9_SM 1 F06 aqueous phase -9.35044260669287 -9 PCT_INHIBITION I 
1 F07 organic phase 44.1641723119768 44 PCT_INHIBITION U 
SM9_SYP 1 G06 aqueous phase -6.49696181120667 -6 PCT_INHIBITION I 
1 G07 organic phase -15.393944291485 -15 PCT_INHIBITION I 
Blank_M19 2 A09 aqueous phase -15.6567923974916 -16 PCT_INHIBITION I 
2 A08 organic phase -2.10002212103608 -2 PCT_INHIBITION I 
Blank_M400 2 B09 aqueous phase -10.9010123355822 -11 PCT_INHIBITION I 
2 B08 organic phase -13.8862908525537 -14 PCT_INHIBITION I 
Blank_MMM 2 C09 aqueous phase 0.119051147794806 0 PCT_INHIBITION I 
2 C08 organic phase -5.46933472085097 -5 PCT_INHIBITION I 
Blank_OM 2 D09 aqueous phase 5.05340793139645 5 PCT_INHIBITION I 
2 D08 organic phase 2.20544491827684 2 PCT_INHIBITION I 
Blank_SGG 2 E09 aqueous phase -4.52394361620365 -5 PCT_INHIBITION I 
2 E08 organic phase 6.7976619660846 7 PCT_INHIBITION I 
Blank_SM 2 F09 aqueous phase -3.43368573639833 -3 PCT_INHIBITION I 
2 F08 organic phase -4.33920233442994 -4 PCT_INHIBITION I 
Blank_SYP 2 G09 aqueous phase 4.0383402501984 4 PCT_INHIBITION I 
2 G08 organic phase -2.37412139386205 -2 PCT_INHIBITION I 
Table 11: Assay category: anti-inflammatory, Assay name: TNF_THPAIF. 
Concentration 100 µg /ml. Extracts are considered to be active if the inhibition is at least 50 %. A= 









Table 9 shows the anti-fungal activity results, with SM9 showing anti-fungal activity against 
C. glabrata CBS138 in crude extracts from SGG, SM, M19, M400 media and  in the organic 
phase extracts  from aqueous extracts from the  M19, M400 and OM media . This suggests that 
SM9 produces bioactive anti-fungal metabolites which are active against C. glabrata CBS138 
when grown in OM, M19, M400, SGG and SM culture media (Table 9). The M19 and M400 
extracts displayed the highest bioactivity, thus it is clear that the optimum nutrient source for 
the SM9 isolate to produce potential antifungal metabolites that are active against C. glabrata 
CBS138, are both the M19 and M400 media, as extracts from these growth media displayed 
the best anti-fungal activity (Table 9).  
Table 10 shows the result obtained from the anti-cancer activity screen, with both SGG and 
SM extracts containing anti-cancer metabolites with anti-cancer activity using the human 
melanoma cell line A2058 assay (Table 10). In this assay system, extracts are considered to be 
active if the cell survival rate is <50%. Aqueous extracts from SM9 grown on SGG media 
resulted in survival rates of 41%, while organic phase extracts from SM9 grown on SM medium 
resulted in survival rates of 10% (Table 10). Overall, an average of 50% and 35% of cell 
survival rates were observed from SGG and SM crude extracts respectively, calculated from 
both organic phase and aqueous phase extracts together. This indicates that both the SGG and 
SM growth media are optimal for the production of anti-cancer metabolites by SM9. 
Crude extracts from SM9 grown in M19 and SM media displayed partial anti-inflammatory 
activity by inhibiting   LPS induced TNF-α production in Thp-1 cells, a monocytic cell line 
(Table 11). This is reflected in a total  of 45% and 44%  inhibition of LPS induced TNF-α 
production in Thp-1 cells in the crude extracts from both M19 and SM organic phase crude 
extracts respectively (Table 11). This indicates that the SM9 isolate produces bioactive 




media. Thus, both M19 and SM media appear to be optimal to induce production of metabolites 
with potential anti-inflammatory activity in SM9. 
Taking together, these bioactivity results show that in some instances there is a lack of 
uniformity with respect to the observed activities from the extracts.   For example, SM and 
SGG extracts were the most active in terms of anti-cancer activity, while the M19 and M400 













Number of potential new 
metabolites detected 
Relevant tested bioactivities 
Anti-fungal 




melanoma cell line 
A2058 
Anti-inflammatory 
against LPS induced 
TNF-α production in 
Thp-1 cells 
M19 organic phase 7    
aqueous phase 3    
M400 organic phase 10    
aqueous phase 3    
MMM organic phase 5    
aqueous phase 3    
OM organic phase 7    
aqueous phase 7    
SGG organic phase 3    
aqueous phase 3    
SM organic phase 2    
aqueous phase 9    
SYP organic phase 11    
aqueous phase 8    
 
Legend Visualization Activity level 
Bioactivities  Inactive 
 Partly active 
 Active 
 Very active 
Chemistry Visualization Definition 
 >5 potential new 
metabolites 
Table 12: Composite table of SM9 crude extracts bioactivities results, together with the 







In addition, when focusing on the extracts containing the highest number of potential new 
metabolites, together with the observed bioactivities, some of the extracts that contained the 
highest number of potential new metabolites were those which displayed less activity. For 
example, SYP and OM organic phase extracts contained 11 and 7 potential new metabolites 
respectively; but no activity was observed in any of the bioassays tested (Table 12). In contrast, 
the extracts which displayed the best activity appeared to contain the lowest number of 
potential new metabolites.  For example, the SGG and SM extracts which displayed the highest 
levels of bioactivity had the lowest number of potential new metabolites (Table 12). However 
despite these trends  some of the other extract such as  those from the M400 and M19 growth 
media, showed high number of potential new metabolites and good levels of bioactivity. (Table 
12). 
Based on this  the media extracts which were the most interesting in term of both production 
of potential new metabolites and metabolites with potential bioactivity from the SM9 isolate 
were identified as : M19 (organic phase), M400 (organic phase) and OM (aqueous phase). 
Thus, the media extract which was selected for large scale fermentation for the production of 
potential new and bioactive metabolite, for further analysis was the M19-organic phase extract. 
 




4.1.2.1 Anti-cancer activity mapping 
 
Regarding anti-cancer activity mapping, from Figure 25, it is clear that a total of 13 of the 177 
molecules (=7.34%) were predicted as having a statistically significant anti-cancer activity 
score (r> 0.6) against the human melanoma cell line A2058. Twelve of these 177 molecules 




replication dataset; and 2 of the 177 molecules (1.13%) were predicted as having both a 
statistically significant anti-cancer bioactivity score and were matched to the potential new 
metabolites (Figure 25a). Although, the possibility does exist however that some of the 






The bioactivity scoring is visualized directly in the molecular network with the node size proportionally representing the molecule predicted bioactivity score. 
The bioactivity score was defined herein as the Pearson correlation coefficient (r) between the molecule relative abundance derived from the LC-MS peak (area 
Figure 25: Bioactivity mapping of the anti-cancer activity against the human melanoma cell line A2058, from SM9 crude extracts, with legend of the 
bioactive molecular network (a). View of the bioactive clusters containing the bioactive metabolites with significant bioactivity score and/or potential new 




under the curve) and the selectivity index (SI) value obtained from the evaluation of the extract anti-cancer activity. The largest nodes represent molecules with 
statistically significant bioactivity score [strong Pearson correlation value (r > 0.6) and a significance (FDR corrected, p value <0.03) after Bonferroni correction]. 
In addition, the relative abundance of detected molecule in extract can be visualized in each node with a pie chart diagram [colours correspond to the fraction 
bioactivity level]. Some of the metabolite were manually matched to the LC-MS and manual de-replication result dataset by metabolome mining through there 
[M+H] + masses. Only closest masses up to 0.0006 of differences were matched. n/a= not available. Additional information: the following molecules 547.3445, 
557.2875, 573.3235, 595.3053, 600.2565, 621.3217 and 623.3373, have shown high anti-cancer bioactivity scores of 0.737, 0.689, 0.885, 0.868, 0.628, 0.601 






When considering the bioactive cluster containing the metabolites with a significant bioactivity 
score in Figure 25b, it is clear that among this cluster, 11 metabolites displayed a low p_value 
and a high bioactivity score in the human melanoma cell line A2058, with bioactivity score 
from 0.610 to 0.870, which represent a bioactivity level of approximately 61% to 87% (Figure 
25b). In addition, 3 metabolites in this cluster were linked as being potential new metabolites 
(from a correlation with the LC-MS dataset) including 2 metabolites which were predicted as 
both potential new metabolites and having statistically significant anti-cancer bioactivity 
scores.  
During this bioinformatics and metabolomics analysis, the interesting potentially new 
metabolites were represented in red cube in the bioactive molecular networks by metabolome 
mining after correlation of their [M+H] + masses to previous LC-MS/MS analysis (Figure 25 
b, c). However, while the not-red metabolites in the bioactive molecular network, which were 
not linked to our potential new metabolites list may still be potentially new metabolite as well 
as already known metabolites. Only chemical characterization by NMR of these metabolites 
will confirm if this is the case or not. 
Furthermore, some of the metabolites were matched to the previous LC-MS and manual de-
replication dataset through their [M+H] + masses, with only closest masses up to 0.0006 of 
differences being matched. Two interesting molecules with high significant bioactivity scores 
of 0.870 and 0.631 were matched to the previously identified Desferrioxamine E and pro-thr-
ala-ile metabolites from the LC-MS and manual de-replication dataset (Figure 25b;  also in 
Table 7 from Chapter 2). Another interesting molecule, with a 0.610 bioactivity score of 0.610 
and a 0.020 p_value, was matched to a potential new metabolite which was only detected  in 
the M19 organic phase extract,  had the following molecular formula C24H52N2O12 (Figure 
25b). The two remaining molecules with bioactivities scores of 0.819 and 0.169 were matched 




replication dataset. Indeed, their [M+H] + masses could be linked to two other [M+H] + masses 
from our LC-MS and manual dereplication dataset. For example, the bioactive molecule with 
[M+H] + masse of 587.3389 in the bioactive molecular network (with the high bioactivity score 
of 0.819) could not only be linked to the potential new metabolite with the [M+H] + mass of 
587.3386 and the molecular formula C22H44N12O7, but could also be linked to the another 
potential new metabolite with the [M+H] + mass of 587.3387 and the molecular formula 
C25H50N2O13 (Figure 25b). In the same way, the bioactive molecule with the [M+H]
 + mass of 
585.3187 in the bioactive molecular network (with low bioactivity score of 0.169) could be 
linked to both [M+H] + masses of 585.3186 and 585.3187 from both metabolites with the 
molecular formula C21H44N8O11 and C20H48N4O15 respectively (Figure 25b). Only subsequent 
full chemical characterisation using NMR analysis will allow the definitive identification of 
the metabolite, thus in the meantime both of the aforementioned options are possible.  
 
4.1.2.2 Anti-inflammatory mapping 
The anti-inflammatory activity mapping is presented Figure 26. This resulted in the 
identification of a total of 14 of the 177 molecules being predicted as having a high bioactivity 
score (r> 0.6) with an acceptable p_value <0.03 (7.91%). This included 6 molecule predicted 
as having a very high and statistically significant anti-inflammatory activity score (r> 0.6) and 
a very low p_value <0.003 (3.39%). In addition 13 of the 177 molecules (7.34%) were matched 
to the potential new metabolites already predicted by the manual de-replication dataset but 
which did not have a significant bioactivity score (low r score) (Figure 26a). When looking 
closely  at the two bioactive clusters containing the metabolites with a significant bioactivity 
score (Figure 26b) it was clear  that among these clusters, there were 4 metabolites which 




α production in Thp-1 cells, with bioactivity scores ranging from 0.732 to 0.881 (which 
represents a bioactivity level of approximately 73% to 88%) making them very interesting 
metabolites to further analysis  (Figure 26b). In addition, 2 metabolites predicted as having 
high bioactivity scores of 0.620 and 0.655 but which also had  high p-values (p_value >0.003) 
could be linked to our LC-MS and manual de-replication dataset, through their [M+H] + masses, 





The bioactivity scoring is visualized directly in the molecular network with the node size proportionally 
representing the molecule predicted bioactivity score. The bioactivity score was defined herein as the Pearson 
correlation coefficient (r) between the molecule relative abundance derived from the LC-MS peak (area under the 
curve) and the selectivity index (SI) value obtained from the evaluation of the extract anti-cancer activity. The 
largest nodes represent molecules with statistically significant bioactivity score [strong Pearson correlation value 
(r > 0.6) and a significance (FDR corrected, p value <0.03) after Bonferroni correction]. In addition, the relative 
abundance of detected molecule in extract can be visualized in each node with a pie chart diagram [colours 
correspond to the fraction bioactivity level]. Some of the metabolite were manually matched to the LC-MS and 
manual de-replication result dataset through there [M+H]+ masses. Only closest masses up to 0.0006 of differences 
were matched. n/a= not available.  
Figure 26: Bioactivity mapping of the anti-inflammatory activity of SM9 extracts against the LPS 
induced TNF-α production in Thp-1 cells, with legend of bioactive molecular network (a). View 
of the bioactive clusters containing the bioactive molecules with significant bioactive score (b) as 





Among the bioactive molecules isolated in the network, with significant anti-inflammatory 
activity, 2 molecules with [M+H] + masses of 541.2639 and 507.2427, with predicted high 
bioactivity score of 0.735 and 0.745 and with very low p_value were detected but could not be 
linked to our previous LC-MS dataset. Therefore, they may still be potentially new metabolite 
as well as already known metabolites and they remain interesting molecules for further 
investigations (Figure 26c). 
 
4.1.2.3 Anti-fungal activity mapping 
 
Regarding the anti-fungal activity mapping, which is represented  in Figure 27,  2 of the 177 
molecules were predicted as having a high and significant bioactivity score against Candida 
glabrata CBS138, with an r> 0.6 and a p_value <0.03, representing (1.13% of the total 
predicted molecules). In addition, 13 of the 177 molecules (7.34%) were matched to the 
potential new metabolites already predicted by the manual de-replication dataset but which did 
not have  a significant bioactivity score and high p_value (Figure 27a). Although, as previously 
mentioned for the anti-cancer activities some of these bioactive molecules could be new 






Figure 27: Bioactivity mapping of the anti-fungal activity of SM9 extracts against C. glabrata 
CBS138, with legend of bioactive molecular network (a). View of the bioactive cluster containing 
the bioactive molecule with significant bioactive score as well as isolated bioactive molecule in the 
network (b). 
The bioactivity scoring is visualized directly in the molecular network with the node size proportionally 
representing the molecule predicted bioactivity score. The bioactivity score was defined herein as the Pearson 
correlation coefficient (r) between the molecule relative abundance derived from the LC-MS peak (area under the 
curve) and the selectivity index (SI) value obtained from the evaluation of the extract anti-cancer activity. The 
largest nodes represent molecules with statistically significant bioactivity score [strong Pearson correlation value 
(r > 0.6) and a significance (FDR corrected, p value <0.03) after Bonferroni correction]. In addition, the relative 
abundance of detected molecule in extract can be visualized in each node with a pie chart diagram [colours 
correspond to the fraction bioactivity level]. Some of the metabolite were manually matched to the LC-MS and 
manual de-replication result dataset through there [M+H]+ masses. Only closest masses up to 0.0006 of differences 





When focusing our attention on these bioactive molecules 443.2305 and 496.1610, we can see 
that their bioactivity score is 0.604 and 0.642 representing approximate 60% and 64% of 
bioactivity against Candida glabrata CBS138, respectively. Furthermore, the 443.2305 
molecule could be matched to the val-glu-pro-val metabolite from our LC-MS dataset, through 
its [M+H] + mass.  
 
4.1.3 Bioactive molecules of interest 
 
When combining all three bioactivities, and focusing  on each individual molecule of interest, 
it is clear that the  bioactivity mappings of SM9 extracts  has  highlighted the potential  of 19 
promising molecules of the 177 molecules analysed, in term of anti-cancer, anti-inflammatory 
and/or anti-fungal activities, with the use of bioactivity scores and p_value (using 
bioinformatics and metabolomics analysis). 
 Of these 19 promising predicted bioactive molecules, 4 bioactive molecules predicted to have 
significant bioactivity scores and low p_value have been identified by matching the bioactivity 
mapping data with the LC-MS and manual de-replication data through their [M+H] + masses. 
The two molecules named by their masses in the bioactivity mapping 601.3551 and 401.239, 
both have high bioactivity score of 87% and 63% with  anti-cancer activities  (0.870 and 0.631)  
were matched to the Desferrioxamine E and pro-thr-ala-ile metabolites. The molecule 
443.2505, which had a high bioactivity score in both the anti-fungal (0.604) and anti-
inflammatory (0.620) assays   can be matched to the val-glu-pro-pro metabolite. Finally, the 
molecule 399.2223, which had a high bioactivity score of 0.655 with a high p_value of 0.011 
in the anti-inflammatory activity assay can be matched to the val-ser-pro-pro metabolite. Those 




metabolites, such as Desferrioxamine E, has already been reported to possess similar types of 
bioactivity. Indeed, iron chelators such as Desferrioxamine (DFO) have been reported to inhibit 
the proliferation of tumor cells and induce cell apoptosis; thus having potential clinical 
importance in the treatment of leukemia. A large number of both in vitro and clinical studies 
have shown that DFO can inhibit the growth of tumor cells by chelating intracellular iron and 
DFO has also been shown to have a clear anti-tumor cell proliferation effect [Wang et al., 2017; 
Benadiba et al., 2017]. Indeed Wang and co-workers have shown that DFO had both growth-
arresting and apoptosis-inducing effects on tumor-associated mesenchymal stromal cells 
(TAMSCs) and on bone marrow associated mesenchymal stromal cells (BMMSCs) from EG-
7 tumors. Benadiba et al., 2017 have reported  that transformed cells from a murine PTEN-
deficient T-cell lymphoma model and from T-cell acute lymphoblastic leukemia/lymphoma 
(T-ALL/T-LL) cell lines were overexpressing CD71, leading to the development of an iron 
“addiction” whose chelation by deferoxamine (DFO) dramatically affected their survival to 
induce apoptosis. Another recent study has reported that DFO inhibits leukemia cell viability, 
induces cell apoptosis, and regulates expression of apoptosis-related genes (Yang et al., 2018). 
Yang and co-workers have also demonstrated that DFO treatment significantly decreased iron 
content in K562 cells, as well as, inhibiting the proliferation ability of K562 cells, both in a 
dose-dependent manner. They also demonstrated that iron chelation was in fact responsible for 
suppression of proliferation of the K562 cell lines by diminishing its antiproliferative effect 
due to the quenching of the iron chelator and that DFO can induce leukemia cell apoptosis and 
may involve a variety of apoptosis-related signal transduction pathways (Wang et al., 2018). 
Finally, Desferrioxamine E, also known as Nocardamin, has previously been reported to exhibit 
inhibitory effects on colony formation of T-47D, SK-Mel-5, SK-Mel-28 and PRMI-7951 tumor 





Furthermore, 2 of the 19 promising molecules, which have high bioactivity scores and low 
p_value scores in the  anti-cancer assay  have been matched to potential new metabolites 
already detected in our LC-MS and manual de-replication dataset, making them even more 
promising molecules of interest. Indeed, the molecule 561.3602 which had a bioactivity score 
of 0.610 and can be matched to a potential new metabolite detected in the SM9-M19 extract, 
with the following molecular formula C24H52N2O12 (Figure 25b). The molecule 587.3389 
which has a bioactivity score of 0.819, could also be matched to two possibilities of potential 
new metabolites detected in the SM9-SGG extracts. These two possibilities were as follows: 
the potential new metabolite with the [M+H] + mass of 587.3386 and the molecular formula 
C22H44N12O7; and the potential new metabolite with the [M+H]
 + mass of 587.3387 and the 
molecular formula C25H50N2O13 (Figure 26b). 
The remaining 13 of the 19 promising molecules predicted as having high bioactivity scores 
and low p_values could not be matched to our LC-MS and manual de-replication dataset, and 
thus, it is not possible to determine whether these molecule are known metabolites or 
potentially new metabolites. As previously mentioned, only NMR analysis will allow the 
definitive identification through full chemical characterisation of these metabolites. Among 
these are: 6 molecules namely 547.3445, 557.2875, 573.3235, 595.3053, 600.2565 and 
623.3373 which have shown high anti-cancer bioactivity scores of 0.737, 0.689, 0.885, 0.868, 
0.628 and 0.806 respectively (Figure 25) ; 5 molecules, namely 507.2427, 541.2639, 549.2811, 
549.2813 and 603.3108, which have anti-inflammatory scores of 0.745, 0.735, 0.786, 0.732 
and 0.750 respectively (Figure 26); 1 molecule, namely 496.1610, which has  an anti-fungal 
score of 0.642 (Figure 27) and finally 1 molecule, namely 621.3217, which has  both an anti-





In addition, some metabolites were matched to potential new metabolites from our LC-MS & 
manual de-replication dataset, but their low bioactivity score and/or high p_value make them 
less interesting to pursue for further analysis. For example, in the bioactivity mapping of the 
anti-cancer activity, the molecules 535.2651 and 1077.5485 with [M+H] + masses of 535.2651 
and 1077.5485, low bioactivity scores of 0.377 and 0.316, and high p_values of 0.183 and 
0.316 were both matched to potential new metabolite with the [M+H] + masses of 535.2652 
and 1077.5479 with the molecular formula of C21H39N5O11 and C49H76N10O17 (Figure 25c). In 
the bioactivity mapping of the anti-inflammatory activity, in the second bioactive cluster, the 
same molecule 535.2651 with [M+H] + with a mass of  535.2651, which had  a bioactivity score 
of 0.547 and a 0.043 p_value was matched to the same potential new metabolite with the 
[M+H] + masses of 535.2652 and the molecular formula C21H39N5O11 (Figure 26b). In the 
bioactivity mapping of the anti-fungal activity against C. glabrata CBS138,  the molecule 
585.3187 with [M+H] + mass of 585.3187, with the low bioactivity score of 0.312 and the high 
p_value of 0.277 was matched to the potential new metabolite with the [M+H] + masses of 
585.3188 and the molecular formula C20H48N4O15 (Figure 27b). As previously mentioned only 
NMR analysis will ultimately allow the definitive identification through full chemical 











4.2 Additional anti-oxidant and anti-microbial screening of SM9-M19 crude 
extract against human bacterial pathogens. 
 
4.2.1 Antimicrobial screening 
 
Following reculturing of SM9 in M19 media, the organic phase crude extract was subjected to 
an additional anti-microbial screen targeting the following human bacterial pathogens:  
Staphylococcus aureus 6538p, Burkholderia metallica LMG 24068, Acinetobacter baumannii 
AB13 and Pseudomonas aeruginosa PA01 (Figure 28).  The Minimal Inhibitory Concentration 
(MIC) as well as the Minimal Bactericidal Concentration (MBLC) and the Minimal 
Bacteriostatic Concentration (MBSC) were determined using the extracts in a liquid inhibition 
assay.  
 
mg/mL B1 E4 DMSO 
Sa 
6538P LB 
1 0.547 -0.018 0.313 0.320 0.001 
0.5 0.461 -0.024 0.273 0.306 0.004 
0.25 0.394 -0.010 0.305 0.293 0.004 
0.125 0.467 0.008 0.340 0.302 0.005 
0.0625 0.463 -0.007 0.300 0.284 0.000 
0.03125 0.425 -0.003 0.332 0.333 0.007 
0.015625 0.482 0.327 0.318 0.304 0.007 











mg/mL B1 E4 DMSO Bm LB 
1 0.905 0.463 0.804 0.882 0.002 
0.5 0.871 0.528 0.838 1.032 0.001 
0.25 0.932 0.537 1.006 0.983 0.001 
0.125 0.967 0.655 1.083 1.026 0.002 
0.0625 1.003 0.772 1.095 0.973 0.004 
0.03125 1.022 0.729 1.019 1.005 0.005 
0.015625 0.935 0.866 1.093 1.101 0.004 




mg/mL B1 E4 DMSO Ab13 LB 
1 0.913 0.587 0.920 0.986 0.002 
0.5 0.926 0.666 0.929 0.997 0.003 
0.25 0.954 0.781 0.973 0.993 0.005 
0.125 0.957 0.846 0.962 0.992 0.005 
0.0625 0.960 0.878 0.933 1.011 0.003 
0.03125 0.949 0.914 0.921 0.975 0.004 
0.015625 0.964 0.956 0.916 0.984 0.006 












  inhibition-bactericidal 
  inhibition-bacteriostatic 
  no to medium inhibition 
  no inhibition 
Figure 28: Anti-bacterial assays against: (a) S.aureus 6538p ; (b) B.metallica LMG 
24068, (c) A.baumannii AB13 and (d) P.aeruginosa PA01. 
E4= SM9-M19 organic phase crude extract (culturing media M19 + SM9, fermentation, then chemically 
extracted); B1= biological control (same culturing condition than SM9-M19 without SM9); control 
negative = LB; control positive =Sa 6538p, B.m, A.b13,  P.a . Absorbance in each well was measured 
at 630nm, at T0 and then at T24h.   
Absolute value of antibacterial activity= (T18 A630nm sample well – T0  A630 nm sample well). 
 
 
The SM9-M19 organic phase crude extract was found to be active against S.aureus 6538p at a 
MIC and MBLC of 0.03125 mg/ml (Figure 28a). The SM9-M19 organic phase crude extract 
also displayed bacteriostatic activity against B.metallica LMG 24068, A.baumannii AB13 and 
P.aeruginosa PA01; at a MIC and Minimal MBSC of 0.125 mg/ml, 0.25 mg/ml and 0.25 
mg/mL B1 E4 DMSO Pa01 LB 
1 0.782 0.566 0.784 0.788 0.002 
0.5 0.844 0.627 0.784 0.841 0.001 
0.25 0.866 0.671 0.839 0.855 0.002 
0.125 0.880 0.753 0.888 0.833 0.002 
0.0625 0.935 0.798 0.942 0.896 0.003 
0.03125 0.882 0.792 0.933 0.885 0.002 
0.015625 0.919 0.794 0.888 0.835 0.002 




mg/ml respectively (Figure 28b, 28c and 28d). The activity was found to be dose-dependent. 
The bacteriostatic activity of the extract is a good indicator of potential anti-biofilm activity.  
 
4.2.2 Antioxidant activity 
 
In parallel, the anti-oxidant activity of SM9-M19 crude extracts was assessed, using the DPPH 
antioxidant assay (2,2-diphenyl-1-picrylhydrazyl) with Vitamin C (Ascorbic acid) being used 
as a positive control. The SM9-M19 organic phase crude extract displayed a total antioxidant 
activity at 0.03125 mg/ml (concentration dependent visible in Figure 29) and displayed a 
radical scavenging activity of 49 % at a concentration of 1mg/ml (Figure 29). Given that the 
positive control Vitamin C, is known to have high antioxidant effect, and displayed 50 % 
activity in this assay, the 49 % activity observed with the crude extract (SM9-M19) is high.  Our 
results are similar to those previously reported from other marine bacteria, with Saurav and co-
workers  who reported the identification of a 5-(2,4-dimethylbenzyl)pyrrolidin-2-one 
(DMBPO) compound extracted from a marine Streptomyces VITSVK5 spp, which exhibited 
significant DPPH radical scavenging activity and total antioxidant activity of 50.10 % at 
5 μg/ml DMBPO (Saurav et al., 2011). Kumaqai et al. (1993), also reported a PC-766 B 
compound, which exhibited a dose dependent antioxidant activity, isolated from the marine 
actinomycete Nocardia brasiliensis. While Dholakiya and co-workers also  reported  
antioxidant activity in extracts from a  marine Streptomyces variabilis RD-5 strain, which  
showed 82.86 and 89 % of 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging activity 













Additional information: E4= SM9-M19 organic phase crude extract (culturing media M19 + SM9, 
fermentation, then chemically extracted); B1= biological control (same culturing condition than SM9-
M19 without SM9); Positive Control = Vitamin C (Ascorbic acid); Negative Control = Methanol 
(MeOH). Absorbance value was measure at T0, then at T30 min at 490 nm.  
% anti-oxidant activity = [(T30 min A490 nm control negative average value - T30 min A490 




It is important to note that the control-M19 extract displayed no activity in any the anti-bacterial 
assays or in the anti-oxidant assay (Figure 28 and 29). This demonstrate that the activities of 
the SM9-M19 crude extract doesn’t derive  from the media itself but from the  secondary 
metabolites that are produced  following  the fermentation of the SM9 isolate in the M19 media. 
Thus, it is clear that the SM9-M19 organic phase crude extract contains secondary metabolites 
which displayed a radical scavenging activity and total anti-oxidant activity; which are 
     
mg/mL E4 B1 C+ C- 
1 49% -33% 50% -33% 
0.5 24% -39% 48% -40% 
0.25 -1% -43% 47% -31% 
0.125 -11% -46% 47% -45% 
0.0625 -14% -42% 46% -41% 
0.03125 -8% -44% 48% -45% 
     
  Radical scavenger activity 
  Anti-oxidant activity 
  No activity  
  
  
Figure 29: Anti-oxidant activity of SM9-M19 crude extract, at T30min, 490nm, visible 




bactericidal against S.aureus 6538p; bacteriostatic against B.metallica LMG 24068, 
A.baumannii AB13 and P.aeruginosa PA01. This antioxidant property of the extract could be 
further studied by in vivo animal model studies. It would also be interesting to investigate on 
the anti-biofilm activity of these metabolites against B.metallica LMG 24068, A.baumannii 





The SM9 isolate was selected from amongst the others strain isolates because of the high 
bioactivity potential that it exhibited.  The OSMAC approach, revealed different bioactivity 
following cultivation in the various culture conditions, such as an anti-cancer activity when 
SM9 was fermented in SGG and SM media; a strong antifungal activity when SM9 was 
cultured in M19, M400, SGG, OM and SM media; and partial anti-inflammatory activity when 
SM9 was fermented in M19 and SM media. Indeed, the antimicrobial activity screening of the 
crude extracts tested was shown to possess secondary metabolites containing anti-fungal 
activity against C. glabrata CBS138; anti-inflammatory activity against the LPS induced TNF-
α production in Thp-1 cells, with an inhibition of 44-45%; and an anti-cancer activity against 
the human melanoma cell line A2058 allowing a percentage of 10-41%  cell survival. This 
demonstrates that SM9 crude extracts contain secondary metabolites that have an anti-fungal 
activity against C. glabrata CBS138; anti-inflammatory activity against LPS induced TNF-α 
production in Thp-1 cells and or an anti-cancer activity against the human melanoma cell line 
A2058, when SM9 cultured in specific growth media.  
In addition, bioinformatics and metabolomics investigation of these separate bioactivities have 
allowed  the mapping of each bioactivity  within  the chemical diversity of the SM9 isolate, 




a bioactive molecular network for the following activities namely, anti-fungal activity against 
C. glabrata CBS138; anti-inflammatory activity against the LPS induced TNF-α production in 
Thp-1 cells and or an anti-cancer activity against the human melanoma cell line A2058.  
The bioactivity mapping of the anti-cancer activity against the human melanoma cell line 
A2058, has highlighted one bioactive cluster containing 11 promising molecules of interest and 
an additional 2 molecules of interest  in the network. Their bioactivity scores ranged from 0.601 
to 0.885, representing 60% to 89% of bioactivity and included 2 potential new metabolites. 
The bioactivity mapping of the anti-inflammatory activity against the LPS induced TNF-α 
production in Thp-1 cells, highlighted 14 promising molecules and 2 potential bioactive 
clusters. The promising molecules have shown bioactivity scores ranging from 0.620 to 0.881, 
representing 62% to 88% of bioactivity. The bioactivity mapping of the anti-fungal activity 
against C. glabrata CBS138, has highlighted 2 promising molecules and 1 potential bioactive 
cluster. These two promising molecules displayed bioactivity scores of 0.604 and 0.642, 
representing 60% and 64% of bioactivity.  
Furthermore, the bioactivity mapping has highlighted a total of 19 promising bioactive 
molecules from a total of 177, with a high bioactive score and low p_value. Four of these 177 
promising molecules were matched to our previous LC-MS dataset, through their [M+H] + 
mass, such as, Desferrioxamine E, pro-thr-ala-ile, val-glu-pro-pro, val-ser-pro-pro metabolites. 
Two others out of 177 promising molecules were matched to potential new metabolites from 
our previous LC-MS dataset, through their [M+H] + masses. While the remaining 13 promising 
molecules out of 177 could not be matched, they do remain promising as it is not clear as yet 
whether these molecule are known metabolites or potentially new metabolites. Only NMR 
analysis will allow the definitive identification through the full chemical characterisation of 
these metabolites. Among them, 6 molecules have shown high anti-cancer bioactivity scores 




anti-inflammatory scores ranging from 0.732 to 0.786, representing 73%-79% of bioactivity; 
1 molecule has shown an anti-fungal score of 0.642 (=64%) and lastly, 1 molecule has shown 
both anti-cancer score anti-inflammatory activity with scores of 0.601 and 0.881, respectively; 
representing 60% of the bioactivity against the human melanoma cell line A2058cancer and 
88% of the bioactivity against the LPS induced TNF-α production in Thp-1 cells. 
From all the SM9 extracts tested, the SM9-M19 extract was specifically selected for additional 
antimicrobial and antioxidant screening analysis because of its strong antifungal activity and 
partial anti-inflammatory activity, as well as, its high potential for production of secondary 
metabolites including potential new metabolites. The antimicrobial activity screening of the 
extract was shown to possess both bactericidal and bacteriostatic antibacterial activity against 
S.aureus 6538p and A.baumannii AB13, B.metallica LMG 24068, P.aeruginosa PA01, strains, 
respectively, when cultured in the M19 media at a temperature of 28°C. In addition, the extract 
also showed a radical scavenging anti-oxidant activity at a concentration of 1 mg/ml which 
could be further investigated by in vivo animal model studies.  
This demonstrated that the crude extract of interest (SM9-M19, also called E4), contain 
secondary metabolites which have an antioxidant effect (including radical scavenging activity) 
and which are active against C. glabratra CBS , S.aureus 6538p, A.baumannii AB13, 
B.metallica LMG 24068, P.aeruginosa PA01. Fractionation and further characterizations such 
as chemical characterisation NMR followed by toxicity testing on these metabolites would be 








Material and Methods 
 
 Origin of strains 
The bacterial strains SM9 was obtained from the marine sponge Haliclona simulans (class 
Demospongiae, order Haplosclerida, family Chalinidae), at a depth of 15 m in Galway bay 
(Ireland). (See chapter 2 Material and Methods, p188 for more detail). 
 Production of secondary metabolites by fermentation 
The production of secondary metabolites was originally performed following the OSMAC 
approach used in chapter 1 and 2 (see chapter 1 material and methods) with fermentation of the 
strains in different nutrient-sources media and different temperature conditions. In this study, 
we repeated the fermentation process on the Streptomyces SM9 strain in one media, namely 
M19, at a temperature of 28 °C. The composition of the fermentation media M19 is provided 
in Table 2 of the chapter 1. 
Identical methods for production of secondary metabolites by  SM9 in M19 media were 
employed (see chapter 2 material and methods for more details), with two exceptions: for the 
large scale production: 8L of fermentation media was produced instead of 50 mL as in chapter 
1; and at the end of the experiment the pellet was discarded instead of being freeze dried. The 
cell free supernatant (8 L approximate) was stored at -80 °C and/or used immediately for 
extraction.  
 Liquid Liquid Extraction (LLE) 
Cell-free supernatants (8 L) were chemically extracted using Liquid Liquid Extraction (LLE) 
with ethyl-acetate as solvent. The solvent was added to the filtrate in the ratio of 1:1(v/v), 
shaken vigorously and left to stand for 5 min to obtain the organic and aqueous phases. The 




phase extract were then concentrated by evaporating to dryness at 45 °C in a GeneVac to 
generate dry crude extracts. The aqueous phase extract was discarded. 
 
Bioactivity bioassays- guided dereplication 
 Anti-fungal NCCLS assay 
All the crude extract samples were checked for their ability to inhibit the growth of C.glabrata 
CBS138, by performing an NCCLS assay (National Committee for Clinical Laboratory 
Standards) following the protocol of Liu et al,.2007.  The NCCLS assay is a broth colorimetric 
broth microdilution method, which uses the colorimetric indicator Resazurin, which is blue in 
sterile condition and turns pink in presence of yeast, due to a pH change. For this experiment, 
we used a 96-well microtiter plate, the dried crude extracts were mixed with 10 μL of ethyl 
acetate for the organic phase extract samples, or 10 μL of sterile water for the aqueous phases 
extracts. Then the 10μL of the liquid extracts were placed into the well containing 290 of RPMI 
solution, and were serially diluted following a 3-fold dilution to observe the level of activity, 
with a final volume of 200 in each well. 100 μL of Rcs solution, containing both C. glabrata 
CBS138 inoculum and Resazurin, was added to the wells, except the sterility control wells. 
The sterility control wells were then supplemented of 100 µL of R solution containing  distilled 
sterile water with Resazurin. The plate was then incubated at 28 °C and results were taken after 
24 h and after 48 h following incubation. The antifungal activity of the extracts was  then 
visually observable by the pink to blue colour change  in the wells. For confirmation of the 
validity of the method and of the bioactivity of the extracts, the following controls were 
performed: media control, ethyl acetate control, growth control and sterility control. The RPMI 
solution and the R solution was prepared following the protocol of Liu et al,.2007. The Rcs 




overnight at 28 °C. A single colony of the yeast strain was used to inoculate 5mL of sterile 
distilled water in sterile bacteriological tubes, then  suspensions were mixed for 15 s to ensure 
homogeneity and subsequently diluted to a final OD = 0.12–0.15 . Then the working suspension 
of 20mL was supplemented with 0.1ml sterilized solution of Resazurin (20 mg/ ml in water). 
 
 Anti-cancer assay: CellTiter96 Aqueous One Solution Cell Proliferation assay 
The anti-cancer assays were performed as part of a collaboration with the University of 
Tromso, in the Marbio facilities and by the group of  Prof. Jeanette Hammer Anderson, namely 
Kirsti Helland and Marte Albrigtsen .  
The CellTiter 96 ® AQueous One Solution Cell Proliferation assay is a colorimetric method 
for determining the number of viable cells in proliferation or cytotoxicity assays. Metabolically 
active cells will reduce the tetrazolium compound MTS (yellow) into a colored formazan 
product (blue) that is soluble in tissue culture medium. The assays are performed by adding 
AQueous One Solution to cells in a tissue culture plate and incubating the cells for 1-4 hours 
and reading Absorbance at 490 nm (450-540 nm). The quantity of formazan product as 
measured by the absorbance at 490 nm is directly proportional to the number of living cells in 
culture. 
The cell line A2058 were seeded in 96 -wellplates at a density of 2000 cells/well and then 
incubated overnight at 37°C and 5 % CO2. The cells were then observed under the microscope 
to check that they were healthy and evenly distributed in the plate. The cell media were 
removed then, RPMI w/10 % FBS were added.  Then samples were added (in triplicates) to a 
total volume of 100 μL/well. Samples were placed in a 96-well plate and incubated for 72 h at 
37 °C and 5 % CO2. After 72 h, 10 µl AQOS were added to each well and the plates were then 




well plate reader. Results were represented as follow: A= active 50% > survival; Q= 
questionable 50 - 60 % survival; I= Inactive > 60 % survival. 
 
 Anti-inflammatory assay- ELISA assay: TNF_THPAIF assay 
 The anti-inflammatory assays were also performed as part of a collaboration with the 
University of Tromso, in the Marbio facilities with the group of Prof. Jeanette Hammer 
Anderson, namely Kirsti Helland and Marte Albrigtsen.  
The anti-inflammatory effect of the extracts was measured in Thp-1 cells, a monocytic cell 
line. Thp-1 cells will secrete the cytokine TNF-α when treated with lipopolysaccharides (LPS). 
LPS are components of the Gram-negative bacterial cell wall and will induce an immune 
response in the Thp-1 cells. Extracts with anti-inflammatory effect will inhibit the LPS induced 
TNF-α production in the cells. Thp-1 cells differentiated from monocytes to macrophages are 
added to the crude extract samples (Concentration 100 µg /ml of crude extracts). After one hour 
of incubation LPS is added and the cells are incubated for 6 hours. TNF-α secreted into the cell 
culture media is measured by a TNF-α ELISA assay.  Duplicate of each sample were generated.  
Cells were seeded in microtiter plates at a density of 1 x 106 cells/mL. 50 ng/mL PMA was 
added to the cell suspension (0,5 µl PMA stock solution pr 10 ml) to differentiate cells from 
monocytes to macrophages. A 10 mL cell suspension was generated for each microtiter plate 
and 5 mL extra were added. 100 µl of cell suspension was added to each well in a microtiter 
plate, then incubated at 37 °C with 5 % CO2, for 48 hours. The cells were monitored after 24h 
by microscopy to ensure that they had started to differentiate. After 48h, the cells were washed 
with endotoxin tested PBS and new growth media was added before incubation at 37 °C with 
5 % CO2 for a further 24 hours. The cell media was removed and 80 µl RPMI growth media 




added to cell controls.10 µl of samples were added to each respective well (and 10 µl of controls 
solution was added to the control wells). Cells were then incubated at 37 °C with 5 % CO2 for 
1 hour. Then 10 µl of 10 ng/mL LPS solution was added to each well except the cell control. 
Cells were incubated for 6 h at 37°C with 5 % CO2. The reactions were stopped by immediately 
freezing the plates at -80°C.  
One day prior to the ELISA testing, Affinity purified anti-human TNF-α to 2 µg/mL was  
diluted into in 10 mM TBS then 100 µL of the mixture was  added to each well in a 96-well 
Maxisorp plate before being incubated  overnight at 4°C. Plates were washed with the 
Aquamax plate washer, then 200 µl 10 mM TBS with 2 % BSA were added to each well before 
incubation for 1hour with on shaker. The washing step was repeated 3 times, then samples and 
standards were diluted in the assay diluent, directly in ELISA plate for a total volume of 100 
µL in each plate before incubation for 2 hours on shaker. The washing step was repeated three 
times and  then the Biotin anti-human TNF-α was diluted to 3 µg/mL in 10 mM TBS. 100µl of 
the mixture was then added to each well and incubated for 1 hour on shaker. The plates were 
then washed again. Dilution of 1:20000 of ExtrAvidin-Alkaline phosphatase in 10 mM TBS 
was made, then 100µl of the mixture was then added to each well and incubated for 30 min on 
shaker. Plates were washed again. 100 µL of 1 mg/mL Solved pNPP in 1 M diethanolamin 
buffer were added to each well for 30-45 minutes then the absorbance was readed at 405 nm.  
Extracts which display an anti-inflammatory effect will inhibit the LPS induced TNF-α by at 
least 50 %. A= active; U = unclear but can be considered partly active; I= inactive. U=unclear 
but can be considered partly active 
 
 




The liquid inhibition assays were performed in the Consiligo Nazionale Delle Ricerche, 
Institute of Protein Biochemistry (IBP-CNR), at Napoli (Italia) during my secondment. 
The crude extracts (sample and biological controls) were checked for their ability to inhibit the 
growth of a selected panel of human pathogenic bacteria using a 96-well microtiter plate and 
in vitro Minimal Inhibitory Concentration (MIC) assay. The selected panel of human bacterial 
pathogens used for the antimicrobial screening were as follows: Acinetobacter baumannii 
Ab13; Burkholderia metallica LMG 24068; Pseudomonas aeruginosa PA01 and 
Staphylococcus aureus 6538P. These bacteria were plated on LB agar and grown overnight at 
37 °C. The extracts were placed into the well of the 96-well microtiter plate at an initial 
concentration of 1 mg/mL and were serially diluted 2-fold in LB. A positive control column 
did not contain any extract but contain the human bacteria pathogens used as a growth control. 
Two percent (v/v) DMSO was also used as a control, to assess the toxicity of the solvent on 
the bacterial growth. B1 extract was used as a biological control and LB was used as a sterility 
control. A single colony of each pathogen strain was used to inoculate 3 mL of liquid medium 
in sterile bacteriological tubes. After 5-8 hr of incubation, growth was measured by monitoring 
the Abs600 nm and approximately 4x103 CFU/mL was dispensed into each well (with the 
exception of the sterility control). The plates were then incubated at 37 °C for 18 hours. Growth 
was measured at T0 and T18, by using a 96- well plate reader (VICTOR X Multilabel Plate 
Reader, PerkinElmer, USA) by monitoring the Abs630 nm. The activity level was determined 
by calculation of the antibacterial activity:  
Absolute value of antibacterial activity= (T18 A630nm sample well – T0  A630 nm sample 
well). 
 




The liquid inhibition assays were also performed in the Consiligo Nazionale Delle Ricerche, 
Institute of Protein Biochemistry (IBP-CNR), at Napoli (Italia) during my secondment. 
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) assay was conducted as previously described   
(Raes et al., 2004).  100 µL of Methanol (MeOH) was added to each well, followed by an 
additional 96 µL MeOH to the first row + 8 µL of extract or control was added to the same 
row, and a 2x-fold serial dilution was then performed to dilute the extracts in the plate. Finally, 
100 µL of 0.3 mM DDPH (prepared in MeOH) was then added to all the wells, including the 
controls. Ascorbic acid (Vitamin C) was prepared at 50 mg/mL in Milli-Q water (MQ H2O) 
and used as a positive control and methanol was used as a negative control. The plates were 
measured at an Abs 490 nm and incubated at 15 °C in the dark for thirty minutes.  Following 
this he plates were again measured at an Abs 490 nm, and the % antioxidant activity was 
calculated as follows:  
% anti-oxidant activity = [(T30 min A490 nm control negative average value - T30 min A490  
nm sample value) / T30 min A490 nm control negative average value] x100. 
 
Metabolomics analysis 
 Spectral Feature Detection.  
This step was performed following as previously described by the Dorrestein laboratory, with 
the corresponding online documentation on GitHub : 
https://github.com/DorresteinLaboratory/Bioactive_Molecular_Networks . The popular 
MZmine2 toolbox, version MZmine2.51, was used for LC-MS feature detection, integration, 
filtering, and visualization. Raw data  from the previous LC-MS/MS experiment  (Chapter 2), 
were re-invested and imported into MZmine2, in mzXLM format. MZmine 2 data processing 




zip file and the README file from the Dorrestein laboratory. In the Peak list row filter module, 
two options were selected:  "Keep only features with MS/MS scan (GNPS)", 'Reset the peak 
number ID". The MGF file and the CSV table were both exported using the module “Export 
for GNPS” which includes 'Export row ID', 'Export row m/z', 'Export row retention time', and 
'Peak area'. The MGF file generated, containing MS/MS spectral data for each feature was 
uploaded on GNPS, and a Data Analysis was performed as described below. The CSV table, 
named (feature_quantification_matrix.csv), containing relative quantitative information such 
as the aligned list of features and their intensity across the crude extracts analyzed by LC-
MS/MS, was used for both the calculation of the bioactivity score and the visualization of the 
relative abundance in the molecular networks. 
The CSV table file was used to predict the: anti-cancer, anti-inflammatory  and anti-fungal 
activity scores. Then the value of the bioassay experiments for each sample analyzed by LC-





 Prediction of Bioactivity Score Significance : Jupyter notebook 
An R-based Jupyter notebook, called Bioactive Molecular Networks, was used from GitHub, 
https://github.com/DorresteinLaboratory/Bioactive_ Molecular_Networks along with a step-
by-step tutorial and the representative input/output files needed (Nothias et al, 2018). We 
obtained new CSV format tables (.csv) of spectral features’ intensity edited with bioactivity 
data. In our study, three bioactivity were analysed via Jupyter notebook, therefore we obtained 




This step involved three steps: scaling samples by normalizing the intensity to the total ion 
current TIC (van den Berg et al, 2006), calculating the Pearson correlation score (r) and its 
significance (r_pval) between each feature and the bioactivity value, as well as the multiple 
hypothesis testing correction (the Bonferroni correction), and output the node attribute table 






ation_pvalue_corrected.csv)  can all be imported (separately) into the Cytoscape software to 
map back the bioactivity score onto the corresponding MS/MS molecular network. 
 
 Bioactivity mapping into the Molecular Network.  
The molecular network was created using the GNPS platform (http://gnps.ucsd. edu). The 
spectral information (MGF file) previously generated by MZmine2 was uploaded on GNPS. 
The precursor ion mass tolerance was set to 0.01 Da and to a product ion tolerance of 0.0075 
Da (allowing a maximum error of 25 ppm at m/z 300 and 12 ppm at m/z 600) as previously 
described (Nothias et al., 2018). The fragment ions below 10 counts were removed from the 
MS/ MS spectra. MNs networks were generated using 12 minimum matched peaks and a cosine 
score of 0.7. The molecular networking data was  imported using the Cytoscape 3.4.0 software 
for visualization of the molecular network. Then, one of our previous output tables of the 
Jupyter notebook was imported into Cytoscape into the molecular network 
(features_quantification_matrix_anticanceractivity_transposed_with_significant_correlation_




workflow was subsequently repeated to create molecular networks for  the anti-fungal  and the 
anti-inflammatory activity mapping. 
Finally, metabolome “mining” was  used on each bioactive molecular networks. A cosine score 
factor was used and nodes were filtered for their significant bioactivity based on their r score 
and their false discovery rate (FDR) corrected p value, in the Seclect function of Cytoscape. 
The style of these nodes was then bypassed with a larger node size to allow the direct 
visualization of the bioactive molecules and a piechart diagrams was generated to display the 
distribution of the ions across the different samples.  Only molecules having a bioactivity score 
above r > 0.6 and p value <0.03 (for anti-fungal and anti-cancer activity mapping) or p value 
<0.003 (for anti-inflammatory activity mapping) were represented as having a larger node on 
the bioactive molecular networks. 
 
 Potential new metabolite into the molecular network- bioactivity network updated 
For this part, we re- analysed our previous data from LC-MS/MS experiment from chapter2 
(prior MZmine2 data processing). This data included the identification of potential new 
metabolites which were not in the ChemSpider, Antibase, PubChem, Reaxys and the 
Dictionary of Natural Products libraries. The [M+H] + masses of these potential new 
metabolites were compared and matched to the [M+H] + masses of the Cytoscape molecules.  
The matched masses were then highlighted using metabolome mining by integrating the value 
“no hit” to Cytoscape then bypassing the style of the nodes on all “no hit” nodes with a red 
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Contributing to the fight against Global AMR threat 
AMR has been recognized as a serious global threat to public health worldwide; which has 
resulted in a large number of high-level policy initiatives, being led by institutions such as the 
World Health Organisation (WHO), the United Nations (UN), and many others. These 
initiatives have been undertaken due to the potential negative effects of AMR which are likely 
to adverse morbidity, mortality and financial consequences such as forcing up to 24 million 
people into extreme poverty by 2030; the prediction of 10 Million deaths globally due to AMR 
by 2050; and the loss of a total Gross Domestic Product (GDP) of $100.2 trillion by 2050 if 
nothing is done to prevent AMR (Dadgostar.2019; O’Neill.2014). 
In an effort to address  this growing and challenging threat, this study aimed to contribute to 
the global fight against AMR by employing an  OSMAC based approach, together  with new  
marine “omics” based methods such as metabolomics and genomics, to study  marine sponge 
derived Streptomyces isolates. By characterizing these new marine bacterial strains and 
targeting specific bioactivity towards clinical pathogens that have been prioritised by the 
WHO; we hoped to identify secondary metabolites produced by these isolates that may have 
potentially new bioactivities. The other aim was to investigate  and describe potential novel 
biosynthetic pathways that may encode for any of the new bioactivities that were observed in 
these strains. 
Following the screening regime isolates were identified that produced metabolites which were 
active against categorized “Urgent” and “Serious threat” microorganisms from the WHO/CDC 




baumannii and Pseudomonas aeruginosa, which are registered as being an “urgent threat” and 
classified as “critical pathogens”, together with activity against Candida spp (Candida glabrata 
and Candida albicans in our study) and Staphylococcus aureus which is registered as being a 
“serious threat”. In addition, activities were identified which are not in the list of priorities but 
which are also important and of biomedical interest, namely anti-cancer, anti-inflammatory and 
antioxidant activities were also observed which are also of biomedical interest. 
 Specifically the deep sea isolate B226SN104 displayed bioactivity against C. glabrata 
(CBS138), the shallow water isolate SM3 displayed bioactivity against P. aeruginosa (PAO1) 
and B. subtilis (IE32) while the shallow water isolate SM9 displayed bioactivity against C. 
glabrata (CBS138) and Candida albicans (Table 3 from chapter 1 and Table 6 from chapter 
2). Furthermore, crude extracts from SM9 displayed bactericidal activities against Candida 
glabrata, Candida albicans and Staphylococcus aureus (6538p); bacteriostatic activities 
against Acinetobacter baumannii (AB13) and P. aeruginosa (PAO1) ; as well as biostatic 
activity against B. metallica (LMG 24068). In addition, SM9 crude extract were also active 
against a human melanoma cell line A2058 (indicating potential anti-cancer activity) and also 
displayed activity against LPS induced TNF-α production in Thp-1 cells (indicating potential 
anti-inflammatory activity). Therefore, in total, we found extracts containing metabolites 
which displayed activity against five of the bacteria on the “emergent microbial threat” 
pathogen list of the CDC and WHO organisations (Table 1), and considered as serious and 
urgent threats. 
 
One of the First Large-Scale marine OSMAC – multi-fields perspectives study 
As previously mentioned in the introduction, marine ecosystems offer a large variety of 




availability, salinity and pressure, which taken together has resulted in the evolution of marine 
microorganisms which has help them to adapt and  survive in these extreme environments 
(Romano et al., 2018; Gribble et al., 2015; Antoraz S et al., 2015). The repertoire of NP which 
are isolated from marine ecosystems keeps expanding day by day as researchers around the 
globe/world start to used MGR more and more; together with the increasing visibility and 
benefits of using culture based approaches such as the OSMAC approach on marine strains, to 
facilitate  the discovery of new natural product (NPs) (Romano et al., 2018; Bentley et al., 
2002; Williamson et al., 2006). In this context the work presented here represents to our 
knowledge, the first studies to investigate  a large scale based OSMAC approach involving  3 
different bioactive marine bacterial strains, cultured in 7 different growth media, at 2 different 
temperatures; from which  both organic and aqueous phases extracts were analysed from a 
genomics, metabolomics and chemical perspective. 
Having employed  different OSMAC conditions including different temperatures and different 
nutrient sources, when culturing the bioactive B226SN140 and SM3 isolates, we could clearly 
see that each strain had its own particular metabolome, cluster, and network. It was evident that 
subtle changes in nutrient source or in temperature, even if only involving a difference of 2 
degrees (28-30°C) resulted in quite marked changes to their metabolome. Thus it is clear that 
production of these metabolites is likely to result from the differential regulation of 
transcription of different BGCs encoding these metabolites in both B226SN140 and SM3 under 
different physiological conditions. This is also evident in changes in their molecular networks.  
In addition to revealing the  likely complexity of the  regulation of these metabolites in both 
strains, it is also indicates that OSMAC based approaches may prove to  be useful  in  re-
culturing already cultured strains from existing culture collections, to induce production of  
different sets of metabolites and potentially new ones (Romano et al., 2018; Schwarz et al., 




potential of strains that have already been isolated in many different laboratories, but that are 
likely to possess the potential to produce more and different types of metabolites, by subjecting 
these strains to growth under different sets of physiological parameters.  Such an approach will 
of course be both strain dependant, and parameter dependant, as certain change could result in 
either a higher or reduced number of metabolites being produced. However not withstanding 
this, these approaches involving existing strain collections could  reduce the  need to re-collect 
new samples, thereby saving time and expenses such as  expedition costs,  and also reduce 
barriers that may exist in the future in  sample collection in certain oceanic regions.  However, 
it should also be considered that finding new physiological parameters that induce the 
production of metabolites in specific strains, may also be time consuming.  
 
Streptomyces are good producer of secondary metabolites and bioactive metabolites 
 From all the nutrient sources and temperatures modifications tested, we detected and identified 
a total of 472 metabolites produced by SM3 and B226SN104, including 192 potential new 
metabolites; together with 140 metabolites produced by SM9 including 60 potential new 
metabolites. These  high number of metabolites confirms that these three marine Streptomyces 
strains like other marine Streptomyces strains (Yang et al., 2020) are potent  producers of 
secondary metabolites and that they  are likely to be very promising strains for production of 
potential new metabolites. Further investigations on those potential new metabolites would be 
interesting to pursue, to confirm the potentiality novelty of the metabolites themselves, by 
performing chemical characterization of the metabolites by NMR but based on our evidence to 
date, they do appear to be very promising from a novelty perspective. 
Another interesting finding from the study were the results of using M19 media and 28°C as 




combination of mannitol and peptone present in the culture media when fermented at 28°C 
resulted in an increase in the production of secondary metabolites and of potential new 
metabolites when compared to the other conditions tested, indicating that growth on mannitol 
and peptone at 28°C appear to be the optimal parameters for the production of secondary 
metabolites from the various parameters tested. In contrast for the SM9 isolate, the optimum 
culture conditions to produce the highest number of secondary metabolite including potential 
new metabolites was when the strain was fermented in SYP media at 28°C, while in contrast 
extracts from the strain grown on  SYP  did not result in any interesting activities (Table 4, 
Chapter 3). The extract which showed the best activity results was the organic phase from the 
SM –grown cultures, however this extract did not appear to contain any  potential new 
metabolites. Therefore, for strains such as SM9, the optimum media which promotes the 
production of potentially novel metabolites may be not necessarily be the same media that 
results in promising biological activity. 
Regarding biological activity , this study   also demonstrated that the SM9 strain is  a good 
producer of bioactive secondary metabolites with   both bactericidal and bacteriostatic 
antibacterial activity against S.aureus 6538p and A.baumannii AB13, B.metallica LMG 24068, 
P.aeruginosa PA01, an anti-fungal activity against both C. glabrata CBS138 and C. albicans 
Sc5314. In addition SM9 produced metabolites with  radical scavenging anti-oxidant activity; 
anti-inflammatory activity against the LPS induced TNF-α production in Thp-1 cells and  anti-
cancer activity against the human melanoma cell line A2058, when  cultured in specific 
fermentation parameters, as highlighted in chapter 3.   
 
Overall this study also illustrates that data from different analytical approaches can be 




biological activity, extract phase, chemical weigh, chemical identification, chemical 
prediction; together with genomic characteristics such as the identification of BGCs. This data 
coupled with metabolomics characteristics such as metabolites identification of components of 
the metabolome of the strain can then be used to allow us to visualize all the relationships 
between the data combined together through a molecular network and in this way help to 
facilitate our understanding of the metabolomic and genomic potential of the strain. This allows 
one to ‘zone in’ on a specific research topic (e.g. analysis of specific metabolite and or specific 
metabolite clusters) while at the same time broadening the scope of the research to allow 
exploration of unexpected avenues of interest. 
 
 
Opening potential for metabolomics based prediction of “silent” gene clusters   
The aforementioned multi-field perspective, allows  us to link microbiological culture regime 
conditions to metabolite production, and to couple this to the genomics and chemical diversity 
of the strain; thereby  allowing  us to link metabolites and  chemical diversity involving 
potential BGCs under different culture regimes. Indeed, the annotation of metabolites into the 
molecular network that mapped exclusively to a certain medium, is likely to be  indicative of 
the activation of silent BGCs due to growth of the strain in the varying culture parameters. For 
example, a specific metabolite represented in a single colored node in the metabolomic network 
represent a metabolite only produced following growth under one specific set of conditions, 
such as Cyclo (L-leucyl-L-propyl) metabolite, which was only detected in M19 extract from 
the SM3 isolate (Figure 4a and 4c, Chapter 1); while metabolite represented in a multi-colored 




fermentation process, such as Sarmentoside B which was detected in 5 different media extracts 
from SM3 (Figure 4a and 4b, Chapter1). 
 
 Therefore, the more “shared metabolites” there are among the different media extracts, the  
easier  it is to produce these metabolites. Easy in this context refers to the fact that these 
metabolites  can be produced in different culture regimes or following not specific cultures 
parameters and are thus likely to be commonly produced metabolites and therefore potentially 
less interesting.  In contrast, the more metabolites that are “not shared” or which are specifically 
produced under only one cultural  parameter regime, the more unique they are potentially likely 
to be.  Thus metabolomic based analysis helps to provide a visual hint as to which metabolites 
are likely to be synthetized from a cryptic or “silent” BGCs, allowing us to focus and 
subsequently analyze the hypothetical production of this metabolite; using additional relevant 
genomics analysis  as a confirmatory step. It is important to note that metabolomics predictions 
only provide visual hints that need to be confirmed by supplementary analysis. 
 
In addition, if the metabolite which is present in a metabolite sub network cluster with a high 
cosine score (observable with the thickness of the edge), it also suggests that the metabolites 
in this cluster (including the one you are interested in) may be synthetized by the same 
biosynthetic route (NRPS, PKS, or others). This is the case in our chapter 1 with the SM3 
metabolome investigation revealing the presence of a specific metabolite cluster of 7 unique 
metabolites with a high cosine score, all of which were only present when the strain is cultured 






 Reducing time of “time-consuming” analysis  
Both chemical analysis (LC-MS, manual de-replication) and genomic analysis (genome 
mining, AntiSMASH,) can be very time-consuming, since chemical analysis requires the 
analysis of a mixture of thousands of metabolites or more,  while  genomics based analysis 
requires the investigation  of thousands of genes from several genomic regions. Both fields can 
therefore benefit from an overall time perspective from the use of metabolomics based analysis.  
Indeed, employing metabolomics based approaches greatly increases the efficiency of the 
discovery process by allowing the detection of the vast majority of the metabolites present in a 
mixture prior to the manual dereplication and helps in the identification of some of these 
metabolites by comparing their chemical profile simultaneously using several libraries. Instead 
of conducting experiments on thousands of metabolites by LC-MS, to attempt to identify all 
the detected metabolites one by one using manual dereplication and then identify the interesting 
ones; metabolomics analysis allows us to predict metabolites as interesting compounds, in a 
much shorter time frame; because they can be identified prior to manual dereplication as a 
result of the libraries comparisons. Manual dereplication can then be conducted by focusing 
primarily on the interesting metabolites, as opposed to having to consider all the metabolites in 
the sample.  
Manual dereplication is by far the most time consuming component of the chemical analysis 
of extracts from bacterial cultures, because it is not yet clear what is precisely being looked for 
in the sample, which means that everything requires analysis. However by employing 
metabolomic analysis, it becomes be clearer what specific metabolite was being targeted or 
conversely what not to target if the metabolite is already a known one; and then redirect the 




Of course metabolomics based analysis as  with bioinformatic analysis is also time consuming,  
but comparing the time of metabolomics analysis with the manual dereplication targeting  
specific metabolites of  interest, to the time involved in the manual dereplication time of 
potentially  thousands of metabolites present in a which has not been subjected to  metabolomic 
analysis, is vastly different.    
From a genomics perspective, metabolomics analysis allows for a more focused in-depth 
analysis and also increases the efficiency in metabolite identification, as it is allows more time 
to be spent in connecting metabolites to the genomic regions clusters from which they are likely 
to be produced. This was the case in Chapter 2, with Antimycin A1 being linked to a NRPS 
region; Desferrioxamine B and Desferrioxamine E being linked to a siderophore region and 





Employing both genomics and metabolomics together should be standard practice in 
drug discovery 
While data from both metabolomics and genomics are only “predictions”, the use of both sets 
of predictions together can offer a more accurate overall assessment of the likelihood of 
identifying novel metabolites, thereby reducing the instances of identification of previously 
identified and well characterised natural products, resulting in a reduction in resources and 




The data from this study clearly shows the benefits of using both genomics and metabolomics 
together in the discovery of natural products; indicating that this should perhaps become 
standard practice. Many laboratories favour using either genomics or metabolomics based 
approaches for natural product discovery, but the time involved could be drastically reduced if 
both were employed simultaneously.  
 
The advantages of bioactivity mapping 
As previously mentioned, the optimal conditions for bacteria to produce potential new 
metabolites may not be the same as the optimal conditions required for them to produce 
metabolites which are bioactive. In general, in drug discovery research, there are usually two 
approaches  that  researchers employ : one is to focus  on biological activities to ensure that 
metabolites that are discovered exhibit the desired bioactivity, but in many cases, this results 
in uncovering a new activity from  an already known compound (Firsova et al., 2017; Jakubiec-
Krzesniak et al., 2018; Romano et al., 2018). The second and opposite approach, is to focus on 
the discovery of novel metabolites, which unfortunately in many instances results in the 
identification of new metabolites but which do not display the desired bioactivity.   
However, in this study, we were able to overcome these limitations and generated a far greater 
list of potential new bioactive metabolites than is typically reported (Romano et al., 2018;  
Pullen et al., 2002; Nothias et al, 2018) by elucidating both biological activity and novelty in 
parallel. This allowed us to not only, determine   which conditions  promoted the discovery of  
potential new metabolites and separately, which conditions  promoted  the production of 
biological activity in  our isolates, (with of course taking into account the proviso that NMR 
analysis will be required to  confirm the novelty of these metabolite); but also, to  visualize 




together in one picture through bioactivity mapping. This visual mapping allowed us to 
highlight which of the metabolites had high bioactivity scores and which one has not been 
identified by comparison within the GNPS libraries, which, were therefore more interesting for 
us on further analyse.  This was evident in Chapter 3 with the bioactivity mapping of the anti-
fungal activity against C. glabrata CBS138, which highlighted two promising molecules which 
showed bioactivity scores of 60% and 64% of bioactivity respectively, together with one 
bioactive cluster.  
 
In addition, we expanded upon the approach routinely used in  previous studies on  bioactivity 
mapping by analysing three different bioactivities simultaneously (antifungal, anti-
inflammatory and anti-cancer), as opposed to focusing on one activity  alone which is  typical 
of similar types of studies (Nothias et al, 2018). To our knowledge, this is one of the first 
studies  to maps several different bioactivities to one metabolome using molecular networks, 
offering a template by which to greatly expand upon and exploit future large-scale molecular 
networks for novel bioactive compounds.  
Furthermore, by linking LC-MS data to bioactivity mapping, we were able to predict potential 
novel bioactive metabolites within molecular networks with greater certainty and refine the 
pool of potential candidates for analysis. For example, combining anti-cancer activity of the 
human melanoma cell line, A2058, to [M+H]+ mass data (generated by LC-MS) highlighted 
one bioactive cluster of interest containing 13 bioactive molecules (out of a total of 177 
metabolites) with bioactivity scores ranged from 60% to 89% of bioactivity, including two  that 
are potentially new metabolites. With that, the total pool of candidates identified through three 
bioactivity mappings reduced the pool of potential candidates for analysis from 117 to 19; 




for example, contained [M+H] + data that mapped to previously identified compounds such as 
Desferrioxamine E. Some other candidate also showed double activity, such as  for example, 1 
of the 19 interesting molecules of interest showed 60%  bioactivity against the human 
melanoma cancer cell line A2058  and 88% of anti-inflammatory activity against the LPS 
induced TNF-α production in Thp-1 cells (Chapter 3). 
Therefore, the approach applied in this study can offer greater clarity when identifying potential 
novel candidates for analysis and when identifying bioactive candidates, thereby greatly 
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May 2018: Creation of Marpipe’s flyer. Eight countries & eleven partners: improving the flow 
in the pipeline of the next generation of marine bio-discovery scientists. 
2017-2020: Working alongside the others ESRs for updating the Marpipe Facebook and 
Marpipe Twitter accounts. 
2017-2020: International networking activities and talks at international conferences, 
workshops and meetings. 
 
PhD progress meeting communications 
 
University College Cork:  
April 2017-2020: Several Lab meetings with 10 min oral presentations, UCC, Cork, Ireland. 
December 2017: UCC Annual poster session, UCC, Cork, Ireland, December 05, 2017. 
December 2019: UCC Annual poster session, UCC, Cork, Ireland, December 02, 2019.  
 
Marine Biodiscovery centre, University of Aberdeen: 






October 2017: PhD progress meeting 1 – KU Leuven, Leuven (Belgium). 
May 2018: PhD progress meeting 2 – CNR, Naples (Italia). 
October 2018: Marpipe Midterm review – Brussel (Belgium). 
February 2019: PhD progress meeting 3 – UiT, Tromsø (Norway). 
December 2019: PhD progress meeting 4 – SZN, Naples (Italia). 
 
Short technical or scientific courses 
 
Short scientific course: Zebrafish as an in vivo model for safety assessment of drugs. KU 
Leuven, Leuven, Belgium. October 16-19, 2017. 
Short technical course: Scientific communication and grant proposal writing. CNR, Naples, 
Italy. May 8-10, 2018. 
Short scientific course: Organic structure elucidation, Fundacion MEDINA, Granada, Spain. 
December 10-11, 2018. 
BIOPROSP_19 pre-workshop: Marine biotech entrepreneurship: Capturing the value of 
scientific results, University of Tromso, Tromsø, Norway. February 25, 2019. 
Short scientific and technical course: Bioinformatics workshop, MG-RAST Practical. 






Demonstration activities  
 
As part of UCC, I did some demonstrations to Bachelor’s students, during my second year of 
PhD in 2018. I demonstrated MB2006 and ML2001 modules with specific sessions involving 
the following topics: Minimal Inhibitory Concentration, Nitrate and Nitrification; 




2019: University of Tromso, Marbio facilities – anticancer and anti-inflammatory assays have 
been performed on all the OSMAC crude extracts - performed by the technicians Kirsti Helland 
and Marte Albrigtsen. 
2020: University of Leuven – for toxicity assays on the fractions of the SM9-M19 crude extract 
– performed by ESR6 Arianna Guisti. 
2020: University of Tromso - LC-MS/MS analysis on the fractions – performed by ESR3 
Yannik Schneider. 
 
International secondments:  
 
As part of the EU MSCA Horizon 2020 MarPipe ESR Programme, I was required to spend 
several secondments at academic institutions partners and/or industrial partners. As this is an 
International Training Network (ITN), the goal for spending several secondments abroad is to 
acquire as much transferable knowledge and skills as possible during the PhD study, but also 




with different nationalities. My ESR project, namely ESR7, required me to do 3 secondment 
abroad for a total length of 6 to 7 months flexible abroad out of 36 months of my PhD. 
  
I went to my first MarPipe ESR secondment to the Marine Biodiscovery Centre, at the 
University of Aberdeen, in Scotland (UK) to learn about LC-MS/MS experiments and analysis. 
The goal of this secondment was for me to perform LC-MS/MS analysis on all my crude 
extracts samples, including both organic phase and aqueous phases from the following isolate: 
B226SN104, SM9, SM3, SM18 and B188M101; to analyses and process the data of all the 
crude extracts using manual de-replication. During this secondment, I was under the 
supervision of Prof. Marcel Jaspars, Dr. Rainer Ebel and ESR4 Antigoni Kyritsi. This 
secondment was for a duration of 5 months (one month in July 2018 for most of the LC-MS/MS 
experiments, then from September to December 2018 for the remaining lab experiments and 
the learning of the processing data using manual de-replication). In addition, this secondment 
allowed me to develop contacts with scientists in chemistry and metabolomics who provided 
me with the tools and support I needed to conduct metabolomics analysis when I returned to 
UCC. 
 
For my second MarPipe ESR secondment, I went to the ABS-int in Bruges (Belgium) with all 
the other ESRs to learn about Marine biotechnology entrepreneurship, Biosafety regulations 
and Intellectual property. The goal of the secondment was to familiarize all the ESRs with the 
non-scientific aspects of the marine biodiscovery value chain related to entrepreneurship, law 
and policy. The following key topics were given: commercialisation of scientific results; 
creation of business models and business plans; pitching, communication and presentations; 




secondment, we all gained valuable knowledge and experience in terms of how to valorise our 
scientific research, as well as, how to create our own business. During this secondment, I was 
under the supervision of Dr. Thomas Vanagt and ESR8 Jane Eva Collins. The duration of this 
secondment was 7 days in Bruges, Belgium. 
 
For my third and last MarPipe ESR secondment, I went to the Consiligo Nazionale Delle 
Ricerche, Institute of Protein Biochemistry (IBP-CNR), at Napoli (Italia) to learn about liquid 
inhibition assays, anti-biofilm assays and SPE fractionation. The goal of this secondment was 
for me to perform liquid inhibition assays, anti-biofilms assays and SPE fractionation. During 
this secondment I was under the supervision of Donatella De Pascale and ESR1 Grant January, 
for a duration of one month (December 2019). 
 
Overall, my secondment experiences were very beneficial to me, both in terms of their 
relevance to my scientific studies, but also to my own personal growth and development. In 
terms of the scientific project itself, by giving me new viewpoints and perspectives outside of 
those I had as a microbiologist I was able to adopt new strategies to overcome difficulties or 
obtain new understanding.  Furthermore, I obtained scientific transferable skills such as 
chemical analysis, metabolomics, entrepreneurship, biosafety regulation and intellectual 
property skills, as further development of my microbiological skills e.g. via the liquid 
inhibition, antioxidant, and anti-biofilm assays. In addition, my PhD-ESR in UCC, the 
secondments and the Marpipe progress meeting allowed to develop my skills of working on 
international multi-culture environments. 
There is a huge bridge between the starting position as the ‘PhD student’, who often is 




discovering and learning about their projects, and the destination of the ‘PhD expert’ who is 
capable of investigating their own research independently, following their own knowledge, 
research, background and expertise. I feel this is similar to the bridge between a teenager and 
a full adult. Instead of being simply a PhD student but also an ESR professional employee, I 
was given a greater sense of independence, thus making it easier to follow my scientific 
intuition. Furthermore, the secondments really helped me in the evolution of my scientific 
knowledge and expertise. Thanks to these, I feel like I have been able to cross the bridge from 
student to expert – I am really grateful to have been able to benefit from it. This carries into 
my development as a human being, since I was allowed to develop my adaptation skills with 
























Supplementary figure 1 need to be read together with supplementary table 1, same for 
supplementary figure 2 to 10, with supplementary table 2 to 10. 
 
Supplementary Figure 1: Chromatograms from LC-MS analysis of the aqueous phase crude 
extract samples from SM3 when fermented at 28°C in seven media (M19, M400, MMM, OM, 





Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Colour code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 






Supplementary Figure 2: Chromatograms from LC-MS analysis of the organic crude extract 
samples from SM3 when fermented at 28°C in seven media (M19, M400, MMM, OM, SGG, SM 
and SYP). 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 















Supplementary Figure 3: Chromatograms from LC-MS analysis of the aqueous phase crude 
extract samples from SM3 when fermented at 30°C in seven media (M19, M400, MMM, OM, 
SGG, SM and SYP). 
 
 Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 
















Supplementary Figure 4: Chromatograms from LC-MS analysis of the organic phase crude 
extract samples from SM3 when fermented at 30°C in seven media (M19, M400, MMM, OM, 
SGG, SM and SYP). 
 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 














Supplementary Figure 5: Chromatograms from LC-MS analysis of the organic phase crude 
extract samples from B226SN104 when fermented at 28°C in seven media (M19, M400, MMM, 
OM, SGG, SM and SYP). 
 Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 








Supplementary Figure 6: Chromatograms from LC-MS analysis of the aqueous phase crude 
extract samples from B226SN104 when fermented at 28°C in seven media (M19, M400, MMM, 
OM, SGG, SM and SYP). 
 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 







Supplementary Figure 7: Chromatograms from LC-MS analysis of the organic phase crude 
extract samples from B226SN104 when fermented at 30°C in seven media (M19, M400, MMM, 
OM, SGG, SM and SYP). 
 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 







Supplementary Figure 8: Chromatograms from LC-MS analysis of the aqueous phase crude 
extract samples from B226SN104 – when fermented at 30°C in seven media (M19, M400, MMM, 
OM, SGG, SM and SYP. 
 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 








Supplementary Figure 9:  Chromatograms from LC-MS analysis of the aqueous phase crude 
extract samples from SM9 when fermented at 28°C in seven media (M19, M400, MMM, OM, 
SGG, SM and SYP). 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 






Supplementary Figure 10: Chromatograms from LC-MS analysis of the organic phase crude 
extract samples from SM9 when fermented at 28°C in seven media (M19, M400, MMM, OM, 
SGG, SM and SYP). 
 
Polar compounds elute in the beginning of the run, while moving towards the end of the run (10 min) 
we observe more hydrophobic compounds. Anything after 10min comes from flushing the column, so 
these are not considered real peaks. Color code: M19 pink, M400 blue, MMM yellow, OM gree, SGG 









Supplementary Figure 11: Gene details from the desferrioxamine gene cluster identified by AntiSMASH, 













ChemSpider ID, AntiBase ID, 






0.6 625.1592 C21H24N10O13 no hit 
1.0 553.2621 C24H36N6O9 23194934 
1.1 585.3181 C20H48N4O15 no hit 
  C20H48N4O16 no hit 
1.3 428.1229 C17H35NO11 no hit 
1.4 401.2030 C17H28N4O7 16600422 
   16634341 
   16577693 
1.8 627.3282 C22H51N4O16 no hit 
2.3 561.2786 C24H40N4O11 4470667 
5.1 387.1811 C23H22N4O2 12227 
7.9 403.2317 C17H26N10O2 no hit 







0.6 456.2078 C18H33NO12 8632101 
1.1 585.3181 C20H48N4O16 no hit 
1.6 513.3761 C25H48N6O5 no hit 
1.8 625.3142 C14H31N27O3 no hit 
5.1 387.1808 C22H26O6 54 
7.8 403.2325 C20H34O8 8891446 







0.6 456.2078 C18H33NO12 8632101 
1.1 585.3186 C21H44N8O11 no hit 
1.6 611.2979 C22H42N8O12 no hit 
1.7 455.2143 C20H30N4O8 116946 
1.8 625.3131 C22H48N4O16 no hit 
2.1 397.2086 C12H23N13O3 no hit 
2.5 496.2767 C23H37N5O7 16700487 
5.1 387.1808 C22H26O6 54 











0.4 505.1756 C15H24N10O10 no hit 
  C18H32O16 164804 
3.0 821.4400 C36H48N22O2 no hit 
  C53H68N28O8 no hit 
3.9 1225.5876 C59H84N8O20 no hit 
4.0 1063.5327 C50H66N18O9 no hit 
5.1 387.1808 C22H26O6 
54 
8322 
7.8 403.2325 C20H34O8 8891446 
9.1 683.5551 C35H70N8O5 no hit 







1.1 585.3179 C32H44N2O8 10 substances possible 
1.6 611.2975 C21H46N4O16 no hit 
1.8 625.3131 C22H48N4O16 no hit 
5.1 387.1811 C23H22N4O2 12227 
7.8 403.2325 C20H34O8 8891446 







0.4 373.1174 C6H16N10O9 no hit 
2.3 417.1185 C22H16N4O5 2627683 
   2655868 
   3118415 
5.1 387.1811 C23H22N4O2 12227 
7.8 403.2325 C20H34O8 8891446 
9.2 683.5574 C39H74N2O7 8007098 







0.5 436.1441 C14H17N11O6 no hit 
1.1 585.2506 C24H36N6O11 no hit 
5.1 387.1811 C23H22N4O2 12227 
7.8 403.2325 C20H34O8 8891446 
10 391.2844 C24H38O4 6950 




Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 
real interest. SM3.1 samples represent the SM3 samples which were fermented at 28°C, while 
SM3.2 represent the SM3 samples which were fermented at 30°C. For the interpretation of the 
MS data a lot of different libraries were used, like Chemspider, Antibase, Dictionary of Natural 
Products, Reaxys etc. Some masses didn’t give any hits when searched on these databases, 









ChemSpider ID, AntiBase ID, 






1.6 261.1235 C14H16N2O3 179735 
2.2 211.1446 C11H18N2O2 994 
 421.2812 C22H36N4O4 
7338 
 39374 




3.2 202.1808 C11H23NO2 35106 
3.5 216.196 C12H25NO2 907502 
3.7 249.0703 C20H8 no hit 
  C5H4N12O no hit 
4.1 425.3114 C21H44O8 no hit 
4.6 483.3531 C24H50O9 no hit 
  C25H46N4O5 no hit 
5.1 387.1811 C22H26O6 
54 
8322  
5.4 616.4635 C31H61N5O7 no hit 
  C30H65NO11 no hit 
5.9 674.5038 C34H67N5O8 9171191 
  C33H71NO12 no hit 
6.2 732.5464 C34H65N15O3 no hit 
  C36H77NO13 no hit 
6.7 790.5875 C40H79N5O10 no hit 
7.0 Common impurities 
7.8 403.2321 C24H38O4 11575 










0.6 456.2078 C18H33NO12 9628696 
1.1 585.3190 C21H44N8O11 no hit 
1.8 625.3137 C23H44N8O12 no hit 
  C22H48N4O16 no hit 
5.1 387.1808 C22H26O6 54 
  C23H22N4O2 12227 
7.8 403.2336 C21H30N4O4 no hit 
  C24H38O4 11575 






0.6 474.2183 C19H31N5O9 16605691 
1.1 585. 3187 C21H44N8O11 no hit 
1.6 261.1237 C14H16N2O3 179735 
1.7 455.2141 C20H30N4O8 116946 
1.8 625.3139 C20H36N18O6 no hit 
5.1 387.1811 C22H26O6 54  
  C23H22N4O2 12227 
7.8 403.2336 C24H38O4 11575 






0.4 667.2284 C24H42O21 82582 
5.1 387.1804 C22H26O6 8322 
  C23H22N4O2 12227 
7.8 403.2323 C24H38O4 11575 






1.1 585.3189 C21H44N8O11 no hit 
1.8 625.3132 C23H44N8O12 no hit 
  C22H48N4O16 no hit 
3.0 445.2322 C24H32N2O6 2269889 
4.9 655.2764 C36H38N4O8 411552 
5.1 387.1799 C22H26O6 54  
  C23H22N4O2 12227 
7.8 403.2336 C21H30N4O4 no hit 
  C24H38O4 11575 
     








2.6 433.1132 C21H20O10 4444098 
4.3 353.2305 C20H32O5 4557 
 683.4704 C34H62N6O8 no hit 
4.9 943.5263 C48H78O18 108898 
7.8 403.2323 C24H38O4 11575 






0.6 456.2078 C18H33NO12 9628696 
0.8 490.1922 C17H27N7O10 16593356 
  C21H31NO12 no hit 
  C22H27N5O8 no hit 
1.8 462.1606 C25H18N8O2 2065860 
5.0 409.1623 C20H20N6O4 6170831 
7.8  Common impurities 
Supplementary Table 2: MS data for SM3.1 organic phase crude extracts. 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 













ChemSpider ID, AntiBase ID, 






1.1 439.2960 C27H38N2O3 407513 
2.7 579.2935 C30H38N6O6 16599024 
3.0 421.2238 C9H24N16O4 No hit 
 438.3793 C23H51NO6 no hit 




  C21H30N4O4 No hit 
3.9 424.2828 C19H24N10O2 2395726 
  C22H32O8 9157986 
4.0 384.1947 C23H45NO3 no hit 
  C10H25N9O7 no hit 
  C26H25NO2 no hit 
4.5 465.2767 C22H41NO9 18738112 
  C28H36N2O4 no hit 
  C29H32N6 no hit 
4.9 391.2844 C24H38O4 6950 
6.5 663.4521 C24H65N5O15 no hit 
  C44H58N2O3 No hit 
6.9 750.4056 C8H3NO40 no hit 
  C52H51N3O2 No hit 
7.5 430.9133 C4H2N2O22 No hit 







4.7 387.1799 C22H26O6 54/8322/8324 
6.8 403.3237 C20H34O8 2849784 
7.6 384.1923 C21H25N3O4 36313 







1.7 547.2975 C24H42N4O10 17462342 
 836.4030 C38H57N7O14 6382 




2.6 692.3500 C33H49N5O11 9357029 
4.7 387.1799 C22H26O6 54 
8.1 465.2757 C20H49N7O5 no hit 







4.8 387.1805 C23H22N4O2 2248451 
6.8 403.3237 C20H34O8 2849784 
7.6 384.1923 C21H25N3O4 36313 
8.1 465.2765 C29H32N6 no hit 
  C11H29N17O4 no hit 







4.7 387.1799 C22H26O6 54/8322/8324 
6.8 403.3237 C20H34O8 2849784 
7.6 384.1923 C21H25N3O4 36313 







8.1 465.2778 C29H32N6 no hit 
  C33H36O2 no hit 










4.8 387.1805 C23H22N4O2 2248451 
6.8 403.3237 C20H34O8 2849784 
7.6 384.1923 C21H25N3O4 36313 
8.1 465.2765 C29H32N6 no hit 
  C33H36O2 no hit 
8.5 391.2844 C24H38O4 6950 
7.6 424.282 C23H39NO6 no hit 
Supplementary Table 3: MS data for SM3.2 aqueous phase crude extracts. 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 
real interest. SM3.1 samples represent the SM3 samples which were fermented at 28°C, while 
SM3.2 represent the SM3 samples which were fermented at 30°C. For the interpretation of the 
MS data a lot of different libraries were used, like Chemspider, Antibase, Dictionary of Natural 
Products, Reaxys etc. Some masses didn’t give any hits when searched on these databases, 










ChemSpider ID, AntiBase ID, 













0.8 582.3246 C27H40N11O4 no hit 






2.6 530.2975 C27H39N5O6 65259724 
4.7 387.1807 C22H26O6 54 
8.2 665.5816 C40H76N2O5 no hit 







0.5 409.1815 C16H28N2O10 4451032 
1.4 490.2765 C22H39N3O9 21387440 
1.5 261.1236 C14H16N2O3 179735 
4.7 387.1807 C22H26O6 54 














4.7 387.1807 C22H26O6 54 
6.8 403.2331 C20H34O8 11575 










2.1 417.1185 C21H20O9 4445119 







2.8 821.4384 C37H64N4O16 no hit 
Supplementary Table 4: MS data for SM3.2 organic phase crude extracts 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 









ChemSpider ID, AntiBase ID, 






1.3 395.1365 C20H18N2O3 no hit 
1.4 443.2143 C19H30N4O8 23169586 
1.5 261.1243 C14H16N2O3 179735 
1.6 521.2398 C28H32N4O6 
899298 
 3510615 
2.0 284.1965 C14H24N3O3 no hit 
2.1 211.1444 C11H18N2O2 499509 
2.2 421.2813 C22H36N4O4 8223339 




2.5 245.1288 C14H16N2O2 283250 
2.6 425.1315 C18H16N8O5 no hit 
  C17H20N4O9 no hit 
3.0 301.2489 C16H32N2O3 no hit 
3.4 201.1481 C11H20O3 30297 
3.5 391.1867 C20H26N2O6 574365 
3.7 410.2759 C19H39NO8 no hit 
4.0 425.3115 C21H44O8 2546847 
4.1 485.3445 C22H48N2O9 
no hit 
4.5 483.3529 C18H45N9O6 
no hit 
4.7 498.364 C24H53NO9 no hit 
4.9 541.395 C27H56O10 21989361 
  C28H52N4O6 68006955 
5.0 387.1804 C22H26O6 1937152 
  C23H22N4O6 1314876 
5.2 556.4053 C20H54N6O11 no hit 
5.4 376.2595 C21H33N3O3 
6338385 
 3519209 
5.8 657.4771 C33H68O12 
no hit 





6.4 730.5307 C34H71N9O8 
no hit 
  C33H75N5O12 
no hit 
6.6 811.5167 C39H74N2O15 
no hit 
6.8 788.5724 C35H79N7O12 
no hit 
7.0 528.3931 C18H53N7O10 
no hit 
7.3 906.6712 C46H91N5O12 no hit 
7.7 491.3744 C16H42N16O2 no hit 
8.0 546.4882 C35H63NO3 
59702300 
9988241 
8.5 673.4958 C31H68N4O11 
no hit 
  C29H10N2O18 
no hit 
8.8 702.5191 C25H59N21O3 
no hit 
9.0 421.178 C25H20N6O 
no hit 
9.1 734.0166 C34H11N3O17 
 no hit 
9.4 760.5591 C27H69N17O8 no hit 
9.7 789.5803 C38H76N8O9 no hit 
9.9/1.0 821.0798 C30H12N16O14 no hit 






1.0 450.1985 C20H27N5O7 
16702834 
 16718017 





1.3 712.2767 C28H45N3O18 170050 
1.5 261.1243 C14H16N2 O3 179735 
1.7 521.2394 C28H32N4O6 
2111100 
2141713 
1.9 561.2386 C22H40O16 4450543 
2.0 418.1729 C19H23N5O6 29402336 
2.1 211.1444 C11H18N2O2 499509 
2.2 421.2813 C22H36 N4O4 8223339 
2.6 425.1315 C18H16N8O5 no hit 
  C17H20N4O9 no hit 
2.8 398.1498 C24H19N3O3 42172 
3.0 301.2489 C16H32N2O3 no hit 
3.3 852.5100 C45H73NO14 6273 
5.0 387.1804 C23H22N4O6 1314876 
8.7 788.6101 C40H85NO13 no hit 
9.0 846.6503 C40H83N11O8 no hit 
9.4 904.6909 C42H93N7O13 no hit 
9.6 492.8637 C34H50O2 34949611 











1.5-1.7 521.2394 C28H32N4O6 
2111100  
2141713 
2.0 427.2555 C20H34N4O6 16654556 
2.3 245.1286 C14H16N2O2 90257 
2.5 245.1286 C14H16N2O3 90257 
2.8 398.1497 C17H18N8O4 35007911 
2.8 398.1498 C24H19N3O3 42172 
5.0 387.1803 C22H26O6 1937152 
8.7 788.6101 C41H81N5O9 no hit 
9.0 421.1792 C29H24O3 no hit 
9.4 904.6909 C42H93N7O13 no hit 







5.0 187.1801 C22H26O6 1937152 
8.0 546.4882 C35H63NO3 59702300 







1.5 261.1232 C14H16N2O3 179735 
1.7 521.2394 C28H32N4O6 
2111100 
2141713 
2.2 211. 1441 C11H18N2O2 499509 
2.6 447.1139 C10H20N6O14 no hit 




3.0 445.2334 C24H32N2O6 
2269889 
3289647 
3.7 440.1603 C19H20N8O5 32237821 
4.0 425.3115 C21H44O8 2546847 
  C22H40N4O4 9445222 
4.2 485.3445 C22H48N2O9 
no hit 
4.5 483.353 C24H50O9 
no hit 
  C25H46N4O5 
no hit 
4.7 498.364 C24H53NO9 no hit 
4.9 541.395 C27H56O10 21989361 
  C28H52N4O6 68006955 
5.0 558.4214 C27H59NO10 no hit 
5.1 387.1804 C22H26O6 1937152 
5.4 511.2805 C17H42N4O13 
no hit 
5.6 614.4474 C26H61N7O9 no hit 
5.8 657.4771 C33H68O12 
no hit 
6.0 600.4318 C29H61NO11 no hit 
6.2 737.5013 C34H68N6O11 
no hit 
6.4 730.5304 C31H77N3O15 no hit 





7.0 848.6299 C42H89NO15 no hit 
 1038.7503 C47H103N7O17 
no hit 
7.3 906.6712 C46H91N5O12 no hit 
7.7 491.3744 C24H45N9O2 
no hit 
8.0 546.4882 C35H63NO3 
59702300 
9988241 
8.5 673.4958 C31H68N4O11 
no hit 
  C29H10N2O18 
no hit 
8.7 788.6101 C41H81N5O9 no hit 
8.8 702.5191 C24H63N17O17 
no hit 
8.9 421.178 C9H26N8O11 
no hit 
9.1 846.653 C43H91NO14 
no hit 
9.4 904.6909 C42H93N7O13 no hit 








2.6 273.1707 C14H24O5 9175388 
2.8 398.1498 C24H19N3O3 42172 
3.3 531.1056 C28H14N6O6 no hit 
3.4 285.0762 C16H12O5 
26775 
20493 
 569.1439 C32H24O10 8501123 




3.9 507.1076 C31H14N4O4 no hit 
4.1 537.1182 C31H20O9 4479074 
4.3 523.1023 C30H18O9 8003853 
4.5 583.1227 C32H22O11 4477713 
4.7 523.1027 C30H18O9 26371101 
4.8 507.1081 C31H14N4O4 no hit 
5.0 387.1804 C22H26O6 1937152 
5.2 523.1023 C30H18O9 8003853 







1.4 734.2583 C38H35N7O9 no hit 
1.6 261.1235 C14H16N2O3 179735 
1.9 256.2395 C13H33N15O10 no hit 
  C28H37N3O9 34973344 
2.5 245.1288 C14H16N2O2 283250 
2.6 213.0697 C5H12N2O7 no hit 
2.8 398.1498 C24H19N3O3 42172 
3.3 852.5100 C45H73NO14 6273 
5.0 387.1804 C22H26O6 1937152 




8.0 546.4882 C35H63NO3 
59702300 
9988241 
Supplementary Table 5: MS data for B226SN104.1 organic phase crude extracts 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 
real interest. B226SN104.1 samples represent the B226SN104 samples which were fermented 












ChemSpider ID, AntiBase ID, 






1.1 712.2759 C28H45N3O18 170050 
1.2 712.2762 C26H33N17O8 No hit 
1.4 445.2312 C19H32N4O8 
16603920 
16603958 
1.5 413.1421 C15H20N6O8 141829 
1.7 443.2509 C18H35NO11 8798386 
1.8 394.1714 C19H25N3O6 
3972975 
2.1 414.1251 C18H22O11 8963229 
2.9 574.3604 C30H47N5O6 410355 








7.7 403.2300 C17H27N10O2 
No hit 










1.1 712.2759 C28H45N3O18 170050 
1.5 413.1409 C15H20N6O8 141829 
1.8 434.213 C18H31N3O9 25167892 
1.9 394.1735 C19H32N4O5 16653742 
2.1 425.1254 C20H30N8O2 58248827 
2.3 457.229 C20H32N4O8 
23219440 
4.1 471.3178 C23H42N4O6 
28586695 
57535380 
4.8 655.2753 C35H39N5O8 17252939 
5.0 387.1802 C22H26O6 
54 
5.5 1107.0504 C29H78N20O25 
No hit 
7.1 579.2924 C30H38N6O6 166902 
7.2 301.1408 C14H16N6O2 No hit 



















1.2 505.2144 C20H32N4O11 16617301 




1.5 500.2358 C21H33N5O9 61710562 
1.8 394.1714 C19H25N3O6 
3972975 
1.9 578.2655 C20H31N15O6 
No hit 
2.0 427.2553 C20H34N4O6 
16693511 
2.2 402.2026 C21H27N3O5 
1198691 
2.3 457.229 C20H32N4O8 
23219440 




7.2 301.1408 C14H16N6O2 No hit 
7.8 403.2333 C21H30N4O4 No hit 










1.1 712.2760 C24H41N9O16 28573801 
1.2 412.1836 C17H25N5O7 8607171 
1.3 394.1717 C16H27NO10 26585174 
1.5 413.1403 C14H24N2O12 No hit 
3.8 1242.6119 C59H87N9O20 
No hit 





4.0 901.4784 C42H64N10O12 No hit 
  C45H72O18 354002 




7.2 301.1408 C14H16N6O2 No hit 














1.1 712.2759 C28H45N3O18 170050 
1.1-1.2 712.2745 C24H41N9O16 28573801 
1.5 413.1403 C14H24N2O12 no hit 
1.8 434.213 C18H31N3O9 25167892 
1.9 394.1437 C12H25N7O8 
no hit 
2.1 442.2699 C25H35N3O4 8496558 
4.1 471.3178 C23H42N4O6 
28586695 
57535380 
5.0 387.1802 C22H26O6 
54 
8324 
6.5 507.2288 C32H30N2O4 
1293 
1800 
7.2 301.1408 C14H16N6O2 no hit 










1.1 712.2759 C28H45N3O18 170050 
1.4 445.2304 C19H32N4O8 
16603920 
16603958 
1.5 413.1419 C8H19N11O9 no hit 
1.8 434.213 C18H31N3O9  25167892 











1.1 712.2759 C28H45N3O18 170050 
1.5 413.1421 C15H20N6O8 141829 
2.3 461.2769 C24H36N4O5 2598026 




7.2 301.1408 C14H16N6O2 no hit 
Supplementary Table 6: MS data for B226SN104.1 aqueous phase crude extracts 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 















ChemSpider ID, AntiBase ID, 






0.5 429.1572 C12H24N6O11 no hit 
1.3 712.2769 C28H45N3O18 196239 
5.0 387.1811 C23H22N4O2 12227 
7.1 317.1154 C17H12N6O 
no hit 
 579.2922 C30H38N6O6 no hit 




9.2 384.8468 C23H45NO3 41519 
9.6 465.2799 C16H34N8O8 no hit 







0.5 404.1926 C19H25N5O5 3215137 
0.8 533.1472 C26H34N2O10 9845760 
1.1 712.2769 C28H45N3O18 196239 
1.2 412.1833 C17H25N5O7 8607171 
1.3 712.2757 C25H37N13O12 no hit 
1.6 413.1416 C15H20N6O8 19989181 
1.7 625.3131 C22H48N4O16 no hit 




1.8 403.178 C16H21N9O4 34512811 
2.1 211.1444 C11H18N2O2 2298456 
2.4 245.1288 C14H16N2O2 422943 
2.5 235.0516 C11H9NO5 31422 
2.7 398.1502 C24H19N3O3 42172 
2.9 301.2482 C16H32N2O3 no hit 
3.3 852.5106 C45H73NO14 no hit 
5.0 387.1811 C23H22N4O2 12227 
7.1 579.2922 C30H38N6O6 no hit 











0.5 404.1926 C19H25N5O5 3215137 
1.2 712.2769 C28H45N3O18 196239 
1.3 712.2757 C25H37N13O12 no hit 
1.5 261.1237 C14H16N2O3 179735 
1.8 547.298 C24H42N4O10 2794750 
1.9 578.2652 C22H43NO16 no hit 









2.4 245.1288 C14H16N2O2 422943 
2.7 398.1496 C24H19N3O3 42172 





7.1 317.1154 C17H12N6O no hit 
7.8 403.2317 C17H26N10O3 no hit 







0.4 505.1775 C18H32O16 168531 
1.2 712.2769 C28H45N3O18 196239 





1.5 413.1416 C15H20N6O8 19989181 
2.7 398.1502 C24H19N3O3 42172 
4.2 739.4253 C36H54N10O7 57535864 
4.5 787.4269 C43H62O13 
23249159 
4.9 739.4265 C39H62O13 
9472139 








5.5 387.1946 C22H26O3 no hit 
5.6 781.4366 C39H52N14O4 no hit 
5.7 770.4459 C43H63NO11 no hit 
6.2 723.4309 C31H65NO17 no hit 
  C29H53N15O7 9518027 
7.1 317.1154 C17H12N6O no hit 
7.7 407.3356 C21H43N7O no hit 
7.8 403.2317 C17H26N10O3 no hit 
7.9 546.4877 C35H63NO3 9988241 
8.9 654.3305 C28H41N13O6 no hit 







0.8 533.1463 C17H28N2O7 no hit 
1.2 412.1833 C17H25N5O7 8607171 
1.5 261.1237 C14H16N2O3 179735 
1.8 403.1782 C11H26N6O10 no hit 
2.1 211.1444 C11H18N2O2 2298456 
2.4 611.7316 C41H92N2 no hit 





2.7 398.1494 C24H19N3O3 42172 




3.3 852.5099 C26H76N8O22 no hit 










7.1 317.1154 C17H12N6O no hit 




7.9 546.4877 C35H63NO3 9988241 







1.1 712.2793 C29H41N7O14 17893700 
1.3 712.2769 C28H45N3O18 196239 
2.7 398.1502 C24H19N3O3 42172 
3.1 1269.6127 C60H92N4O25 
no hit 
  C56H88N10O23 
no hit 
3.2 531.1054 C28H14N6O6 
no hit 
3.3 591.1256 C30H18N6O8 
no hit 




4.3 523.1024 C30H18O9 4572736 
4.6 523.1029 C24H13N9O6 no hit 
4.8 545.0612 C30H12N2O9 no hit 
4.9 943.5257 C49H74N4O14 9717317 





5.2 523.1033 C30H18O8 9791 
5.6 539.0965 C27H10N10O4 no hit 
6.2 393.2614 C19H32N6O3 no hit 
7.1 317.1154 C17H12N6O no hit 
7.7 407.3354 C23H42N4O2 34404126 











0.6 437.1767 C17H28N2O11 9628214 
0.8 188.0923 C8H13NO4 16701 
1.2 712.2769 C28H45N3O18 196239 
1.3 712.2757 C25H37N13O12 no hit 




2.0 211.1443 C11H18N2O2 
2298456 
2.1 211.1441 C7H11N7O 54947356 
2.4 217.0974 C12H12N2O2 206710 
2.5 213.0697 C12H12N2O3 
no hit 
  C5H12N2O7 
no hit 
2.7 398.1502 C24H19N3O3 42172 
3.0 623.4707 C31H60N8O5 
no hit 
3.3 852.5106 C45H73NO14 no hit 





4.6 419.1709 C22H26O8 8326 





7.1 317.1154 C17H12N6O no hit 




7.9 546.4877 C35H63NO3 9988241 
10.0 391.2855 C24H38O4 no hit 
Supplementary Table 7: MS data for B226SN104.2 organic phase crude extracts 
B226.1 samples represent the B226SN104 samples which were fermented at 28°C, while 












ChemSpider ID, AntiBase ID, 






0.6 294.1202 C12H16N5O4 26929 
0.7 276.1101 C12H13N5O3 7986 
  C11H17NO7 No hit 
 441.1895 C25H28O7 
35800 
1.0 205.0984 C11H12N2O2 24808 
   28079 
1.3 712.2738 C24H41N9O16 No hit 
7.0 279.1581 C16H22O4 7589 
7.8 Common impurities 







0.5 387.0693 C15H10N6O7 No hit 
0.6 415.1817 C16H26N6O7 No hit 
1.0 450.1972 C19H31NO11 No hit 
1.2 Common impurities 
1.6 413.1408 C15H20N6O8 21113 
1.7 625.3141 C23H44N8O12 No hit 
2.9 574.3594 C29H51NO10 No hit 




7.0 279.1581 C16H22O4 7589 
7.8 Common impurities 







0.6 437.179 C18H24N6O7 No hit 
1.3 Common impurities 
1.6 413.1438 C19H24O10 No hit 
1.8 588.2552 C29H37N3O10 No hit 
2.0 Common impurities 
2.1 427.2577 C25H34N2O4 27796 
7.0 279.1581 C16H22O4 7589 







1.3 Common impurities 
5.5 413.2662 C21H36N2O6 14209 
7.0 279.1581 C16H22O4 7589 






1.2 Common impurities 











1.9 Common impurities 
2.1 415.125 C19H18N4O7 24565 
7.0 279.1581 C16H22O4 7589 







0.6 415.1820 C25H26N4O2 No hit 
1.2 Common impurities 
1.6 413.1408 C15H20N6O8 21113 
7.0 279.1581 C16H22O4 7589 
9.2 Common impurities 
Supplementary Table 8: MS data for B226SN104.2 aqueous phase crude extracts 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 



















ChemSpider ID, AntiBase ID, 






0.8 585.3200 C21H44N8O11 no hit 
0.9 585.3195 C20H48N4O15 no hit 
1.6 455.2140 C20H30N4O8 116946 
1.7 413.2032 C18H28N4O7 16616289 
 545.3658 C25H48N6O7 26389401 
1.9 639.3280 C18H30N28 no hit 
2.1 461.2603 C21H32N8O4 8044569 
  C20H36N4O8 16619974 
2.3 443.2502 C20H34N4O7 16621964 
   16690128 
5.0 387.1813 C22H26O6 319252 
   2559952 
  C23H22N4O2 1314876 
   1315399 
7.0 579.2937 C27H41N5O9 8161241 







0.8 585.3188 C20H48N4O15 no hit 
1.6 455.2134 C21H26N8O4 27443598 
1.7 518.2134 C23H43N5O8 (PubChem) 
1.9 401.2104 C18H32N4O6 16694122 
2 461.2603 C20H36N4O8 16619974 
2.3 443.2502 C20H34N4O7 16621964 
   16690128 
2.9 557.3647 C27H44N10O3 no hit 
5 387.1813 C22H26O6 319252 










ChemSpider ID, AntiBase ID, 
PubChem and Reaxys ID 
7 579293 C10H25N31 no hit 







1 585.3191 C21H44N8O11 no hit 
1.6 455.2140 C20H30N4O8 116946 
1.8 723.4129 C30H62N2O17 no hit 
1.9 502.2399 C22H35N3O10 26574096 
  C23H31N7O6 16642294 
2.0 461.2603 C20H36N4O8 16619974 
2.3 443.2505 C20H34N4O7 16729951 
5 387.1813 C22H26O6 319252 
   2559952 
  C23H22N4O2 1314876 
   1315399 
7 579.2943 C31H34N10O2 no hit 







1.4 486.3043 C22H35N11O2 58840443 
1.5 413.1423 C15H20N6O8 141829 
1.6 455.2144 C14H25N13O5 no hit 
2.0 576.2297 C24H21N19 no hit 
2.4 443.2426 C34H55N9O10 13758052 
2.9 732.1032 C33H57N5O13 
No hit 
4.0 901.4807 C51H68N2O12 3264848 
4.8 912.6273 C48H81N9O8 30770945 










ChemSpider ID, AntiBase ID, 
PubChem and Reaxys ID 
5.0 387.1813 C22H26O6 319252 
  C23H22N4O2 1314876 
5.6 1225.5382 C58H84N2O26 no hit 
  C56H72N16O16 no hit 
  C59H80N6O22 no hit 
5.9 1038.6309 C47H83N13O13 no hit 
  C50H91N3O19 no hit 
  C51H87N7O15 no hit 
7 579.2943 C31H34N10O2 no hit 








1 585.3191 C21H44N8O11 no hit 
1.7 517.3346 C23H44N6O7 8133795 
1.8 561.3594 C37H44N4O 2356339 
2.1 461.2603 C20H36N4O8 16619974 
2.3 587.3387 C25H50N2O13 no hit 
2.5 601.3548 C27H48N6O9 141883 
5 387.1813 C22H26O6 319252 
   2559952 
  C23H22N4O2 1314876 
   1315399 
7 579.2943 C31H34N10O2 no hit 




1.4 486.3043 C22H35N11O2 58840443 










ChemSpider ID, AntiBase ID, 






2.1 461.2603 C20H36N4O8 16619974 
2.4 443.2502 C20H34N4O7 16621964 
   16690128 
2.5 601.3548 C26H52N2O13 no hit 
  C27H48N6O9 141883 
3 1269.608 C55H92N6O27 no hit 
  C56H88N10O23 no hit 
3.2 1107.5614 C34H69N29O14 no hit 
3.4 1077.5479 C49H76N10O17 no hit 
3.8 959.5205 C48H78O19 112 possible hit 
  C45H70N10O13 13166493 
  C49H74N4O15 no hit 
4.8 959.5193 C47H62N18O5 no hit 
5 387.1813 C22H26O6 319252 
   2559952 
  C23H22N4O2 1314876 
   1315399 
5.6 507.2345 C26H30N6O5 29405263 
6.4 535.2652 C21H39N5O11 no hit 
6.8 535.2652 C28H40N2O9 21171714 
  C29H36N6O5 8362966 
7 579293 C30H38N6O6 
no hit 
7.4 708.5399 C37H69N7O6 no hit 
7.8 425.2152 C19H24N10O2 2544392 











ChemSpider ID, AntiBase ID, 






0.9 585.3195 C21H44N8O11 no hit 
1.6 455.2140 C20H30N4O8 116946 
2.4 750.4124 C33H59N5O14 no hit 
  C34H55N9O10 8007677 
  C23H37N5O7 16703145 
   16725901 
2.9 732.4031 C33H57N5O13 no hit 
3.3 716.4078 C42H56N2O8 34531180 
  C37H56N4O10 29214737 
4.2 946.5797 C54H79N3O11 2551896 
4.8 898.615 C51H83N3O10 no hit 
4.9 912.6273 C45H73N19O2 no hit 
  C48H81N9O8 30770945 
5 387.1813 C22H26O6 319252 
   2559952 
  C23H22N4O2 1314876 
   1315399 
5.6 1225.5382 C58H84N2O26 no hit 
  C56H72N16O16 no hit 
  C59H80N6O22 no hit 
5.9 1038.6309 C47H83N13O13 no hit 
7 579.293 C30H38N6O6 
no hit 
7.8 425.2145 C18H28N6O6 57486676 
Supplementary Table 9: MS data for SM9 aqueous phase crude extracts 
SM9 crude extract samples represent the samples which were fermented at 28°C, in the seven 









[M+H]+ Predicted Molecular 
formula 
ChemSpider ID, AntiBase ID, 






1.0 585.3186 C21H44N8O11 no hit 
1.4 419.2500 C18H34N4O7 17588243 
1.5 261.1238 C14H16N2O3 
106647 
1.7 455.2139 C20H30N4O8 62881823 
1.8 517.3352 C23H44N6O7 8133795 
  C22H48N2O11 no hit 
1.9 561.3603 C24H52N2O12 no hit 
2.1 461.2603 C20H36N4O8 16619887 
2.3 399.2235 C18H30N4O6 16733937 
2.4 443.2496 C20H34N4O7 
16690128 
2.6 457.2660 C21H36N4O7 
16621764 
2.9 493.264 C19H36N6O9 no hit 
3.2 303.1708 C26H38N4O6 
no hit 
3.4 503.2844 C26H38N4O6 7634 
3.5 519.2814 C26H38N4O7 4979463 
   4979406 
   4979449 
4.0 454.3032 C22H39N5O5 21375778 
4.9 912.6273 C47H85N5O12 no hit 
5.0 387.1803 C22H26O6 54  
  C23H22N4O2 
12227 
6.2 954.6373 C50H83N9O9 no hit 
6.4 535.2656 C27H38N2O9 7982903 











1 585.3186 C21H44N8O11 no hit 
1.4 419.25 C18H34N4O7 17588243 
 467.2084 C16H30N6O10 no hit 
  C15H34N2O14 no hit 
1.5 261.1238 C14H16N2O3 106647 
1.7 455.2139 C19H34O12 8679289 
 518.3179 C23H43N5O8 no hit 
2.1 461.2603 C20H36N4O8 16619887 
2.3 399.2235 C18H30N4O6 16733937 
2.4 443.2496 C20H34N4O7 16690128 
2.6 479.2477 C19H30N10O5 no hit 
  C22H38O11 9039028 
 599.3402 C27H46N6O9 59052244 
2.8 472.1714 C23H25N3O8 11777969 
2.9 732.4026 C31H45N19O3 no hit 
 493.264 C19H36N6O9 no hit 
3.4 503.2859 C16H40N8O10 no hit 
3.5 519.2814 C23H41N3O10 21387441 
4.0 454.3032 C22H39N5O5 21375778 
4.9 912.6259 C46H89NO16 no hit 
5.0 387.1811 C23H22N4O2 12227 
5.3 376.259 C21H33N3O3 11199111 
6.1 954.6384 C49H87N5O13 no hit 





1.0 585.3186 C21H44N8O11 no hit 
1.5 261.1238 C14H16N2O3 179735 






1.7 455.2139 C20H30N4O8 62881823 
1.8 547.2960 C21H34N14O4 no hit 
2.0 397.2083 C18H28N4O6 15460220 
2.1 461.2603 C20H36N4O8 16619887 
2.2 397.2088 C18H28N4O6 16694007 
2.4 443.2496 C20H34N4O7 16690128 
2.9 732.4026 C31H45N19O3 no hit 
4.9 912.6273 C47H85N5O12 no hit 
5.0 387.1803 C22H26O6 
54  








1.0 585.3186 C21H44N8O11 no hit 
1.4 419.2500 C18H34N4O7 17588243 
1.8 517.3352 C23H44N6O7 8133795 
  C22H48N2O11 no hit 
1.8 561.3610 C25H48N6O8 2867 
2.1 461.2603 C20H36N4O8 16619887 
2.2 573.3200 C32H42N6O4 10592905 
2.3 587.3386 C22H44N12O7 no hit 
2.4 443.2496 C20H34N4O7 16690128 
2.5 601.3546 C27H48N6O9 141883 
2.9 445.2348 C24H32N2O6 2269889 
   3289647 
3.4 503.2844 C26H38N4O6 
16529241 
   16529256 
   16529271 
4.9 912.6273 C48H81N9O8 30770945 










1.5 223.0942 C8H10N6O2 21374769 
2.0 462.2916 C19H43NO11 no hit 
2.6 265.1408 C11H16N6O2 336159 
   22153576 
   22348155 
2.7 243.1592 C13H23O4 no hit 
2.9 241.1441 C13H21O4 no hit 
3.1 265.1410 C11H14N6O2 1078806 
3.3 213.1494 C12H20O3 
Reaxys: 65 substances possible 
3.9 453.3205 C26H44O6 34241116 
4.1 247.1302 C11H14N6O no hit 
5.3 376.2590 C21H33N3O3 
11199111 
5.6 696.3436 C31H53NO16 no hit 
 717.2733 C32H40N6O13 
no hit 
6.1 954.6371 C49H87N5O13 no hit 
6.6 790.5885 Impurity 
7.6 780.4001 C33H53N11O11 17351786 







1.0 585.3186 C21H44N8O11 no hit 
1.3 712.277 C28H45N3O18 170050 
1.7 518.3179 C23H43N5O8 no hit 
1.8 561.3619 C25H48N6O8 2867 
2.0 401.2391 C18H32N4O6 16694122 
2.1 461.2603 C20H36N4O8 16619887 
2.3 399.2235 C18H30N4O6 16733937 




2.5 601.3546 C27H48N6O9 141883 
2.6 599.3402 C27H46N6O9 59052244 
2.8 472.1714 C23H25N3O8 11777969 
3.2 255.0652 C15H10O4 Reaxys : 60 substances possible 
3.7 271.0601 C15H10O5 29831 
5.0 387.1803 C22H26O6 
54 
5.3 376.259 C21H33N3O3 11199111 
5.6 507.2353 C25H34N2O9 8566920 
6.4 535.2664 C28H34N6O5 8362445 
  C27H38N2O9 7982903 







1.3 712.277 C28H45N3O18 170050 
1.4 467.2084 C16H30N6O10 no hit 
  C15H34N2O14 no hit 
1.4 585.7333 C22H46N8O11 no hit 
  C38H46O6 
5 substances possible 
1.5 261.1238 C14H16N2O3 106647 
1.6 455.2134 C20H30N4O8 
116946 
1.7 455.2139 C20H30N4O8 62881823 
2.1 461.2603 C20H36N4O8 16619887 
2.4 750.4137 C34H55N9O10 8007677 
  C33H59N5O14 no hit 
2.5 392.2534 C13H36N4O9 no hit 
2.9 445.2338 C23H29N3O6 3685208 
3.3 852.5073 C45H73NO14 
6273 
  C52H69NO9 
no hit 




3.9 453.3205 C26H44O6 
34241116 
4.1 247.1302 C11H14N6O no hit 
4.9 912.6288 C49H77N13O4 no hit 
5.0 387.1811 C23H22N4O2 12227 
5.4 599.4374 C21H33N3O3 417389 
5.6 1225.5426 C48H80N12O25 no hit 
  C47H84N8O29 no hit 
6.6 790.5895 C40H79N5O10 no hit 
7.8 403.2329 C20H34O8 9048392 
Supplementary Table 10: MS data for SM9 aqueous phase crude extracts 
Possible molecular formulas as predicted from the Bruker software used for Data Analysis 
based on two criteria: mass error (ppm) and isotope pattern matching (mSigma). In some cases 
two or more possible molecular formulas or molecules came up with the same possibility, so 
they are all included on the table. Compounds labelled as ‘common impurities’ are often 
present in various samples, therefore even though their structure is not defined, they are of no 
real interest. SM9 crude extract samples represent the samples which were fermented at 28°C, 
in the seven media above. Underlined= compounds only present to this extract, represent 
potential unique compound. 
 
 
 
 
 
